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Gene Therapy Strategies to 
Enhance Anti-Angiogenic Therapy, 
Chemotherapy and Radiotherapy in 
the Treatment of Malignant Glioma
A Pre-Clinical Evaluation
Malignant glioma is a devastating 
cancer with a dismal prognosis. The 
outcome of this thesis work confirms 
the feasibility of successfully com-
bining anti-angiogenic gene therapy 
with suicide gene therapy to treat this 
condition. It also describes a novel 
mechanism to account for the syn-
ergism and a treatment protocol that 
does not increase the adverse effect 
profile when suicide gene therapy is 
combined with temozolomide. Fur-
thermore, the results also highlight 
the efficacy of a novel gene therapy-
based targeted therapy strategy with 



















































































































































The objective of this thesisworkwas to evaluate the feasibility of using gene therapy
strategies to enhance antiangiogenic therapy, chemotherapy and radiotherapy in the
treatmentofMG.The first studydemonstrated theabilityofadenovirusmediatedHerpes
simplexvirustype1thymidinekinase(AdHSVtk)andprodrugganciclovir(GCV)suicide
gene therapy in combination with adenovirusmediated soluble vascular endothelial






MLH1, when combined with AdHSVtk/GCV suicide gene therapy, was described. The
study was further extended to delineate the optimal treatment protocol so that the






mayhavebeen the reason for the lackofefficacy.This studyrevealedanefficient invivo
treatmentprotocol tocombinesuicidegene therapywithTMZthatwouldhavepotential
clinicalapplications.
The fourth study described the invivo efficacy of an efficient gene therapybased
targeting system for inoperable tumours, where lentivirusmediated lowdensity
lipoprotein receptor (LDLR)avidin fusion protein gene therapy was capable of binding
biotinylated compounds invivo and significantly enhanced the survival of the animals
when treatedwithbiotinylated 90yttruim.The studyhighlights thepossibilityofutilizing
genetherapytotargetradiotherapyintoinoperabletumours.
Inconclusion,thisworkshowsthatthecombinationofdifferentgenetherapystrategies
or gene therapy with chemotherapy is a feasible way to achieve synergistic outcomes.
Careful consideration of the therapeutic protocol is important in obtaining maximum
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Maligni gliooma (MG) on aggressiivinen ja erittäin huonoennusteinen syöpä.
Viimeisimpien kliinisten kokeiden mukaan keskimääräinen potilaan elinajanennuste
diagnoosinjälkeenonainoastaannoin15kuukauttajavääjäämättätapahtuvankasvaimen
uusiutumisenjälkeenelinajanennustejääalle10kuukauden.
Tämän väitöskirjatyön tarkoituksena oli selvittää miten geeniterapia parantaa
pahanlaatuisen aivokasvaimen hoitotuloksia, kun se yhdistetään verisuontenkasvua
estäävään, solusalpaaja tai säteilyhoitoon. Ensimmäisessä osatyössä osoitettiin, että
adenovirusvälitteisen itsemurhageeniterapian (Herpes simplex virus1 tymidiinikinaasi
(AdHSVtk) ja aihiolääke gancicloviiriin (GCV) ) yhdistäminen adenovirusvälitteiseen
ihmisen liukoisen verisuonten kasvutekijän reseptori1:n (AdsVEGFR1) geeniterapiaan
tehostaa hoitoa syngeenisessä pahanlaatuisen gliooman rottamallissa. Vaikka anti
angiogeenisellä geeniterapialla ei ollut merkittävää vaikutusta kasvainten
uudisverisuonituksen määrään, se kuitenkin vähensi tuumorigeneesiä edistävien CD68
positiivistenmikrogliasolujenesiintymistäkasvaimessa.
Toisessa osatyössä yhdistettiin AdHSVtk/GCV geeniterapiaan klassinen, gliooman
rutiinihoitona käytetty solusalpaajahoito temotsolomide (TMZ). Geeniterapiahoito sai
aikaankahdenDNAkorjausmekansimiin liittyvänproteiinin ilmentymisenlisääntymisen,
joka taas vaikutti positiivisesti TMZ hoidon tehokkuuteen. Geeniterapian avulla TMZ:n
sytotoksisuutta voitiin tehostaa paikallisesti ja siten parantaa hoitovastetta ja hoidon
turvallisuutta.
Kolmannessaosatyössäkäytetty edelliseenyhdistelmään lisättyhistoniendeasetylaasi
inhibiittori valproaatti (VPA) ei tehostanut hoitotehoa eläinmallissa vaikka
soluviljelykokeissa saadut tulokset olivat lupaavia. Syynä tähän saattoi olla VPA:n lyhyt
puoliintumisaika plasmassa, jolloin konsentraatio jäi terapeuttista tasoa alhaisemmaksi.
Tutkimuksessaselvitettinmyösparashoitoaikataulu,jollasaataisiinmaksimoituahoitojen
yhteisvaikutus.
Neljännessä osatyössä lähestyttiin aivokasvainhoidon tehostamista hoidon paikallisen
kohdentamisen kautta. Tässä geeniterapiassa lentivirusvälitteinen LDLkolesterolin
reseptorin (LDLR) ja avidiinin muodostama fuusioproteiini pystyi sitomaan ja
soluunottamaan biotinyloituja aineita. Kohdennettu hoito merkittävästi pidensi
biotinyloidulla 90Yttriumilla hoidettujen eläinten elinaikaa. Tutkimus korostaa
geeniterapian luomaa mahdollisuutta kohdentaa radioterapiaa leikkauskelvottomia
kasvaimiahoidettaessa.
Väitöstyössä osoitettiin, että erilaisten geeniterapioiden yhdistäminen sekä keskenään
ettäkemoterapiankanssavoitehostaahoitotuloksia.Tarkkahoitoaikataulujensuunnittelu
onkuitenkintärkeäämaksimaalisenhyödynsaavuttamiseksi.Geeniterapiasoveltuulisäksi













This thesis work was carried out in the Department of Biotechnology and Molecular




First and foremost, I wish to thank Professor Seppo YläHerttuala, MD.PhD, my
principal supervisor, for giving me the opportunity to work in his research group. His









thesis, Professors, VeliMatti Kähäri, MD.PhD, and Heikki Minn, MD.PhD, for their
thorough evaluation of this work and invaluable comments. I would also like to thank
EwenMacDonald,PhD,fortheexcellentlinguisticrevisions.
Iamextremelygrateful tomydear friendandcoworker, JerePikkarainen for sharing
theburdenofworkandforcreatingsuchapleasantandcheerfulworkenvironment.Ihave





HannaRiikka Kärkkäinen, Svetlana Laidinen, Miia Tavitsainen, Thuomas Mäntylä and
Laura Alasaarela. This work would not have been possible without your valuable
contributions.
Dear friends from the University of Eastern Finland, especially, Galina Dragneva,
AgnieszkaPacholska,FarizanAhmed,NihayLahamKaramandVenlaTuppurainen;you




















Iwould like to thankall the technicians fromSYHgroup,especiallyAnneliMiettinen,
TiinaKoponen,Sari JärveläinenAnneliMartikainenandSeijaSahrio,and the technicians
fromArkTherapeutics,especially JoonasMalinen, JanaSiponenandthe lateRiikkaEisto
for the excellent technical support. I also wish to thank Pekka Alakuijala, Jari Nissinen,
JuokoMäkäräinenandJarmoAsikainenforcreatingasuperbworkingenvironment.
IthankHelenaPernuandMarjaPoikolainenfromthebottomofmyheartforbeingthere
for me always and helpingme in every possible way, even going beyond the limits of
duties. My gratitude is extended to the academic and nonacademic staff of Faculty of












































































































































































































































EORTC European Organisation for











































































































































STAT signal transducer and
activatoroftranscription
SV simianvirus

















USFDA United States Federal Drug
Administration










Every year over 12 million new patients are diagnosed with cancer and over 750 000
succumbtothisdisease.Itissaidtobethecauseofdeathinoneineverythreeadultsinthe




therapeutic success.Temozolomide (TMZ) is the latest chemotherapy tobe approved for
thetreatmentofMGalongwithantiangiogenictherapybevacizumab(BV).Largelyunmet
clinicalneedsofMGpatientshaveinspiredthesearchforbettertherapies.Genetherapyis
thedeliveryofgeneticmaterial into thebodywitha therapeutic intent,and isoneof the
mostwidelyexplorednoveltherapiesforcancerincludingMG.Herpessimplexvirustype1
thymidinekinase(HSVtk)suicidegenetherapywithprodrugganciclovir(GCV)isbeing
evaluated for MG and several other cancers in clinical trials, while soluble vascular
endothelialgrowthfactorreceptor1(sVEGFR1) isapromisingnewantiangiogenicgene
therapy strategy. Valproic acid (VPA) is a commonly used antiepileptic drug (AED) to
controlseizuresinMGpatientsbutitseemstopossessdiverseanticancerpropertiesthat
couldmodulatetheeffectsofchemotherapyaswellasgenetherapy.Combiningtherapies
acting through differentmodesofaction is an attractiveway to overcome the resistance
duetotumourheterogeneityandtoreducethedoselimitingtoxicities.
The aim of this thesis work was to evaluate the feasibility of combining different
treatment options available for MG in order to maximise the synergistic effects while
maintaining or even reducing the adverse effect profiles, and to understand the possible
mechanisms of synergisms. Thiswork explores the possibility of combining adenovirus
mediatedHSVtk/GCV(AdHSVtk/GCV)suicidegene therapywithadenovirusmediated
sVEGFR1(AdsVEGFR1)antiangiogenicgenetherapyinthetreatmentofMG,describing
the possible antitumour mechanisms. It identifies a novel mechanism of synergism
betweenAdHSVtk/GCVgenetherapyandTMZthatenhancesthetherapeuticindexofthe
latter,anddelineatesanoptimaltreatmentprotocoltomaximisethesynergisticeffectwith
potential clinical applications in many cancers in combination with multiple
chemotherapeuticagents.AdditionofVPAtotheAdHSVtk/GCVandTMZcombination,
even though apparently beneficial, failed to further improve the synergistic effect,
warrantingfurtherindepthinvestigations.Finally,thethesisworkdemonstratestheinvivo
efficacy of lentivirusmediated lowdensity lipoprotein receptor (LDLR)avidin fusion
protein gene therapy as a universal targeted therapy strategy to deliver targeted RT or
chemotherapy into cancers including MGs; a strategy that could have widespread
applicability,especiallyininoperableMGs.
TheresultsconfirmthefeasibilityofcombiningAdHSVtk/GCVsuicidegenetherapyin























or lymphatic system [Yokota, 2000]. More than 90 % of cancer deaths are due to this
metastatic phenomenon that often renders simple surgical resection ineffective as a
therapeutic option [Fidler, 2003] [Hanahan andWeinberg, 2011]. A cancer in the site of




diagnosed with cancer, and it accounts for over 750, 000 deaths throughout the world
[GLOBOCAN 2008 International Agency for Research on Cancer (IARC)
http://globocan.iarc.fr/factsheet.asp#BOTH]. According to statistics from United States,
malignantneoplasmswererankedsecondafterdiseasesoftheheart,astheleadingcauses
of death in 2009 [Kochaneck, 2011].Moreover, theNationalCancer Institute ofUSAhas
estimatedthecostofcancercareinUSin2010exceeded$124billion[Mariottoetal.,2011].
2.1.2Pathophysiology
Cancer is a complex, multifactorial disease involving dynamic changes in the genome
[Hanahan and Weinberg, 2000], orchestrated by host and environmental interactions
[Lichtensteinetal.,2000].AlterationsinthegenomecanbechangesinDNAsequenceand




of apoptosis [Hanahan and Weinberg, 2000]. These properties render cancer cells with
acquired functional capabilities during the course ofmultistep tumorigenesis [Vogelstein
and Kinzler, 2004]. In a sequel, the authors highlighted the importance of deregulating
cellular energy metabolism and avoidance of immune detection and destruction as
emerging hallmarks [Hanahan and Weinberg, 2011]. Genomic instability and tumour
promoting inflammation have been identified as the major enabling characteristics that
fosterthesehallmarks.Furthermore,thetumourmicroenvironment,whichiscomposedof
various nonmalignant cells, their cellular products and the extracellularmatrix, plays a
pivotal role in the initiation andprogressionof cancers [Tlsty andHein, 2001] [Hanahan
andWeinberg,2011].
2.2 MALIGNANT GLIOMA AS A PRIMARY BRAIN TUMOUR 
The brain is important from an oncological pointofview because many malignancies
elsewhere in thebody, suchas lung,breastandcolorectum,canmetastasise to thebrain




acquire a malignant phenotype, giving rise to primary brain tumours. Primary brain
tumours are less frequent compared to metastatic brain tumours [Eichler and Loeffler,
2007]. Apart from their general dismal prognosis, out of the 17 cancers studied brain
tumourshavethehighestaverageyearsoflifelosti.e.morethan20years,surpassingmost
ofthecommoncancers,highlightingtheheavyburdenofbraintumourstotheindividual
patient. Furthermore, the ratio of percentage years of life lost over percentagemortality
from a particular cancer is also the highest in brain tumours, highlighting the higher
populationburdenofthediseasethatexceedsthesimplemortality[Burnetetal.,2005].
2.2.1Classificationandgrading




Figure 1: Classification of brain tumours 
Approximately6070%ofallprimaryintracranialtumoursareofneuroepithelialorigin
[Stewart and Kleihues, 2003] [Ohgaki and Kleihues, 2005a]. Glial cells comprising of
astrocytes, oligodendrocytes and microglia are the most abundant cell in the nervous
system.Neuroepithelial tumoursofglialoriginarecollectively termedgliomasand these
are themost common primary brain tumours in adults [Lonn et al., 2004]. Gliomas are





clinical evidenceof a lowergradeprecursor [Ohgaki andKleihues, 2005b].Theobstacles
encountered in thisclassificationsystemare thatcelloforigin isunknowninmanybrain
tumoursandthatsometumourcellsaresoatypicalmakingitimpossibletocomparethem
withanynormalcelltype[Collins,2004].
Diagnostic classification based on histogenetics for brain tumours was originally






[Kleihues and Cavenee, 1997] [Kleihues and Cavenee, 2000]. The aim of the WHO
classificationistoclearlydefineuniversalhistopathologicalandclinicaldiagnosticcriteria.
Thefourtheditionofthisseries;i.e.theWHOclassificationofthetumoursoftheCNS,was
published in 2007 [Louis et al., 2007a], and it described several new entities, histological
variants, an updated WHO tumour grading scheme and genetic profiles [Louis et al.,
2007b]. Nonetheless, these classifications still contain more than 100 clinicopathological






microvascular proliferation and focal pseudopalisading necrosis [Nakamura et al., 2007],
with increasing biological aggressiveness with increasing tumour grade [Collins, 2004]
[KleihuesandCavenee,2000](Table1).

Table 1: WHO grading of primary brain tumours 
WHO grading of primary brain tumours 
Grade I II III IV 





Anaplastic astrocytoma GBM, 
Giant cell GBM, 
Gliosarcoma 










Malignant glioma - - + + 
Anaplastic glioma - - + - 




grade III and IV gliomas for which there are both histological evidence and biological
behaviour of malignancy such as anaplasia, invasiveness and tumour recurrence; this
group includes GBMs, anaplastic astrocytomas (AAs), anaplastic oligodendrogliomas
(ODGs) andoligoastrocytomas (OAs), andanaplastic ependymomas [Louis et al., 2007b].
The term “anaplastic glioma” collectively describes WHO grade III gliomas [Wick and
Weller,2009].TheemphasisfromhereonwardswillbeonMGandGBMwithonlyrelevant
referencestoimportantaspectsaboutthelowergradegliomas.
The differentiation between grade II and III astrocytomas, classification of
oligodendroglial tumourswithnecrosisandthediagnosisofmixedgliomassuchasOAs,
are areas not clearly defined in the currentWHO classification leading to subjectivity in
diagnostic neuropathology [Wick andWeller, 2009]. Overall the poor reproducibility of
diagnostic criteria based on current classification and grading systems is reflected in the
highdiscrepancyrateamongdifferentdiagnosticreviews[WickandWeller,2009].
2.2.2Epidemiology
According to GLOBOCAN 2008 (IARC), ~240,000 new cases of primary tumours of the
brain and nervous system were diagnosed worldwide during that year (accessed
19/01/2012). This is less than 2 % of all newly diagnosed malignancies (excluding non
melanomaskincancer)during thatperiod.However,mortalitydue tobrainandnervous
system tumours during the same yearwas ~ 175,000,which is about 2.3% of all cancer
relatedmortality.Asimilarpatternofrelativelyhighermortalitycomparedtothenumber








Primarybrain tumours show less geographic orpopulation to populationvariation in
incidence than other human neoplasms [Ferlay et al., 2001]. The higher age adjusted
incidenceobserved indevelopedand industrialized countries [Parkin et al., 2002] and in
Caucasians compared to African or Asian populations is attributed to socioeconomic
differences and underreporting rather than true genetic susceptibility [Ohgaki and
Kleihues, 2005a]. Primary brain tumours have an overall incidence of 68 new cases per
100,000 population per year [Stewart and Kleihues, 2003]. Higher incidence rates for










The mortality from nervous system tumours varies from 47 deaths per 100,000
population per year inmen and 35 forwomen inWestern Europe,NorthAmerica and
Australia[Ferlayetal.,2001][Parkinetal.,2002]andshowsasimilarworldwidepatternto
theincidence,inbothsexesandinmostgeographicalareas[OhgakiandKleihues,2005a].




2002]. The most frequent primary brain tumour types in adults are diffuse astrocytic
tumours and meningiomas, whereas in children they are pilocytic astrocytomas,
ependymomas and medulloblastomas [Collins, 2004]. Gliomas are the most common
primarybraintumoursaccountingformorethan50%inmanyserieswithanincreasein
theincidencewithage[Lonnetal.,2004]butinsomestudies,theincidenceisashighas70
% [Ohgaki and Kleihues, 2005a]. According to some population based studies, GBMs






elderly (mean age at diagnosis 62 years),while for secondaryGBMs, themean age is 45
years [Ohgaki and Kleihues, 2005b]. The incidence of GBMs in the elderly has been
increasing at a rate of 12% per year over the last decades though some of this can be
attributedtoimprovementsindiagnosticfacilities,especiallyneuroimaging[Modanetal.,
1992].Themeanageatclinicalmanifestationincreaseswithincreasinggliomagradewith




tumours associated with familial cancer syndromes and those attributed to therapeutic








of astrocytomas, GBMs and medulloblastomas [Ohgaki and Kleihues, 2005a] [Li et al.,
1995]. Neurofibromatosis1 (NF1) is associated with an increase in optic nerve gliomas
(pilocyticastrocytomas),diffuseastrocytomasandGBMs[Listernicketal.,1999],whereas
NF2isassociatedwithmeningiomas,ependymomas,astrocytomasandgliomasinmedulla
[Ohgaki and Kleihues, 2005a] [Collins, 2004]. Turcot syndrome type1 (B) with germline
mutationsinDNAmismatchrepair(MMR)genespostmitoticsegregation2(PMS2),MutS
homologous2 (MSH2) and MutL homologous1 (MLH1) presents with GBMs and
hereditary nonpolyposis colorectal carcinoma (HNPCC) [Hamilton et al., 1995],whereas
the type 2 (A) with germline mutation of adenomatous polyposis coli (APC) gene is
associated with medulloblastoma and familial adenomatous polyposis [Cavenee et al.,
2000] [Hamiltonetal.,1995].SeveralothersyndromessuchasBasalcellnevus (Gorlin’s),
Cowden disease, Melanomaastrocytoma [Collins, 2004] and Rhabdoid tumour
predispositionareassociatedwithbraincancer[Louisetal.,2007b].
Therapeutic irradiation is theonlyenvironmental factorunequivocallyassociatedwith
brain cancer [Ohgaki and Kleihues, 2005a], i.e. both highdose and lowdose irradiation
have increased the risk formeningiomas [Ronet al., 1988].Prophylacticbrain irradiation
for acute lymphoblastic leukaemia in children increased their risk for MG [Ohgaki and
Kleihues,2005a].ItisnotclearwhetherdiagnosticXrays,irradiationduetoatomicbombs
and the Chernobyl accident have increased the brain cancer risk [Ohgaki and Kleihues,
2005a].
Though some epidemiological studies demonstrated an increased risk of brain cancer
associatedwithcertainoccupations,thesehavenotbeenconfirmedbyindependentstudies
in other populations and none of them progressed to identify the putative carcinogen
[OhgakiandKleihues,2005a].An increasedriskofbraincancerhasbeenassociatedwith
exposure to certain substances such as plastic, rubber products, vinyl chloride, arsenic,
mercury, petroleum products, polycyclic aromatic hydrocarbons and lead [Ohgaki and
Kleihues, 2005a]. The IARC Monograph on the Evaluation of Carcinogenic Risks in
Humans (volume 188) reports a possible or weak association with nervous system
tumoursinhumanswiththeexposuretoberyllium,epichlorohydrin,chlordane/heptachlor,
methylthiouracil thiouracil, propylthiouracil, lead, diisopropyl sulphate and
dichloromethane [http://monographs.iarc.fr/monoeval/crthall.html].Aparentaloccupation
in chemical industry (and exposure to polycyclic aromatic hydrocarbons) or agricultural
work,hasbeenclaimedto increase therisk forbraincancer in theoffspring [Ohgakiand
Kleihues,2005a].
A higher socioeconomic status is associated with an increased risk of gliomas and
meningiomas inwomen andmany other studies have shown similar effectwith white
collarjobs[OhgakiandKleihues,2005a].
The role of diet as an aetiological agent for brain cancer is unclear but some reports
suggest that a high intake of food containingNnitroso compounds and protein can be
associated with an increased glioma risk in adults, with an inverse association with a
frequentintakeoffreshfruits,vegetables,vitaminC,totalfat,cholesterol,calcium,sodium
[OhgakiandKleihues,2005a]andtotalcoffeeandteaconsumption[Michaudetal.,2010]
[Holick et al., 2010], but available data inmost studieswere insufficient to establish any
doseresponse relationship [Blowers et al., 1997] [Boeing et al., 1993].No causal link has
beenobservedbetweensmokingandadultgliomasbut somestudies implicatedparental
smokingintheriskofchildhoodgliomas[OhgakiandKleihues,2005a].Ontheotherhand,





Exposure to electromagnetic fields as a causative factor for glioma still remains
controversial,withmixedresultsfromdifferentstudieswithinsufficientevidencetodrawa
causal link [Ohgaki and Kleihues, 2005a] [Baldi et al., 2011]. In a similar manner, no
consistentassociationhassofarbeenfoundbetweentheuseofcellularphonesandbrain
tumours, [Aydinetal.,2011] [Larjavaaraetal.,2011] [Kheifetsetal.,2010] [Deltouretal.,
2012].
Epidemiological studies have shown a weak but inconsistent or nonsignificant
associationwithtraumaticheadinjuryandbraincancer;howeverthecausalrelationshipis
difficult toprove[OhgakiandKleihues,2005a].Asignificant inverseassociationbetween
glioma and allergic diseases such as asthma and eczema, and autoimmune diseases has
beendemonstrated[OhgakiandKleihues,2005a].Thereisevidencetosuggestthatfemale
sex hormones, hormone replacement therapy and oral contraceptive use could be
protectiveagainstgliomabutmay increase the riskofmeningioma [CowppliBonyetal.,
2011].
Incountrieswherepoliovaccinescontaminatedwithsimianvirus40(SV40)wereused,
several studies have shown a higher occurrence of SV sequences in brain cancerswhen




There is evidence suggesting aswell as disproving familial clustering of brain cancer
[Malmeretal., 2001] [Scheureretal., 2010].Theriskofglioma is thought tobe increased
with the polymorphism in the genes encoding enzymes involved in the metabolism of
chemicalcarcinogens[OhgakiandKleihues,2005a].Genomewideassociationstudieshave
identified singlenucleotide polymorphisms in the cyclindependent kinase inhibitor 2A
(CDKN2A),CDKN2B,regulatoroftelomeraseelongationhelicase1(RTEL1)andtelomerase




AAs often develop as progressions from lowgrade diffuse astrocytomas. Mean age at
diagnosisis4550years[OhgakiandKleihues,2005a].Sincetheyhavearapidgrowth,they
often progress toGBMswithin 23 years [Stewart andKleihues, 2003]. Tumour cells are
more pleomorphicwith distinct nuclear atypia,mitotic activity and increased cellularity,
and histological and immunohistochemical features of astrocytes. AAs do not show
evidenceofspontaneoustumournecrosisorabnormalmicrovascularproliferation[Collins,
2004]. The distinction between WHO grade II and III astrocytomas is primarily by
assessmentoftumourcellproliferation.However,WHOgradingdoesnotprovidecutoff






5562 years [Ohgaki and Kleihues, 2005a]. In general, GBMs have cerebral hemisphere
preponderance[Collins,2004].Usuallythereisashortclinicalhistoryoflessthan3months
andGBM has a very poor prognosis despite progress in surgery and adjuvant therapy,
largelyduetoincompleteresectionandresistancetoradioandchemotherapy[Kleihueset
al., 2002]. In general, high cellularity, increased mitosis, marked nuclear atypia and
characteristicspontaneoustumournecrosissurroundedbypseudopalisadingtumourcells,






[Collins, 2004] [Takei et al., 2007a], which histologically places GBMs in astrocytic class.
However, their precise origins remain elusive [Huse and Holland, 2010]. Imaging may
reveal large areas of central necrosis with ringlike zones of contrast enhancement from
viabletumourtissue[Collins,2004].Asthename“multiforme”implies,GBMshaveawide
spectrum of histologicalmorphologies ranging from smallcell type to very pleomorphic
giantcell forms with poor differentiation [Collins, 2004] and gliosarcomas [Louis et al.,
2007b]. Foci resemblingODG are seen in someGBMs [Louis et al., 2007b], especially in
youngpatients,wherenecrosisisuncommonandhasafavourableoutcome[Vituccietal.,
2011].Thesmallcellsubtypedisplaysamonomorphic,small,roundtoslightlyelongated,
densely packed cell population with oval, mildly hyperchromatic nuclei containing
occasionalnucleoli [Perryet al., 2004], and increasednuclear: cytoplasmic ratioandmild
atypia. Frequent mitoses, inconspicuous cytoplasmic borders, vascular endothelial
proliferation and necrosis are other features. They have some resemblance to anaplastic
ODG such as chickenwire vasculature, clear haloes, perineuronal satellitosis and
microcalcifications[Louisetal.,2007b].GiantcellGBMsarisedenovo,haveashortclinical
history and account for about 5 % of GBM, with a mean age at diagnosis of 42 years.
Histologically there is giant cell predominance in conjunctionwith cohesion, distinct cell
borders and reticulinrich stromawith a strongGFAP reactivity [Louis et al., 2007a].De
novo and secondary GBM are morphologically indistinguishable [Godard et al., 2003]
exceptfortherelativerarityofnecrosisinthelattertype[Tohmaetal.,1998].
The median age at diagnosis for ODG and OA is between 4649 years [Ohgaki and
Kleihues, 2005a]. Anaplastic ODGs display nuclear pleomorphism, hyperchromatism,
hypercellularity, increased mitotic activity, microvascular proliferation, delicately
branching chickenwire vasculature, clear haloes, perineuronal satellitosis,
microcalcification, microcysts and/or spontaneous necrosis, with uniform tumour cells




The anatomical location of MGs has a significant impact on the patient outcome. In
adults,supratentorialtumourspredominate[Inskipetal.,1995].Mostofthetumours(>85
%)areincerebrallobes;infrontal(40%),temporal(29%),parietal(14%)andoccipital(3
%) in a decreasing order of frequency [Larjavaara et al., 2007]. GBMs follow a similar




et al., 2007], the majority of which were bifrontal [Inskip et al., 2003]. Precursor cell of
tumourorigin,differencesinthemicroenvironment,structuralandfunctionaldifferencesin




growth factor signalling by amplification and mutational activation of receptor tyrosine
kinase (RTK) genes, activation of phosphatidylinositol 3kinase (PI3K) pathway and















[Clarke andDirks, 2003].However, coexpressionof receptor and ligandplateletderived
growth factor (PDGF)B creates a possible autocrine/paracrine loop enhancing the






Figure 2: A schematic presentation of major molecular pathways dysregulated in malignant 
glioma.  and  indicate activation and inhibition, respectively. ARF-alternate reading frame, 
CDK-cyclin dependent kinase, EGF-epidermal growth factor, EGFR-EGF receptor, ERBB-
erythoroblastosis oncogene B, FOXO-forkhead box O, HER-human EGF receptor, HGF-
hepatocyte growth factor, MAPK-mitogen-activated protein kinase, MDM-murine double minute, 
MET-HGF receptor, mTOR-mammalian target of rapamycin, NF-neurofibromatosis, PDGF-
platelet-derived growth factor, PDGFR-PDGF receptor, PI3K-phosphatidylinositol 3-kinase, 





seen in 15 % of GBM, whereas its primary negative regulator phosphatase and tensin
homolog (PTEN) is inactivated in 1540%,whileAKT is amplified in only 2% ofGBM











35 % had TP53 inactivation by mutations or deletions [2008] [Parsons et al., 2008].
Furthermore,TP53 inactivation for treated anduntreated sampleswas 58% and 37.5%,
respectively.Inp53intactGBMs,amplificationofantagonistMDM2(14%)andMDM4(7
%),andmutationordeletionofCDKN2A (~50%) thatencodes forp53positive regulator
p14/ARF was observed [2008] [Parsons et al., 2008]. These findings suggest that p53
inactivationisalsoafrequenteventindenovoGBM.
RB tumour suppressor pathway is defective in a significant fraction of highgrade
astrocytomasandODGsandin6878%ofGBMs[2008][Parsonsetal.,2008].Theycouldbe
duetoinactivationmutationsorhomozygousdeletionsofRB1geneitself(~11%)[Parsons
et al., 2008]or activationofnegative regulators cyclindependentkinase 4 (CDK4) (18%)







2009] [Hartmann et al., 2009]. They can be associated with TP53 mutations and 1p/19q
deletions but not with EGFR amplification or loss of chromosome 10 [Yan et al., 2009]
[Sansonetal.,2009].Thepossiblemechanismsofactionareinductionofhypoxiainducible
factor1 (HIF1) [Zhao et al., 2009], by changing the DNA methylation profile and
causingwidespreadepigeneticchanges[Dangetal.,2009][Wardetal.,2010][Noushmehr
etal.,2010].
Common moleculargenetic dysregulations and their frequencies of occurrence in
gliomasofdifferentWHOgradesarepresentedinFigure3.

Figure 3: Frequent molecular-genetic dysregulations in gliomas. Frequencies of occurrence of 
the dysregulations and the WHO grades of the tumours are given in brackets. CDK-cyclin 
dependent kinase, EGFR-epidermal growth factor receptor, GBM-glioblastoma multiforme, HRK-
hara-kiri, IDH-isocitrate dehydrogenase, LOH-loss of heterozygosity, MDM-murine double 
minute, ODG-oligodendroglioma, PDGF- platelet-derived growth factor, PDGFR-PDGF receptor, 










 (NFKBIA) is deleted especially in nonclassical GBM (mesenchymal, neural and
proneural) with a near mutual exclusivity with EGFR activation, resulting in a poor
prognosissimilartoEGFRactivation[Bredeletal.,2011].
Recent studies have implicated several micro RNAs (miR) in glioma development,
including overexpression ofmiR26a,which represses PTEN,RB andMAP3K2,which is
seenin12%ofGBM[Huseetal.,2009][Kimetal.,2010],miR21,miR7,miR124a,miR
137,miR221,miR222andmiR181family[Novakovaetal.,2009].Ontheotherhand,miR







Several studies identified prognostically distinct molecular subgroups, within defined
morphological groups and among these groups, especially when the morphological
diagnosis was ambiguous. In most instances, molecular grouping displayed a better
correlationwithoutcome.Thesestudiesgroupedgliomas/GBMintobetween24molecular
subgroups. In spite of not having a standard nomenclature, subgroups from different
studies displayed significant molecular overlap, similar molecular signatures and
prognosticoutcome[Vituccietal.,2011].However,mostgliomasonrecurrenceshiftedthe
mRNA profile towards a mesenchymal phenotype, in spite of retaining the original
molecularsubgrouping[HuseandHolland,2010].

Table 2: Molecular classification of malignant gliomas 
Features Proneural (HC1A) Classical Proliferative 
(HC2A) 
Mesenchymal (HC2B) 
WHO grade III or IV, majority 
non-GBM  
IV IV IV 
Mean age at 
diagnosis 
40-51 years  50-55 years 50-55 years 
Median survival 175 weeks/ 1.4-4.8 
years 
 61 weeks/ 0.6-
<1.3 years  





Neurogenesis  Haematopoietic/ 
neural stem cells/ 
cell proliferation 
Extra-cellular matrix/ 





























Mutations: NF1, p53, 
PTEN 
LOH: 10 
Gains: chromosome 7 
Deletions: NF1 
Activations: STAT3, 






GBM with ODG 
features but without 
necrosis, 





necrosis is typical, 


















 Respond to chemo-
radiation 
References for the table are [Phillips et al., 2006] [Lee et al., 2008] [Vitucci et al., 2011] [Carro et al., 




differentiation, CDKN2A- cyclin-dependent kinase inhibitor 2A, C/EBP-CCAAT/enhancer binding protein-, 
CHI3L1-chitinase 3-like protein 1, DLL-delta-like, EGFR-epidermal growth factor receptor, GBM-
glioblastoma multiforme, G-CIMP-GBM CpG island methylator phenotype, IDH-isocitrate dehydrogenase, 
LOH-loss of heterozygosity, NF-neurofibromatosis, ODG-oligodendroglioma, OLIG-oligodendrocyte 
transcription factor, PCNA-proliferating cell nuclear antigen, PDGFR-platelet-derived growth factor 
receptor, PIK3CA/PI3KR1-phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit / PI3K 
regulatory subunit 1, PTEN-phosphatase and tensin homolog, STAT- signal transducer and activator of 
transcription, VEGF-vascular endothelial growth factor, WHO-World Health Organization 

ThemolecularcharacterisationofMGshelpstoprovideamoreprecisesubgroupingof
tumours within an individual morphological category by accurately defining specific
molecular,geneticandcellularfeaturesofgliomagenesis.Thispavesthewayforsuccessful
augmentation of standard treatment regimens and to rationally design novel targeted
therapies [Huse and Holland, 2010] enabling better prediction of clinical outcomes and
responsetotherapy.Eventuallythiswillprovidethegroundworkforpersonalisedcancer
therapy[Vituccietal.,2011].Ontheotherhand, themolecularandcellularheterogeneity




During theirprogression frommicroscopic tomacroscopic tumourswithdenselypacked
cells, cancers tend to outgrow their vascular supply. The resulting hypoxic environment
restrictsgrowthfurther,makingangiogenesisanintegralpartintumourdevelopment.For
thetumourgrowthtocontinue,itisvitalthatitmustdevelopnewbloodsuppliestomeet










mechanisms. In sprouting angiogenesis, new blood vessels are formed from preexisting
vessels [Carmeliet and Jain, 2000] [Carmeliet, 2005]. Glomeruloid angiogenesis, which is
especiallyseeninGBMs,occurswhentumourcellsobtainavascularsupplyfromseveral
closely associatedmicrovessels surroundedbybasementmembrane of variable thickness
withinwhichareembeddedalimitednumberofpericytes(Glomeruloidbodies)[Bratand
Van Meir, 2001]. De novo formation of new blood vessels from bone marrowderived
endothelial progenitor cells (BDEPC) [Santarelli et al., 2006] or haematopoietic
stem/progenitor cells (BDHSC/BDHPC) [De et al., 2005] incorporated into the tumour
vessels from the circulation is calledvasculogenesis,which is importantduring the early
stages of tumour development [Nolan et al., 2007]. Its contribution to tumour
neovascularisation is variable (1.558%) [De et al., 2003] [Santarelli et al., 2006], and has
even been questioned [Purhonen et al., 2008]. New blood vessel generation by septal
formation inside the existing blood vessels is termed intussusception, which has been
described inbrainmetastaticmodels.However, its contribution toprimarybrain tumour
development is unclear [Jain et al., 2007]. Vasculogenic mimicry describes vascular












variety of stimulating and inhibiting mediators converging to trigger the “angiogenic
switch”[HanahanandFolkman,1996].Themainangiogenicmediator,vascularendothelial
growth factor (VEGF), is highly expressed inMGsby the tumour [Plate et al., 1992] and
stromalcells[Fukumuraetal.,1998],andinfiltratingimmunecells[Murdochetal.,2008].
TheVEGFfamilyincludes6secretedglycoproteins,namelyVEGFA(VEGF),B,C,D,E
and placental growth factor (PlGF) (Figure 4). The main angiogenic mediator, VEGFA
(VEGF), has 4 main isoforms VEGF121, VEGF165, VEGF189 and VEGF206 of which
VEGF165 is the predominant isoform expressed in tumours [Ellis and Hicklin, 2008]
[Ferrara, 2004]. VEGF secretion is regulated by hypoxia through HIF1 [Shweiki et al.,
1992],acidosis[Fukumuraetal.,2001],transcriptionfactors(HIF1,ETS1,STAT3),genetic
alterations (EGFR activation, PTENmutation), oncogenes (Ras, SRC), tumour suppressor
genes (TP53), growth factors (epidermal growth factor (EGF), PDGFB, basic fibroblast
growth factor (bFGF)), hormones, cytokines (transforming growth factor (TGF)), and
signallingmolecules (nitric oxide (NO)) andMAPK [Jain et al., 2007] (Figure 4). VEGFs
exert their effects through cognate VEGFR receptors (RTKs) VEGFR1 (Flt1), VEGFR2
(Flk1/KDR)andVEGFR3(Flt4)aidedbytwocoreceptors,neuropilinreceptor1(NRP1)
andNRP2 [Fischer et al., 2005a]. The angiogenic effects ofVEGFs are exerted primarily
through VEGFR2 (KDR) [Stratmann et al., 1997] expressed mostly on endothelial cells
[EllisandHicklin,2008],byinducingtheirsurvival,proliferationandmigration[Carmeliet
and Jain, 2000] [Ferrara, 2004]. MGs overexpress VEGFR1 (Flt1) and VGFR2 (Flk1)
[Plate et al., 1994],which alongwithVEGF expression correlateswith the tumour grade
[Samotoetal.,1995]andmaycollectivelycreateanautocrine/paracrinegrowthsignalling
loop[Kerbel,2008].VEGFsplayarole invasculogenesisbyenhancing therecruitmentof
VEGFR1 and/or VEGFR2 expressing BDHPCs [Murdoch et al., 2008] and VEGFR2
positive BDEPCs [Ellis and Hicklin, 2008]. VEGFs can inhibit the antitumour immune
response[OhmandCarbone,2001]byimpairingthedifferentiationofVEGFR1expressing
progenitor cells into dendritic cells (DCs) [Gabrilovich et al., 1996], by affecting Tcell
development [Ohm et al., 2003], by recruitingmyeloidderived suppressor cells (MDSC)
that suppress antitumour Tcell and natural killer (NK) cells, by recruiting tumour
promoting, VEGFR1 or 2 expressing monocytes/macrophages [Kerber et al., 2008]




(TSP2), stem cell factor (SCF), PDGF and PDGFR, interleukin8 (IL8), IL6, stromal
derived factor 1 (SDF1) and its receptorCXCR4, EGF, insulinlike growth factor 1 and 2
(IGF1&2),HGF, tumournecrosis factor& (TNF/), interferons (IFN),cathepsinB,
urokinaseplasminogenactivatorreceptor(uPAR),angiostatin,endostatin,solubleVEGFR
1andplateletfactor4(PF4),andbFGF,granulocytemacrophagecolonystimulatingfactor









Figure 4: A schematic presentation of the regulation of VEGF production, VEGFs and VEGFR 
family interaction, and their contributions to cancer development. BCR-ABL-breakpoint cluster 
region-Abelson, bFGF-basic fibroblast growth factor, EGF-epidermal growth factor, EGFR-EGF 
receptor, ETS-E twenty six, HER-human EGFR, HGF-hepatocyte growth factor, HIF-hypoxia-
inducible factor, IGF-insulin-like growth factor, IL-interleukin, MAPK-mitogen-activated protein 
kinase, NO-nitric oxide, NRP-neuropilin receptor, PDGF-platelet-derived growth factor, PlGF-
placental growth factor, PTEN- phosphatase and tensin homolog, Ras-rat sarcoma, SRC-
sarcoma, STAT- signal transducer and activator of transcription, TGF-transforming growth 
factor, TNF-tumour necrosis factor, sVEGFR-soluble VEGFR, VEGF-vascular endothelial growth 




cells, pericytes and astrocytes which together form the bloodbrain barrier (BBB). This
structure selectively restricts the exchange of molecules between extracerebral and
intracerebralcirculatorycompartments[Jainetal.,2007].Thelackoffenestrationsbetween
adjacent endothelial cells and pinocytotic and endocytotic endothelial vesicles, and the
presenceofcontinuouslyextendingtightjunctionsconnectingtheadjacentendothelialcells
limit passive diffusion. This barrier for passive diffusion is further increased by the
presence of astrocytic processes enveloping the gapjunctions [Huber et al., 2001]. The
passiveentryofhydrophilicmoleculeslargerthan500kDispreventedbytheendothelial
cell tight junctions. The presence of active carriermediated transport systems on the
endothelialcellsurfacecompensatesforthelimiteddiffusion.Moreover,theycontainactive













aberrant in nature [Deane and Lantos, 1981a] [Deane and Lantos, 1981b] with
heterogeneous flow rates [Wolf et al., 2005] and increased permeabilities [Takano et al.,
1991],leadingtoelevatedinterstitialfluidpressurewithinthetumours[BoucherandJain,
1992]. The increasedVEGF levelswithin these tumours [Plate et al., 1992] through their
actiononVEGFR2[FerraraandBunting,1996]generatingimmature,dysfunctionalvessels
along with impaired BBB, is mainly attributed to this property [Jain et al., 2007]. The
increasedvascularpermeabilityandthelackoflymphaticdrainageleadtoanequilibrium
in the oncotic and hydrostatic pressures between the tumour microvasculature and
interstitialspace[Boucheretal.,1997]andthisstasishinderschemotherapeuticdeliveryto
the tumours [Netti et al., 1996]. VEGF induced vascular leakiness leads to a vasogenic
oedema that contributes to the pathophysiologyof these tumours [Berkman et al., 1993].
Tumour vessels also carry abnormalities in the endothelium, pericyte coverage and
basement membrane, such as “Glomeruloid tufts” formed by multilayered mitotic
endothelial and perivascular cells [Plate and Mennel, 1995] [Benjamin et al., 1999], and
increased open endothelial gaps and cytoplasmic vesicles [Deane and Lantos, 1981b]
[VajkoczyandMenger,2000].Collectivelytheseabnormalitiesresultinprogressivetumour






et al., 2006a]. These cells resemble neural stem cells (NSCs) and have the ability to
proliferate over a long period of time, selfrenew, differentiate into multiple cell types
(multipotency)[Wangetal.,2010a][RicciVitianietal.,2010]andaretumorigenic[Galliet
al., 2004] [Yuan et al., 2004] [Johannessen et al., 2008]. Cluster of differentiation 133+
(CD133+)hasbeenconsideredasamarkerforCSLC[Singhetal.,2003][Singhetal.,2004]
[Baoetal.,2006a],howeverCD133cellswithCSLCpropertieshavebeenreported[Beieret
al., 2007] [Wang et al., 2008] [Prestegarden et al., 2010]. Nestin, CD90, CD44, CXCR4,
musashi1(Msi1)andmaternalembryonicleucinezipperkinase(MELK)[Johannessenetal.,
2008] andmany others have been reported representing as CSLCmarkers [Lathia et al.,
2011]butnoneseems tobeexclusive [Prestegardenetal., 2010].They resistapoptosisby
overexpressing antiapoptotic genes such as Bcl2, Bclx and survivin [Liu et al., 2006]
[Johannessen et al., 2008]. Overexpression of DNA repair genesmakes them resistant to
chemotherapyandRT [Beieretal., 2007] [Baoetal., 2006a] [Svendsenetal., 2011],hence
havebeenimplicatedintumourrecurrence.Thisisfurtheraidedbytheiroverexpressionof
gene formultidrug resistanceproteins [Salmaggi et al., 2006],ABCG2 [Chua et al., 2008]
and VEGF [Bao et al., 2006b]. There does not seem to be any difference in the methyl
guaninemethyl transferase (MGMT)promotermethylationbetweenCD133+andCD133
CSLCs.However,CD133 cells have amore pronouncedMGMT expression [Beier et al.,
2008]. In contrast to the conventional MG cells, MG CSLCs with mutant p53 are more
resistant toTMZ[Bloughetal.,2011].SurvivalandproliferationofCSLCsaredependent
on the activationof several cellular signallingpathways, includingNONotchdill,wnt
catenin,sonichedgehog(HH)Gli [Clementetal.,2007]andVEGFVEGFR2NRP[Becket
al.,2011].AnichefortheCSLChasbeenextensivelydiscussed[Borovskietal.,2011].There
is evidence to suggest thatCSLC reside in the perivascular niche [Calabrese et al., 2007]
[Zhuetal.,2011]aswellasadjacenttothehypoxictumourareas[Mathieuetal.,2011].The
origin of CSLCs andMGs remains controversial [Visvader, 2011] [Bjerkvig et al., 2005].
There issomeevidencetosuggest thatCSLCcanarisefromdifferentiatedcells [Guptaet










MGsare composedof tumour cells aswell as interminglingparenchymal cells including
cellsof thetumourvasculature,microglia/macrophages,peripheral immunecells,stromal
cells,astrocytesandneuralprecursorcells.TheheterogeneityofMGisnotonlyduetothe
heterogeneity of the tumour cells but also due to the heterogeneity of these tumour
associated cells [Charles et al., 2011]. Collectively these cells play a vital role in the
tumorigenicprocessandprogressionofthetumour.
Microglia/macrophagesformthebulkoftumourassociatedcells,whichcanbeupto30
% of the tumour mass [Graeber et al., 2002] [Watters et al., 2005]. Whether TAMs are
derivedfromresidentmicrogliaorfromtheperipheralcellsremainselusive.TheMGcells
secrete monocyte chemotactic protein3 [Okada et al., 2009], colonystimulating factor1
[Alterman and Stanley, 1994], granulocyte colonystimulating factor (GCSF), HGF/SF
[Suzuki et al., 2008], VEGF [Rogers and Holen, 2011] and chemokines that act as
chemoattractants. TheEGF secretedbyMG cells can also act as a chemoattractant and a
proliferatingsignalforTAMthroughtheirexpressionofEGFR[Nolteetal.,1997].Thereis
evidence to suggest that tumour secreted VEGFmediated monocyte/macrophage
infiltration into tumours is dependent on the expression of VEGFR1 by macrophages
[Barleon et al., 1996] [Muramatsu et al., 2010] [Kerber et al., 2008]. However, there is
evidencetopointtoaroleforVEGFR2inothercancermodels[Dineenetal.,2008].TAMs
are believed to reside in the hypoxic areas of the tumour.  Within MGs, TAMs are
suppressedbythesecretionofIL10,IL4,IL6andTGF,prostaglandinE2(PGE2)bythe
MG cells [Charles et al., 2011], reducing the production of TNF. It is believed that the
majority of TAMs carry an M2phenotype with CD163 and CD204 expression  and the
number ofM2TAMs correlateswith the histological tumour grade [Charles et al., 2011]
[Bingleetal.,2002].InhibitionofNotchsignallingalsopromotedtheM2phenotype[Wang
et al., 2010b]. Once activated, TAMs release a variety of growth factors, cytokines,
inflammatorymediators andproteolytic enzymes.The IL1 secretedbyTAMsenhances
theproductionofTGFbyMGcells[Naganumaetal.,1996].TGFinturnsuppressesthe
antitumourimmuneresponsebyinhibitinglymphocyteproliferation,antigenpresentation
and immune cell activation [Letterio andRoberts, 1998]. Furthermore, an increase in the
levelofTGFenhancesMGangiogenesis,proliferationandinvasionthroughupregulation
ofVEGF,EGFRandmatrixmetalloproteinase9(MMP9)production,respectively[Watters





DNA repair pathways are essential for genomic integrity. SeveralDNA repair pathways
have evolved tomaintain genetic fidelity, to protect the genome from thewide range of
DNAdamagingagentscausingdiverseformsofDNAdamages,andtofunctionatdifferent
stagesinthecellcycleinacelltypespecificmanner.Thecellularmechanismswhichhave
evolved to combat the threats of DNAdamage are collectively termed asDNAdamage
responses (DDR),which  includedetection and repair of theDNAdamage [Jackson and
Bartek, 2009]. The major  DNA repair pathways include direct reversal DNA repair by






distorting lesions such as bulky chemical adducts or DNA crosslinks, and homologous
recombination (HR) and nonhomologous end joining (NHEJ) pathways to repair DNA
doublestranded breaks (DSB) [Helleday et al., 2008].  Sometimes these pathways act in
concert,sincetheyhavesomedegreeofredundancytowardssometypesoflesions[Jackson
and Bartek, 2009]. Mammalian DDR signalling pathways include two protein kinases;





the cellcycle atG1S, intraS orG2M cellcycle checkpoints [Jackson andBartek, 2009].
ThisprovidesampletimeforDNArepairbeforetheonsetofreplicationormitosis. If the
damage is irreparable continuous DDR signalling triggers cell death by apoptosis or
cellularsenescence/autophagy[Halazonetisetal.,2008].
ImpairedDNArepairisassociatedwithembryoniclethality,shortlifespan,rapidaging,
impaired growth, immunodeficiency, neurological disorders and a variety of inherited









mediated cytotoxicity following treatment with monofunctional alkylators [Karran and
Marinus, 1982], such as TMZ [Kaina et al., 2007], cisplatin [Fram et al., 1985], and 6
thioguanine (6TG) [Swann et al., 1996]. On the other hand, most cancer cells harbour
defectsinatleastoneDDRcomponentbuttheirsurvivalisensuredbythefunctionofother











process involving a single protein that leads to irreversible inactivation of that repair
protein[Kainaetal.,2007].MGMTisabletoremovealkylationadductsfromO6positions
ofguanine.MGMTiscapableofremovingmethyl,ethyl,propyl,chloroethylandisopropyl





1996] and proteasomal degradation [XuWelliver and Pegg, 2002]. Hence, one MGMT
molecule can remove only one alkyl adduct. Phosphorylation increases nuclear




fromO6methylguanine (O6mG) irrespectiveofwhether it ispairedwithcytosine (C)or
thymine(T)[LipsandKaina,2001](Figure5).

Figure 5: A schematic presentation of the regulation of MGMT gene expression and the 
mechanism of MGMT-mediated DNA repair. AP-activator protein, CH3-methylation, G-CIMP- 
GBM CpG island methylator phenotype, GRE-glucocorticoid responsive element, IDH-isocitrate 
dehydrogenase, IFN-interferon, LOH-loss of heterozygosity, MGMT-methyl guanine methyl 
transferase, NF-B- nuclear factor of -light polypeptide gene enhancer in B-cells P-




spleen and colon but a low expression in brain [Kaina et al., 2007], and clear inter
individualvariations [Janssenetal.,2001].Breast,colon, lungandovariancancershavea
higherMGMTexpression [Chenet al., 1992] [Preuss et al., 1996],whileMG,melanomas,
pancreaticandtesticularcancersdisplayavery lowexpression.Roughly1730%ofMGs
totallylackMGMTexpression[Preussetal.,1995][Kainaetal.,2007].Epigeneticsilencing
of theMGMTgene bymethylation of CpG islands in the promoter region is a common
mechanismofgenesilencing[BhakatandMitra,2003](Figure5).Thisisseenin3050%of
MG patients [Esteller et al., 2000] [Hegi et al., 2004] [Hegi et al., 2005] and ~70 % of
secondary GBM patients [Weller et al., 2010]. However, there is no correlation between
MGMT promotermethylation and protein expression [Maxwell et al., 2006] [Brell et al.,
2005]. Furthermore, intratumoural variation inMGMTexpressionhas alsobeen reported
[Lees et al., 2002] [Zaidi et al., 1996] [Mollemannet al., 2005] [Silber et al., 1996].MGMT
promotermethylationisassociatedwithlossofheterozygosity(LOH)of1p/19qandIDH1
mutationinODG/OAs[Mollemannetal.,2005][Brandesetal.,2006a]andwiththelatterin
AA [Sanson et al., 2009]. TheMGMTpromotermethylation seems to be associatedwith
methylation of many other cancerrelated genes [Gerson, 2004] leading to a methylator
phenotype [Noushmehr et al., 2010] (Figure 5). MGMT gene expression is induced by
alkylatingagenttherapy,RT,andcorticosteroidtherapy[Kainaetal.,1991][Grombacheret
al., 1996] leading to increased production ofMGMT protein that could have a negative
effectonalkylatingagentchemotherapy.ActivationofproteinkinaseC(PKC)increasesthe
MGMTexpression through transcription factorAP1,which has twobinding sites in the
MGMTpromoter[Boldoghetal.,1998].ItcanbetransactivatedbyexpressionofcFosand




promoter [Lavon et al., 2007]. The presence of wildtype p53 also tends to increase the
MGMT gene expression by direct binding to MGMT promoter irrespective of its
methylation status [Blough et al., 2007] [Hermisson et al., 2006] and dysfunctional p53
increasesthecellsensitivitytoTMZ[Xuetal.,2005a][Xuetal.,2005b].RTinducedMGMT
promoteractivation isdependenton thepresenceof functionalp53[Raffertyetal.,1996].
However,IFNdownregulatesMGMTexpressioninap53dependantmanner[Natsume
etal.,2005].Thepresenceoftwoglucocorticoidresponsiveelements(GRE)intheMGMT
promoter makes it inducible by corticosteroids [Grombacher et al., 1996] [Biswas et al.,




and O6chloroethylators, lomustine/[1(2chloroethyl)1nitrosourea] (CCNU),
carmustine/[1,3bis(2chloroethyl)1nitrosourea] (BCNU),nimustine/[1(4amino2methyl






to accumulation of frameshifts in long stretches of mono and dinucleotide repeats
(microsatellites) scattered throughout the genome that is termedmicrosatellite instability
(MSI).InheritedgermlinemutationsinMMRgenes,andthesubsequentinactivationofthe
otherallele results in familial cancer syndromessuchasHNPCC[Vasenetal., 2007] and
Turcot syndrome type1 [Cavenee et al., 2000]. It is reported that 515 % of sporadic
colorectal, gastric, endometrial, cervical, ovarian, breast and lung cancers andMGs also
carry MSI [Peltomaki, 2003]. There is evidence to suggest that p53 increases the gene
expression of some MMR proteins [Chen and Sadowski, 2005]. In eukaryotic cells,
mismatch recognition is undertaken by MSH2, MSH3 and MSH6 proteins. MSH2 and
MSH6formtheMutSheterodimercomplex,whichisthemajorhumanMMRcomplexto
recognise basesubstitution mismatches and IDLs up to one or two nucleotides. MutS
complex formed by MSH2/MSH3 heterodimer recognises IDL up to 16 nucleotides
[Kinsella,2009].MutSformsaslidingclampencirclingtheDNAstrandinthevicinityof
themismatch.MutLcomplexformedbyMLH1andPMS2heterodimerorMutLformed
by MLH1 and MLH3 is recruited to the ternary complex as the second step. MutS,
proliferatingcellnuclearantigen(PCNA)andreplicationfactorC(RFC)activatethelatent
MutL endonuclease to provide the incision that serves as the entry point for MutS
activated exonuclease1 (EXO1) to commence mismatch excision [Jiricny, 2006a]. The
removal of themismatch isdonebyEXO1 in anATPandmismatchdependantmanner.
EXO1maybedirectedtothenascentstrandbythepresenceofnicksorlackofmethylation.
EXO1mediatedexcisionremoves>1000nucleotidesaroundthemismatch.EXO1activityis
inhibitedbyMutLand replicationproteinA (RPA)once themismatch is removed.The
resultingsinglestrandgapisstabilisedbyRPAandthegapisfilledbyDNApolymerase	




2004] or by loss of protein expression [Felsberg et al., 2011]. It is associated with an
increased resistance to DNA monofunctional alkylating agents such as TMZ and
dacarbazine, [Koi et al., 1994] [Cejka et al., 2003], platinum analogues cisplatin and
carboplatin[Papoulietal.,2004][Branchetal.,2000],antimetabolitessuchas6TG[Swann





Erie, 2005]. MMRmediated processing of the O6mG DNA lesions is essential for the
cytotoxicityofthesedrugsandlossofMMRfunctionimpart2100foldresistancestothem




resulting in hypermutation phenotype recurrences. Development of MSI high acute
myelogenous leukemiaafter treatmentof lymphoblastic leukaemiawith6TGand6MCP
are examples of this phenomenon [Kinsella, 2009]. There is recent data suggesting that
treatment with TMZ leads to loss of MMR function through mutations in MG patients
[Cahilletal.,2007][Hunteretal.,2006][2008]andlossofMMRproteinexpressionwithout
affecting promoter methylation [Felsberg et al., 2011]. HSVtk/GCV gene therapy was





Figure 6: A schematic presentation of the mechanism of action of mismatch repair (A) and 
base-excision repair (B) pathways. APE-abasic/ apurinic site endonuclease, EXO-exonuclease, 
FEN-flap structure specific endonuclease, LIG-DNA ligase, MLH-mutL homologous, MPG-
methylpurine glycosylase, MSH-mutS homologous, PCNA-proliferating cell nuclear antigen, 
PARP-poly-ADP ribose polymerase, PMS-post-mitotic segregation, Pol- DNA polymerase, RFC-
replication factor C, RPA-replication protein A, SSB-single-strand break, XRCC-X-ray repair 
complimenting defective repair in Chinese hamster cells. Modified from 
http://www.nature.com/nrc/posters/dnadamage 
   
Baseexcisionrepairpathway
BER is themajor repairpathway for endogenousandexogenousadductinducednon
bulky base damages such as oxidative base modification, deamidations, hydroxylations
[Davidetal.,2007],N7methylguanine(N7mG)andN3methyladenine(N3mA)causedby
alkylatingdrugs,abasic/apurinic(AP)sitesandDNASSBscausedbyRT,monofunctional
alkylating agents and antimetabolites [Helleday et al., 2008]. BER is also amultiprotein,




lesions removing thosebycleaving theNglycosidicbondgeneratingAPsites [Hitomiet
al.,2007].APendonuclease1(APE1)recognisesandremovestheAPsitesbycleavingthe
phosphodiesterbondcreatingnucleotidegaps.It isreportedthatAPE1isfrequentlyover
expressed inMG [Bobola et al., 2001]. Subsequent repair process of either a shortpatch
repair foronenucleotideora longpatch repair for 215nucleotides, is initiatedbyDNA
polymerase (pol)and involvesPARP1 (Figure6B).Theshortpatchrepair seems tobe
importantinrepairingRTandchemotherapyinducesDNAdamage,henceBERprocessing
can lead to therapy resistance [Kinsella, 2009] [Trivedi et al., 2008] and inhibitionofBER
pathway components such as pol [Frosina, 2000],APE1 [McNeill andWilson, III, 2007]
[Bobola et al., 2007] potentiated alkylating agent cytotoxicity. Furthermore, possible
suppressionofMSH6asaresultofAPE1overexpressionmaycontributetoTMZresistance
[Changetal.,2005a].






repairs them through two different subpathways, transcriptioncoupled NER or global
genomeNER [Hoeijmakers, 2001].DSB repair has twoprinciplemechanisms;NHEJ and
HR. InNHEJ,Kuproteins recogniseDSBs and activatedDNAprotein kinase (DNAPK)
thatrecruitsendprocessingenzymes,DNApolymerasesandligases.MSH6isbelievedto
interactwithKuproteins inDSB repair [Shahi et al., 2011].This is an errorprone repair
process that can operate in any phase of the cellcycle [Lieber, 2008]. Expression of
adenovirus E4orf6 inactivates DNAPK and inhibited DSB repair by NHEJ in human
gliomacells,andincreasedtheirradiosensitivity[Hartetal.,2005].HRisrestrictedtoSand





general, the clinical features largely depend on the anatomical location of the tumour.
Headache [Forsyth and Posner, 1993], focal or secondary generalised seizures, altered
mentalstatusandprogressiveneurologicaldeficits includingparesis,speechdisturbances
and personality changes are the most common clinical features [Stewart and Kleihues,
2003].Symptomsaremostlyattributedto infiltrationand/orcompressionofnormalbrain
tissue by the enlarging tumour, oedema and haemorrhage [Chamberlain andKormanik,
1998].
Headache due to brain tumours is thought to originate from either dura or brain
vasculaturesincethebrainitselfisnotsensitivetopain.Itcanbemildandintermittentor
constant and severe, typically occurring in early morning caused by raised ICP due to
recumbency and hypoventilation during sleep. Although frontal and temporal lobe
tumours can sometimes produce frontal, retroorbital or temporal headaches, a focal
headachelocalisationcanbemisleading[ForsythandPosner,1993].Slowgrowingtumours
can grow to become large without causing headache, whereas their fastgrowing
counterparts can evoke headaches at very early stages. Apart from headache, nausea,
vomiting, personality changes, slowing of psychomotor functions and somnolence can
resultfromelevatedICP[Fineetal.,2005].IncreasedICPcaneventuallybelifethreatening
with visual disturbances, unconsciousness and respiratory arrest [Stewart and Kleihues,
2003].







varieswith tumour grade. A lowgrade tumour in temporal lobe can ultimately present
with seizures aftergrowing large asymptomatically.On theotherhand, rapidlygrowing
tumours in deeper structures appear to cause noseizure symptomsdue to amass effect
[Leeetal.,2010].
Focalneurologicalsymptomssuchaspersonalitychanges,lossofinitiative,contralateral
weakness, expressive aphasia, impairment of memory, urinary incontinence, dementia,




Over thepast fewdecades, advances in imaging techniqueshavevastly improved the
early diagnosis, staging, and assessment of therapeutic response in MGs. From the
conventional anatomical characterisation, the focus of imaging has recently shifted to
functionalandmetabolicimagingoftumours[Hricaketal.,2005].
Computerassisted tomography (CT) and magnetic resonance imaging (MRI) are the
most widely used imagingmethods inMG. Imaging helps in diagnosis, in defining the
preciseanatomicallocalisation,aswellasanassessmentoftumourvolumeforplanningof
surgeryandRT,evaluatingtheresidualtumourvolumeaftertherapyandinthedetection







CT and as an area of low signal intensity in T1weighted images and as an area of high
signalintensityinT2weightedimagesintheMRI.ItisbelievedthatMRIissuperiortoCT
in diagnosing hydrocephalus and its causes. In CT, acute haemorrhage appears as high
attenuation, whereas subacute haemorrhage is isodense and hard to detect. Acute
haemorrhage is seen as low signal intensity in the T2 images whereas subacute
haemorrhages produce a bright signal in both T1 and T2 MRI. Disruption of the BBB
increasescontrastenhancementofbothCTandMRI.ContrastenhancedCTandMRIscans
arebettercapableofdifferentiatingbraintumoursfromotherpathologicallesions,different
types of brain tumours fromoneanother and highgrade brain tumours from lowgrade
ones [Fine et al., 2005]. Apart from its high sensitivity in lesion detection, MRI has the






of 2 or 3 treatments. Continued followup is helpful in assessing response, detecting
recurrence or other treatment complications [Bracard et al., 2006]. Macdonald criteria
provide clear guidelines to monitor the treatment response by MRI [Macdonald et al.,
1990a],but there isnoconsensuson tumour recurrence. Increase in radiographic tumour
volume,developmentofnewareasof contrast enhancement and increase inT2weighted
changesaresomeof theparameterswhichneed tobeconsidered.Differentiating tumour
progression from treatmentrelated effects such as radiation necrosis and MRI features
suggestive of tumour progression in the absence of clinical deterioration, such as




[Barbagallo et al., 2008].MRI resolution is not sufficient to accurately demarcate distant
tumour infiltration [Hricak et al., 2005]. Surgical biopsy is the goldstandard for
differentiating lateradiationnecrosis fromrecurrence.Other techniquessuchasmagnetic




response seen in oedema, mass effect and contrast enhancement with these drugs
complicate the interpretation of conventional contrast enhanced MRI. Noncontrast
enhancing tumour progression is common with these therapies making uncertain the
validity of theMacdonald criteria for response assessment.  Fluid attenuation inversion
recovery(FLAIR)MRIanddiffusionMRImaybemorehelpfulinthissituation[Gurwara
etal.,2010].
MRSprovidesdataon the regionaldistributionofchemicals, suchascholine,Nacetyl
aspartate(NAA),lipidsandlactate,associatedwithtumourmetabolism[Hakumakietal.,
1998] [Hakumaki et al., 1999]. Choline and NAA are markers of cell proliferation and
neuronal integrity, respectively,while lipids and lactate canbe considered asmarkers of
necrosis. Reduced levels of choline in areas of radiation necrosis compared to increased
levelsinareasofrecurrencehelpstodifferentiatethetwoconditions[Rabinovetal.,2002].
MRS is useful in assessing the treatment response and guiding biopsy but is unreliable
whenthelesionsarelessthan2cminsize,orwhentheyareadjacenttobone,fatorCSF
duetosignalcontamination[Rees,2003].
PerfusionMRI canmeasure the relative cerebral bloodvolume (rCBV), cerebral blood
flow (CBF) andmicrovascular permeability. It is useful in assessing tumour vasculature
especially after treatment with antiangiogenic therapy [Batchelor et al., 2007] and in




weightedMRI too canbehelpful indifferentiating amalignant tumour froma radiation
effects. The apparent diffusion coefficient is increased in response to treatment and
decreasedintumourrecurrence[Heinetal.,2004].
Functional MRI (fMRI) is useful in preoperative planning to reduce the surgical
morbidityanddamage tovitalbrainareas [Hricaket al., 2005]. Intraoperativehighfield





information aboutbrain tumours [Amin et al., 2012].These canbe combinedwithCTor





in spite of the advances in noninvasive imaging modalities, their role remains
complementary.Clearly,accuratetissuediagnosisandgradingisvitalinthedetermination
oftheoptimaltreatmentregimen[WickandWeller,2009].Furthermore,sincethediagnosis
is dependent on identification of characteristic histological patterns and initial focal
progressionoflowgradegliomasintohighgradegliomaswithtime,adequatesamplingof










site for biopsy. However, the malignancy grading obtained by these types of limited
biopsies is always theminimal grading due to the possible existence ofmore anaplastic













patients (>70 years) sometimes receive less aggressive therapy with either RT or
chemotherapy[KeimeGuibertetal.,2007][Glantzetal.,2003].
2.2.12.1Surgery




invasive and infiltrative nature of MGs [Kelly et al., 1987], and due to the possible
neurological deficit resulting from widemargin of excision, especially in the eloquent
cortex[Sawayaetal.,1998].
Under these circumstances,maximumdebulkingof the tumourwithminimal risk for
the patient seems to represent a reasonable compromise [Fine et al., 2005]. Debulking
reduces thesecondary tumoureffectssuchasoedema,hydrocephalusand increased ICP,
achieving symptomatic control. It also provides tissue samples for accurate histological
diagnosis,which is paramount for appropriate treatment planning [Hentschel andLang,
2003]. Furthermore, surgical resection improves efficacyof adjuvant therapy [Pang et al.,
2007] [Ryken et al., 2008]. Even though the recent advances in surgical approaches,
techniques and instrumentation have made most tumours surgically amenable, the


















al., 1998], delays symptom progression, reduces corticosteroid doses and improves
responsetochemo/RTinselectedpatients[Barkeretal.,1998][Barbagalloetal.,2008].
Intraoperativecriticalfunctionalcorticalmappingbyelectricalcorticalstimulation,pre
operative fMRI [Mueller et al., 1996], magnetoencephalography, motor and speech
mapping [Berger et al., 1989] [Nimsky et al., 2006a], intraoperative ultrasonography,
fluorescenceguided surgery with 5aminolevulinic acid [Stummer et al., 2006] and
frameless imageguided neuronavigation systems have improved the safety of surgery
[McDermott and Gutin, 1996]. In spite of the recent advances in imaging and surgical
techniques, many CNS tumours still remain only partially resectable or are even
unresectable [Fine et al., 2005]. For example, one study reported that only 54 % of the
patientswithGBMhad undergone surgery at the population level [Ohgaki et al., 2004].




Irrespective of the extent of surgical resection, MGs warrants further treatment with
adjuvant therapy.Radiotherapyhasbeenconsideredas themainstayof treatmentofMG
fordecades[WenandKesari,2008].Pooledmetaanalysisdatasuggeststhattheadditionof
adjuvant RT at a dose of 4560 Gray (Gy) after surgery can increase theMS of theMG





Inmostcentres, conventional fractionatedexternalbeamradiation isadministeredata






normal brain with microscopic tumour infiltration and a margin of normal brain is
included in the treatment field [Fine et al., 2005]. Thus, the tolerance of normal brain
becomesavital limitingfactor inRTandisdependentonthetotalradiationdose,sizeof
the dose per fraction, overall treatment time, irradiated brain volume, host factors and
adjuvanttherapies[Fineetal.,2005].Theriskofbraininjuryincreaseswithdosesexceeding
60 Gy and with fractions exceeding 2.2 Gy. Radiation doses exceeding 60 Gy have not
demonstrated any benefit in spite of increasing the incidences of side effects [Lee et al.,
1999][Salazaretal.,1979].
Side effects of cranial irradiation can be divided into three groups; 1) acute reactions
occurringshortlyafterRT,2)earlydelayedreactionsappearinga fewweeks to4months
after RT and, 3) latedelayed injuries which can occur a few months to years after
irradiation. The clinical picture of radiation injuries can vary from asymptomatic white
matterchangestofatalbrainnecrosis.Upto49%oftheMGpatientscandevelopclinically
detectable radiation necrosis following 5060Gy of conventional fractionatedRT and this
canbeashighas1022%atautopsy[Fineetal.,2005].Exactpathologicalmechanismsof
these injuries are unclear but damage to vascular endothelial cells and direct effects on
oligodendroglialcellshavebeenpostulated.Cerebralcorticalatrophywasreportedin1739







The poor response for standard RT in MG is mainly attributed to the inherent
radioresistance of the tumours, tumour hypoxia [Hockel and Vaupel, 2001] and the
radiosensitivityofthesurroundingnormalbraintissue[Fineetal.,2005].TheroleofRTin
recurrent MG is controversial. Some benefit is seen in younger patients with a good
performance score when the gap between previous RT is >6 months. The use of
radiosensitizers,doseescalationschemesusingalteredfractions,interstitialbrachytherapy,
radiosurgery and threedimensional conformal RT, boron (10B) neutron capture therapy
(BNCT),andprotonRTaresomeofthenewermethodstoimproveRT[Fineetal.,2005].
Withtheuseofanimagingcompatiblestereotacticdeviseforprecisetargetlocalisation,
stereotactic radiosurgery (SRS) delivers a highly focal, closed skull external irradiation.
Thiscanbeadministeredeitherbygammaknifeunitsmadeofmultiplecobaltbeamsorby
modified linearaccelerators.Theability todeliver ahighdoseof radiation to theprecise
intracranialtargetvolume,inasinglesessionwithoutsignificantirradiationoftheadjacent
normal brain tissue in a noninvasive manner are the advantages of this method.
FractionatedSRS(fSRS)isadministeredinfractions,fortheimprovementofthetherapeutic














with thismethod [Prados et al., 2004].Acceleratedhypofractionatedintensitymodulated
RT with TMZ are under clinical evaluation [PanetRaymond et al., 2009] [Chen et al.,
2011a].
First evaluated for brain cancer therapy in 1950s, BNCT is being rejuvenated for the
treatmentofGBMand isnowin theexperimentalstage [Joensuuetal.,2003]. 10Bhas the
ability to capture thermal neutrons after which they disintegrate into particles and Li








the chemotherapeutic agent through either the preexisting or the tumourassociated
microvasculature. Secondly, since themajority of normal cells within the CNS are post
mitotic,chemotherapeuticagentswithapreferentialactionondividingcellsshouldhavea
high therapeutic index in theCNS.Neurotoxicity isminimal formany chemotherapeutic







only place for chemotherapy was as salvage therapy in recurrent MG [Brandes and
Fiorentino,1996].
Metaanalysesrevealedamodestsurvivaladvantageof610%atoneyearand58%at
two years for newly diagnosed MG patients with adjuvant nitrosoureabased
chemotherapywithanincreaseintheMSfrom9.4to12months.Furthermore,regardlessof
thetypeofchemotherapy,allpatientswithGBMandAAwhohadadjuvantchemotherapy
demonstrated a significant survival advantage [Fine et al., 1993] [Stewart, 2002]. It was




not experience a survival benefit with adjuvant chemotherapy. TMZ is the preferred
chemotherapy fornewlydiagnosedGBMinaconcomitantandadjuvantsettingwithRT.
ForAA, the usual regimen is RTwith adjuvant TMZ. For anaplasticODG andOA, the
chemotherapyregimenofchoiceisthecombinationofprocarbazine,lomustin(CCNU)and
vincristine(PCV)[WenandKesari,2008].Otherchemotherapeuticsusedassingleagentsor
incombination in the treatmentofnewlydiagnosedMGare thenitrosoureas,carmustine
(BCNU),lomustine(CCNU),nimustine(ACNU)andfotemustine,procarbazine,vincristine,
cisplatin,etoposideandcarboplatin.





[Brem et al., 1995], CCNU, procarbazine, tamoxifen [Ben Arush et al., 1999], irinotecan
[Stupp et al., 2006], ifosfamide, etoposide and carboplatin [Schafer et al., 2011], are
commonlyusedassingleagentsorincombinationsforthetreatmentofrecurrentMGwith
minimaltomoderateactivityatthebest[WenandKesari,2008].
The primary reason for chemotherapeutic failure in CNS is intrinsic drug resistance
partlyduetothetumourheterogeneityatdosesattainableduetosystemictoxicity,aswith
tumours elsewhere. Secondly, there is impaired drug delivery into CNS tumours. The
presenceoftheBBBisbelievedtobetheculpritforimpaireddrugdelivery.However,BBB
function is almost completely disrupted in GBMs, especially in the contrast enhancing
portion of the tumour.On the other hand, the leading front of the infiltrating tumour is
located within normal brain parenchyma with an intact BBB. In spite of being highly
angiogenic, tumourvasculature isaberrant,dilated, tortuousand leaky[Groothuis,2000].
Disruption of BBB and increased permeability increases the interstitial fluid pressure,
thereby effectively reducing not only the entry of O2 and nutrients but also that of
chemotherapeutics into the tumours. Furthermore, drug delivery is still reduced due to
poorperfusionandnonpatencyof thetumourinducedneovasculatureandtherelatively
long distance between tumourinduced angiogenic vessels and individual tumour cells.
Thirdly,theresultingsublethalexposureofthetumourcelltothedrugpromotesacquired
drug resistance [Fine et al., 2005]. Finally, the physiochemical characteristics of the drug
itselfdeterminesitsabilitytocrosstheBBB,withsmaller,ionicallyneutral,lipophilicdrugs
withahighoctanol/watercoefficientbeingabletobetterpenetratetheBBB[Greig,2001].




adjacent normal brain areas leading to neurotoxicity and also tumours may draw their





Convectionenhanceddelivery (CED)usingbulk fluid flow is anothermethodof local
drugdelivery.InCED,acatheterimplantedinthebrainprovidesacontinuousinfusionof





it is an invasive procedure and the ultimate efficiency depends on the physiochemical
characteristicsoftheadministereddrug[Fineetal.,2005].
EmergingevidencesuggeststhatadditionofchemotherapyintothestandardcareofMG






g/ml (0.572mol/l) and 0.161.93g/ml (0.810mol/l), respectively [Ostermann et al.,
2004].VPAdecreasestheclearanceofTMZ(www.temodar.com).Itundergoesspontaneous
hydrolysis at physiological pH to its active form 3methyl(triazen1yl) imidazole4
carboxyamide (MTIC), which is further processed to form DNA methylating
methyldiazonuim ions [Newlands et al., 1997] (Figure 7). The active form canmethylate
DNAatmanysites,withthemostsignificantbeingthemethylationsatO6positionandN7
position of guanine and N3position of adenine to form O6mG, N7mG and N3mA,
respectively [Kaina et al., 2007] andAP sites [Adhikari et al., 2008].Even thoughO6mG




Themechanism of TMZ induced cytotoxicity has been studied extensively [Ochs and
Kaina,2000][Roosetal.,2007b][Roosetal.,2007a]andisschematicallypresentedinFigure
7.ThecytotoxicityofTMZ isdependenton the functionofmajorDNArepairpathways;
namelyMGMTdirectrepair,MMR,BERandDSBrepairpathways[Kainaetal.,2007].O6
mGitselfisnottoxictothecells.MGMTactinginasuicidemannerwillrepairthepretoxic
O6mG by transferring the methyl group from O6mG onto the cysteine residues of the
protein and this will trigger its subsequent degradation [Pegg, 2000]. The expression of
MGMTby the cells imparts aprimary resistance toTMZby removing themethylgroup
[Kaina et al., 1991]. If not removed, in subsequent DNA replication cycles O6mG will
mispair with T [Toorchen and Topal, 1983] or pair with C. The O6mG/T mismatches
promotenucleartranslocationofMMRproteins[ChristmannandKaina,2000].Mismatches








MMR function confersup to 100fold resistance toTMZ  aswell as toothermethylating
agents [Stojic et al., 2004] [Branch et al., 1993]. Checkpoint activation and subsequent
apoptosisisimpairedincellswithreducedMMRproteinlevels[Lettierietal.,1999][Cejka








2001]. In cells with mutant p53, apoptosis occurs via the mitochondrial pathway by
decreasingBcelllymphoma2(Bcl2)andincreasingcytochromeC[OchsandKaina,2000].
In cells with wildtype p53, apoptosis is triggered via the deathreceptor pathway
(FasR/CD95/Apo1) [Dunkern et al., 2003] [Roos et al., 2004]. Both mechanisms seem to
contribute toMG cell apoptosis [Roos et al., 2007a]. Another schoolofthought suggests
that binding ofMutS/MutL complexes to the O6mG/Tmismatchwill directly trigger
apoptosis by activating ATR/ATRinteracting protein (ATRIP) [Yoshioka et al., 2006]
[Caporalietal.,2004].Theproposedmechanismindicatesthatcellshavetoundergoatleast
twocelldivisions [Kainaetal., 2007],whichmay takeup to46days [Roosetal., 2007a]
beforetheydie.

Figure 7: A schematic presentation of the mechanism of action of TMZ induced O6-mG. O6-mG-T 
mispairs can be further processed either by MMR-mediated futile cycling or by MMR and 
ATR/ATRIP-mediated direct signalling. ATM-ataxia-telangiectasia mutated, ATR-ataxia 
telangiectasia and Rad3 related, ATRIP- ATR-interacting protein, Bcl-B-cell lymphoma, C-
cytosine, CH3-methyl group, DSB-double-stranded break, FasR-Fas receptor, HR-homologous 
recombination, mG-methyl guanine, MGMT-methyl guanine methyl transferase, MLH-mutL 
homologous, MMR-mismatch repair, MSH-mutS homologous, MTIC-3-methyl-(triazen-1-yl) 
imidazole-4 carboxyamide, NHEJ-non-homologous end joining, PMS-post-mitotic segregation, T-
thymine, TMZ-temozolomide. 





cells. They can be depurinated spontaneously or byNmethyl purine glycosylase (MPG)
into cytotoxic AP, which are cleaved by APE1 and repaired by the downstream BER
mechanisms [Kainaet al., 2007].N3mA is toxic to the cells and isprocessed in the same
manner as N7mG. Thus, a functional BER pathway seems to protect the cells from
alkylatingagentsbutimbalancesinthepathwaymayincreasecytotoxicityindependentof








22981 andNationalCancer Institute ofCanada (NCIC) trialCE.3 randomised 573 newly
diagnosedGBMpatients intoTMZ+RT(n=287)andRTalone (n=286)arms.TMZ+RTarm





3years, 12.1 % vs. 3 % at 4 years and 9.8 % vs. 1.9 % at 5years was observed for the





months for both groups [Stupp et al., 2009]. The combination proved superior in all
prognostic subgroups irrespective of the MGMT methylation status. However, MGMT






Theadverse effectsofTMZ includealopecia, anorexia,nausea,vomiting, constipation,
diarrhoea, headache, fatigue, convulsions, hemiparesis, opportunistic infections, skin
reactions and myelosuppression with thrombocytopenia (26d), neutropenia and
lymphocytopenia (28d) (www.temodar.com). In melanoma studies, it was revealed that




Resistance to TMZ can occur through modulations in the MGMT, MMR and BER
pathways, by activation of PI3K/AKT pathway through PTEN inactivation [Jiang et al.,
2007],byactivationofNFB[Bredeletal.,2006]andbypromoting/selectiveovergrowthof
the CSLC phenotype [Gaspar et al., 2010]. Epigenetic silencing of the MGMT gene by
promotermethylationofMGcells[Estelleretal.,1999]wasassociatedwithanincreasein





Immunohistochemistry (IHC) [Zaidi et al., 1996] and highperformance liquid
chromatography(HPLC)[Dolanetal.,1989]areoftenusedtoassess theMGMTstatus in
preclinical work, whereas the methylationspecific polymerase chain reaction (MSP) is
usedinclinicalstudies[GalmandHerman,2005].Othermethodsinusearemethylation











and downregulated by IFN [Natsume et al., 2008]. The presence of wildtype p53
increased the MGMT gene expression in MG cells independent of MGMT methylation




rate of 3050 % [Esteller et al., 2000] [Hegi et al., 2004]. MG CSLCs tend express more
MGMT,whichmakesthemresistanttoTMZtherapy[Liuetal.,2006].Incontrast,another
study suggested that TMZ reduced the proliferation, abolished tumourigenicity and
preferentiallydepletedCSLC[Beieretal.,2008].
Attempts have beenmade to deplete the cellularMGMT in cancer cells by nontoxic
pseudosubstrateinhibitorsofMGMTsuchasO6benzylguanine(O6BG),RNAinterference
(RNAi)mediated MGMT gene silencing and MGMT depletion by dosedense TMZ
therapy. However, attempts at systemic inhibition of MGMT have been hampered by
haematological toxicity [Quinnetal., 2005]. It isunclearwhetheralternativeTMZdosing
scheduleswouldbeabletodepleteMGMTinthetumourtoachieveatherapeuticbenefit
withoutsignificantlyaffectingthedrugassociatedtoxicities[Tolcheretal.,2003][Weileret
al., 2010]. Liposomemediated MGMT smallinterfering RNA (siRNA) gene therapy has
been evaluated as a way to enhance TMZ cytotoxicity [Kato et al., 2010]. MGMT
methylationisassociatedwiththeLOHof1pand19qinODG[Dongetal.,2001],AA,OA
[Sadonesetal.,2009]andGBM[Ishiietal.,2007]thatareparticularlysensitiveforRTand




al., 2004] [Esteller, 2002]. However, it has been claimed that MMR dysfunction is
uncommon innewlydiagnosedMGs [Martinez et al., 2004] [Cahill et al., 2007]. There is
recentdatasuggestingthattreatmentofGBMwithTMZresults intheselectionforMMR
inactivation by mutations [Cahill et al., 2007] [Hunter et al., 2006] or loss of expression
[Felsberg et al., 2011] leading to hypermutation phenotype recurrences. These TMZ




Multiple preclinical attempts have been made to enhance the efficacy of TMZ by
combiningthedrugwithothertherapeuticagents.Invitrodatahavepointedtoapossible
synergism between TMZ and RT [Wedge et al., 1997] but invivo results in MGMT
expressingmodelswereonlypositivewhenMGMTwasinhibited[Chakravartietal.,2006]
[Carlsonetal.,2009].Moreover,thereismoreevidencethattheenhancedefficacywhenRT
and TMZ are combined is dependent on the treatment schedule, where TMZ has to be
started3daysbeforetoachievethemaximumbenefit[Chalmersetal.,2009].TMZhasbeen
combinedwith cisplatin [D
Atri et al., 2000], irinotecan [Houghton et al., 2000], imatinib
[Renetal.,2009],ribonucleotidereductaseinhibitors[Figuletal.,2003],IFN[Motomura
etal.,2010],PARP1inhibitors[Chengetal.,2005]suicidegenetherapy[Rainovetal.,2001]
andconditionally replicativeadenoviruses [Ulasovetal., 2009].ThecombinationofTMZ










brain tumours [Rosenthal et al., 2004] due to their excellent BBB penetration properties
[Levin, 1980].However, their therapeuticutility is severelyhamperedbyhaematological,







GBM (2003). The drug is released in a controlled manner over several days or weeks
providinghighdoselocalchemotherapy.ThesufficiencyoftheBCNUdoseat3.8%could
be a concern due to the lack of proper doseescalation studies [Stupp et al., 2006]. Lipid
solubilityofBCNUallowsbidirectionalpenetrationofBBB leading to systemic toxicities
and increased risk of cerebral oedema and seizures. In addition, the limited diffusion of
BCNUfromtheimplantedsitepreventsthedrugfromreachingdistantinfiltratingtumour
cells [Strasser et al., 1995]. High cost is another drawback associated with this therapy.
However, clinical trials in primary GBM patients have demonstrated a marginal but
statistically significant prolongation of survival and the maintenance of neurological
function and performance status [Westphal et al., 2003] although the data on recurrent
GBMisnotconvincing[Hartetal.,2008].
PCV is the most widely used chemotherapeutic combination for the treatment of
anaplasticODGandOA,andhasbeen the standardcare foroveradecade [Stuppetal.,







al., 2009]. PCV is generally a welltolerated regimen but myelosuppression is not
uncommon[vandenBentetal.,2003a].
Carboplatin and cisplatin have not proven superiority over BCNU as singleagents
[Dropcho et al., 1992] or in combinationwith BCNU in GBM patients [Grossman et al.,
2003].CarboplatinwasnoteffectiveinrecurrentODG[Soffiettietal.,2004].Carboplatinin
combination with etoposide displayed some efficacy in recurrent MG [Franceschi et al.,
2004][Scopeceetal.,2006].
The combination of nimustine (ACNU) and cisplatin in the neoadjuvant setting was
unsuccessfulduetoadverseeffects[Kimetal.,2011a][Hanetal.,2009].Incontrast,ACNU







therapy includes transient vessel normalisation, restoration of BBB and a reduction of
vascular permeability that decreases the interstitial pressure and vasogenic oedema. The
overallactionof thesefunctionsis to increasethedeliveryofchemotherapeuticagentsby





2005] thatwould sensitise tumours to chemotherapyandRT [Winkler et al., 2004],while
othershavepostulatedthatthereisapossiblereductionintumourbloodflowandincrease
in hypoxia [Keunen et al., 2011] [Wachsberger et al., 2005]. There is also evidence for a
reductioninthedeliveryofchemotherapeuticagentssecondarytoBBBrestoration[Claeset
al.,2008][Varallyayetal.,2009].Directantitumoureffectsmaybeachievedbyotheranti
tumour mechanisms e.g. interrupting growth factor and their receptormediated









approved for the treatment of colorectal and nonsmall cell lung cancers in combination




response (PR) [Vredenburgh et al., 2007a]. In a phase II randomised, multicentre, non
comparative trial for recurrent GBM patients, BV alone achieved a median OS of 9.2
months,6monthPFSof42.6%andanobjectiveresponserateof28%,andamedianOSof
8.7 months, a 6month PFS of 50.3 % and objective response rate of ~38 % for BV and
irinotecan group [Friedman et al., 2009], leading to an accelerated USFDA approval
[Tabatabai and Stupp, 2009]. A corticosteroid sparing effect of BV has been proposed
[Vredenburgh et al., 2010]. BV in combination with metronomic chemotherapy was not
effectiveandshowedincreasedtoxicities[Reardonetal.,2011a][Reardonetal.,2009].CNS
haemorrhage, thromboembolic events, cerebral infarctions, hypertension, bowel
perforations, hypophosphatemia, convulsions, confusion, headache, blindness, fatigue,
lethargy, reversible posterior leukoencephalopathy syndrome (RPLS), and thrombotic
thrombocytopenicpurpurawereencounteredasadverseeffects in these trials [Jainetal.,
2007].Up to 30% of patients treatedwith BVhave experienced grade 3 and 4 toxicities







Tables 3 and 4 summarise the antiangiogenic therapies in clinical and preclinical
development,respectively,forthetreatmentofMG.

Table 3: Anti-angiogenic therapies in clinical development for the treatment of MG  









VEGFR-1 & -2 




VEGF and PlGF 
II Minimal efficacy in 















No benefit in recurrent 
GBM patients compared 
to lomustine. Efficacy in 
combination with TMZ in 
newly diagnosed GBM.  










RTK inhibitor PDGFR-, c-
KIT inhibitor 













II Not effective in recurrent 

















Minimal efficacy in newly 
diagnosed GBM patients. 















No efficacy in recurrent 
HGG/ MG patients as 
single agent or when 










VEGFRs 2 & 3, 
EGFR, RET 
inhibitor 
I/II Safe in combination with 
RT and TMZ in newly 
diagnose GBM, under 
evaluation in recurrent 
MG with radiosurgery 
[Drappatz et 











II Promising results in 
progressive GBM patients 












Evaluated in combination 
therapy for newly 
diagnosed and recurrent 









IB/II Under evaluation in 










I/II & II Under clinical evaluation 




















v5 inhibitor I/II  
II 
Under evaluation with 
standard therapy. Modest 
efficacy as a single agent 


























Limited efficacy in 
combination with 
chemotherapy or 
radiotherapy in recurrent 







bFGF & IL-8, 
CD36R 
I Well tolerated with 
standard therapy in newly 







Block HGF/SF II Modest effect as a 
monotherapy in recurrent 
GBM patients 





IgG2 mAb  
VEGFR-2 
inhibition  









By HIF-1 I Modest effect as a 
monotherapy in recurrent 
MG patients 
[Phuphanich 
et al., 2008] 












COX-2 inhibitor By VEGF & 
FGF, & 
endostatin 
II Effective in combination 
in recurrent, but not in 
newly diagnosed MG  





1-3   
II Under evaluation in 
recurrent GBM patients 











HIF-1 II Under evaluation in 
recurrent GBM patients 
[Chi et al., 
2009] 
bFGF-basic fibroblast growth factor, c-KIT-receptor for stem cell factor, COX-cyclooxygenase, CSF-1R-
colony stimulating factor 1 receptor, EGFR-epidermal growth factor receptor, FGFR-FGR receptor, Flt-Fms-
like tyrosine kinase, GBM-glioblastoma multiforme, HGF-hepatocyte growth factor, HIF-hypoxia-inducible 
factor, IgG-immunoglobulin G, IL-interleukin, MET-receptor for HGF, mAb-monoclonal antibody, MG-
malignant glioma, NO-nitric oxide, PDGFR-platelet-derived growth factor receptor, PKC-protein kinase C, 
PlGF-placental growth factor, PI3K-phosphatidylinositol 3-kinase, RET-rearranged during transformation, 
RAF-rapidly accelerated fibrosarcoma, RT-radiotherapy, RTK-receptor tyrosine kinase, SF-scatter factor, 
TMZ-temozolomide, VEGF-vascular endothelial growth factor, VEGFR-VEGF receptor. 

Table 4: Selected anti-angiogenic therapies in pre-clinical development for the treatment of MG  
Name Description Mode of action Efficacy References 
Brivanib alaninate/  
BMS-582664 
RTK inhibitor Inhibits VEGFR-2 & 
FGFR-1 and -2 
Anti-tumour  and anti-
angiogenic effects 
[Bhide et al., 
2010] 
CEP-7055 RTK inhibitor Pan-VEGFR inhibitor Efficacy in GBM 







Binding to integrins & 
inhibition of VEGFR-2 
Prolonged survival. 
Enhanced efficacy with 
chemotherapy. 




DC101 Murine mAb Inhibit VEGFR-2 Reduced tumour 
growth and 
angiogenesis 




FGFR-fibroblast growth factor receptor, GBM-glioblastoma multiforme, IgG-immunoglobulin G, mAb-
monoclonal antibody, MG-malignant glioma, PDGFR-platelet-derived growth factor receptor, RTK-receptor 





normalisation[Popeetal.,2006] [Alietal.,2008] [Boksteinetal.,2008] [Kangetal.,2008]
[Narayana et al., 2009] [Vredenburgh et al., 2007a] [Vredenburgh et al., 2007b]
[Ananthnarayanetal.,2008][Varallyayetal.,2009]isoftendifficulttodisentanglefromthe
antitumourresponse to therapy [Jainetal., 2007],especially in thecaseofmisdiagnosed
pseudoprogression, which also decreases contrast enhancement after antiangiogenic
therapy [Brandsma et al., 2008] [Weinstein et al., 2010] [Wong and Brem, 2007]. Thus, a
reduction in oedema may also be interpreted as a response to therapy, while the
progressionofnonenhancingtumoursmaynotbedetectedbythismethod[Nordenetal.,




been encouraging, and the tumour shrinkage and dormancy has not been spectacular
[Nordenetal.,2008] [PaezRibesetal.,2009].Oncethetransientresponse isovercomeby
resistancemechanisms [Bergers andHanahan, 2008], the tumours have been reported to
becomemore aggressivewith increased invasion andvessel cooption or to causemulti
focal recurrences [Rubenstein et al., 2000] [Kunkel et al., 2001] [GomezManzano et al.,
2008][Fischeretal.,2008][Nordenetal.,2008][Narayanaetal.,2009][Iwamotoetal.,2009]
[Zuniga et al., 2009] [deGroot et al., 2010] [Keunen et al., 2011]. The need for longterm
highdosedrugadministration, systemic toxicities, immunogenicity, short serumhalflife,













release ofglutamateby theMGcells hasbeen thought to be responsible for the seizures
[Buckingham et al., 2011]. AEDs have to be used in patients with seizures in order to
controlthesymptoms.AEDsthatinducehepaticcytochromeP450enzyme(EIAED),such
as phenytoin and carbamazepine carry the risk of increasing the metabolism of
chemotherapeuticdrugsandtheiruseinMGpatientsiscontroversial[Jaeckleetal.,2009]
[Oberndorfer et al., 2005]. Nonenzyme inducing antiepileptics (nonEIAED) such as
levetiracetam(Keppra)arepreferredasthefirstlinetherapy.ArecentEORTC/NCICstudy




patients. The corticosteroid, dexamethasone, is frequently used to alleviate these
symptoms. Longterm highdose use of corticosteroids can lead to Cushing’s syndrome,
corticosteroid myopathy and the risk of opportunistic infections such as Pneumocystis
pneumonia, since corticosteroids prevent immune defence against infection. Other late
complicationsofhighdosesteroidsincludeosteoporosisandfracturesalthoughvitaminD,
calcium supplementation and bisphosphonates may be useful in preventing these
complications [Wen andKesari, 2008]. Furthermore, administration of dexamethasone is
known to inhibit chemotherapeutic induced apoptosis of MG cells by blocking
mitochondrial cytochrome c release, abolition of caspase3 activity and inhibition of





molecular weight heparin is preferred over warfarin for anticoagulation. Intratumoural




Rationallydeveloped targeted therapies are an emerging fieldwithpromising options
forMGtherapy.Withthebetterunderstandingofgeneticsandmolecularpathogenesisof
MG, new therapeutic targets have been identified enabling the development of novel




Table 5: A summary of novel targeted therapies for MG in clinical development  
Name Description Target/s Efficacy References 
Gefitinib (Iressa) RTKi EGFR Unimpressive as monotherapy 
and in combination with mTOR 
inhibitors or bevacizumab in 
recurrent and newly diagnosed 
GBM patients 
[Desjardins 
et al., 2009] 




and in combination with mTOR 
inhibitors or bevacizumab in 
recurrent and newly diagnosed 
GBM patients 
et al., 2009] 
Lapatinib 
(Tykerb/Tyverb 
RTKi EGFR/HER-2 Unimpressive as a monotherapy 





Vaccine EGFRvIII Promising results in newly 




Cetuximab (Erbitux) Chimeric 
mouse/ 
human mAb 
EGFR Unimpressive as a monotherapy 
or in combination with 
bevacizumab +/- irinotecan in 
recurrent GBM 
[Neyns et al., 
2009] 
[Hasselbalch 
et al., 2010] 
Nimotuzumab Humanised 
IgG1 mAb 
EGFR Moderate activity as a 
monotherapy Under evaluation as 









Limited efficacy as a 
monotherapy in recurrent and 
newly diagnosed MG, mixed 
results in combinations   






RTKi PDGFR, SRC, 
BCR-ABL, c-
KIT 
Unimpressive in recurrent GBM 
patients 
[Lu-Emerson 






Ras/ MAPK Limited success in newly 









Ras/ MAPK Under evaluation with TMZ in an 
adjuvant setting in newly 
diagnosed GBM patients 
[Desjardins 







Under evaluation in newly 
diagnosed and recurrent GBM 











Under evaluation as a 










Under clinical evaluation as a 

















PKC inhibitor Under evaluation in newly 
diagnosed and recurrent MG 
patients 





PKC inhibitor Under evaluation in newly 













Valproic acid Aliphatic 
acid-Zn 
chelator 















HDACi Under evaluation for recurrent 









HDACi Modest activity as a monotherapy 
in recurrent GBM, Under 










Under evaluation as a 
monotherapy and in combinations 










Modest efficacy in recurrent MG 
patients in combination therapy  





BCR-ABL-breakpoint cluster region-Abelson, c-KIT-receptor for stem cell factor, EGFR-epidermal growth 
factor receptor, GBM-glioblastoma multiforme, HDACi-histone deacetylase inhibitor, HER-human epidermal 
growth factor receptor, IgG-immunoglobulin G, mAb-monoclonal antibody, MAPK-mitogen-activated 
protein kinase, MG-malignant glioma, mTOR-mammalian target of rapamycin, PDGFR-platelet-derived 
growth factor receptor, PI3K- phosphatidylinositol 3-kinase, PKC-protein kinase C, PPAR- peroxisome 
proliferator-activated receptor, RTKi-receptor tyrosine kinase inhibitor, TMZ-temozolomide, Zn-zinc. 
 
Table 6: A summary of the immunotherapies in clinical development for MG
Approach Method Efficacy Reference 
Cytokine 
modulation 
TNF- (TNF-SAM2) Modest therapeutic benefit in newly 
diagnosed MG 
[Oshiro et al., 2006] 
IFN- Some efficacy in newly diagnosed 
GBM but a modest benefit with 
increased adverse effects in 
recurrent GBM 
[Jackson et al., 2011] 
IFN- Mixed results in newly diagnosed 
and recurrent GBM patients 
[Jackson et al., 2011] 
[Wakabayashi et al., 
2011] 
IFN- Disappointing results, increased 
adverse effects 
[Jackson et al., 2011] 
IL-2 Modest therapeutic benefit, marked 
adverse effects 
[Jackson et al., 2011] 
IL-12 Mixed results in clinical trials [Jackson et al., 2011] 
Poly-ICLC-synthetic  Some efficacy in newly diagnosed 
GBM patients receiving standard 
care 




Significant benefit in recurrent AA 
but some increase in adverse effects  
[Jackson et al., 2011] 






Encouraging results in both newly 
diagnosed and recurrent MG/ GBM 
patients 
[Jackson et al., 2011] 
[Chang et al., 2011] 
[Fadul et al., 2011],  
Autologous tumour 
cell vaccination 
Encouraging results in both newly 
diagnosed and recurrent MG/ GBM 
patients 
[Muragaki et al., 2011], 
[Clavreul et al., 2010] 
[Jackson et al., 2011] 
Personalised peptide 
vaccination  
Evaluated in recurrent GBM 
patients, safety established 




killer cells (LAK) 
Encouraging results in newly 
diagnosed and recurrent GBM  
[Jackson et al., 2011]  
[Dillman et al., 2009] 
Passive-
specific 
Effector T-cell therapy 
from peripheral blood 
or TILs 
Disappointing early trials, 
encouraging results in some later 
studies with newly diagnosed GBM  









Some efficacy in newly diagnosed 
GBM patients with TMZ or RT  
[Li et al., 2010] 
Anti-tenascin mAb 
labelled 131iodine  
Encouraging results in newly 
diagnosed and recurrent GBM  
[Reardon et al., 2008]  
(131I) patients with standard therapy  
 Anti-tenascin mAb 
labelled 211Astatine 
(211At) 
Encouraging results in recurrent 
GBM patients 
[Zalutsky et al., 2008] 
Anti-DNA-histone 1 
mAb labelled 131iodine 
(131I) 
Evaluated in newly diagnosed and 
recurrent MG patients, established 
safety 
[Hdeib and Sloan, 2011] 
EGFR-epidermal growth factor receptor, GBM-glioblastoma multiforme, IFN-interferon, ICLC-polyinocinic-
poly cytidylic acid stabilized with polylysine and carboxymethylcellulose, IL-interleukin, mAb-monoclonal 
antibody, MG-malignant glioma, RT-radiotherapy, TGF-transforming growth factor, TMZ-temozolomide, 









Table 7: A summary of the targeted toxin therapies in clinical development for MG 
Target Ligand Efficacy References 
IL-13 
receptor 2 
IL-13 tagged with 
pseudomonas exotoxin 
(Cintredekin besudotox) 
Well tolerated. No survival 
benefit in recurrent GBM 
patients 
[Jackson et al., 2011] 
[Castro et al., 2011] 
IL-4 
receptor 
IL-4 fused with pseudomonas 
exotoxin (NBI-3001) 
Evaluated in recurrent MG 
patients. Well tolerated 
[Jackson et al., 2011] 
[Castro et al., 2011] 
EGFR TGF- fused with pseudomonas 
exotoxin (TP-38) 
Modest effect in recurrent 
GBM/ MG patients 
[Castro et al., 2011] 
Transferrin 
receptor 
Mutated transferrin fused with 
diphtheria toxin (Tf-CRM107) 
Encouraging results in 
recurrent MG patients 
[Castro et al., 2011] 
EGFR-epidermal growth factor receptor, GBM-glioblastoma multiforme, IL-interleukin, MG-malignant 
glioma, TGF-transforming growth factor 
2.2.13Prognosisandoutcome





and clinical outcome of MG patients. Some of the parameters taken into consideration
include histopathological diagnosis with WHO tumour grading, age of the patient at
diagnosis,gender,neurologicalperformancestatus,tumourlocation,contrastenhancement
in radiology, extentof surgical resection,proliferation indicesandgenetic andepigenetic
alterations [Simpson et al., 1993] [Jeremic et al., 1994] [Louis et al., 2007b]. Even though
theseparametersdonotallowaccuratepredictionofoutcomeforindividualpatients,they
account for the vast majority of prognostic variability in MG [Vitucci et al., 2011]. The
outcome of highgrade tumours is also largely dependent on the availability of effective
treatmentregimens[Louisetal.,2007b].




of EGFR, EGFRvIII mutation [Desjardins et al., 2009], PI3KAKTmTOR [Phillips et al.,
2006] pathways and deletion of NFKBIA [Bredel et al., 2011] [Chakravarti et al., 2002],
upregulation of YKL40 [Pelloski et al., 2005] are associated with poor prognosis, while
IDH1mutations[Hartmannetal.,2010]andactivationofNotchsignalling[Phillipsetal.,
2006] carry a better prognosis in GBM. AA patients withwildtype IDH1 have aworse
prognosisascomparedtoIDH1mutatedGBMpatients[Hartmannetal.,2010].MGswith
anoligodendroglialcomponentrespondbettertothePCVcombination[Macdonaldetal.,









et al., 2006] [van den Bent et al., 2006]. GBMs have aMS between 0.40.9 years and an
averagesurvivalof~811months,withasixmonthsurvivalof42.4%,oneyearsurvivalof








months for those over 80 years old [Ohgaki and Kleihues, 2005b]. MS time of de novo
(primary) and secondary GBM is 4.7 and 7.8 months, respectively, but after age




care have had a MS of ~14 weeks [Avgeropoulos and Batchelor, 1999]. Surgery alone
increased the MS to ~20 weeks (34 months) [Kelly et al., 1984] [Paoletti, 1984]. Post
operativeRT increased theMSup to 712months [Laperriere et al., 2002] [Walker et al.,
1978].Additionofchemotherapy(mainlynitrosoureas)furtherincreasedtheMSfrom9.4to
12months[Fineetal.,1993]andoneyearsurvivalfrom40to46%[Stewart,2002].






salvage chemotherapy is ~6% and 6month PFS is 15% [Wong et al., 1999] with aMS
between47months[ChamberlainandTsaoWei,2004][Chuaetal.,2004].Themajorityof
grade III MGs on recurrence has progressed to grade IV GBM [Ohgaki and Kleihues,
2005b]. Finally, recurrences that are deepseated, contralateral and diffuse, with wide
disseminationhaveaworseprognosis[Rostomilyetal.,1994].
2.3 GENE THERAPY FOR MALIGNANT GLIOMA  
2.3.1Introduction
Gene therapybydefinition is thedelivery of geneticmaterial into cells or tissueswith a
therapeuticintent.Itencompassesawiderangeoftreatmenttypes,allofwhichusegenetic
materialtomodifycellstoattainthedesiredtherapeuticeffect[Mulligan,1993].Technical
developments for themanipulation of geneticmaterial, development of efficient vectors
and advances in knowledge and better understanding of many disease processes at the
molecular level, over the last few decades paved the way for gene therapy. The actual
conceptofgenetherapydatesbackto1960sbutsincethen,genetherapyhasprovenitself







The fundamental basis for gene therapywas laidwith the demonstration in the early
1960sthat,mammaliancellscouldbemodifiedtoincorporateandexpressforeignDNA.By
the late 1960s, it was apparent that exogenous genetic information could be used for
efficient genetic transformation [Friedmann, 1992]. The use of viruses/pseudovirions to
transport therapeutic geneswasproposed in this prerecombinantDNAera [Friedmann,
1992]. The demonstration of the ability ofmodified tumour viruses to transfer a foreign
genetic sequence to mammalian cells was a major milestone in this long journey
[Friedmann,1992].Thediscoveryof thecalciumphosphatechemical transfectionmethod
laid the foundation to introduce therapeutic genes efficiently and functionally into










the infected cells and reversetranscriptase lead to the development of retroviral vectors
thatovercamethebarriersofchemicaltransfection[Friedmann,1992].Severalexperiments
demonstrated the utility of retrovirus vectors with the possibility of transducing many
human cell types [Friedmann, 1992]. The vector armourywas further enlargedwith the
development of adenoviral vectors [Van et al., 1984] and adenoassociated virus vectors
(AAV)[Friedmann,1992].
Attentionofgenetherapyatthisearlystageswasfocussedtowardsmonogenicdisorders
such as LeschNyhan syndrome, adenosine deaminase (ADA) deficiency, familial hyper
cholesterolaemiaofLDLRdeficiency,1antitrypsindeficiency,clottingfactordeficiencies,
andGaucherdisease[Friedmann,1992].
USFDAapproved firstgene therapyprotocolwas carriedout in1989,where tumour
infiltrating lymphocytes collected from advanced melanoma patients were exvivo
transducedwithamarkergene,expandedinvitroandreinfusedtothepatients[Rosenberg
etal., 1990].The firstgene therapy trialwitha therapeutic intentwas initiated in1990 to
treat an inherited immunodeficiency disorder: ADA deficiency, where patients’ T
lymphocyteswereexvivotransfectedwiththemissinggeneusingretroviralvectorsandre
infusedback to thepatients [Blaese et al., 1993] [Blaese et al., 1995]. Since then,multiple
gene therapy clinical trials have been conducted for diseases such as cancer, vascular
diseases, infectiousdiseasesandinheritedgeneticdisorders.Thefirstproofoftherapeutic
cure with gene therapy came in year 2000 when Fisher and colleagues reported the



















GeneTech Co. Ltd), which is an adenovirus vector expressing p53 for the treatment of
advanced cancer, approved by Chinese regulatory authorities [Peng, 2005]. The second
commercial gene therapy product, an oncolytic adenovirus H101 (Shanghai Sunway
BiotechCo.Ltd)wasalsoapprovedinChina[Luetal.,2004a].
ByJanuary2012atotalof1786genetherapyclinicaltrialwereregisteredattheJournalof








Figure 8: Gene therapy clinical trials grouped according to the phase of clinical evaluation (A) 
and the indication (B). Modified from http://www.abedia.com/wiley/genes.php
2.3.3Genetherapyforcancer
The fact that gene therapy is viewed as a treatment strategy for cancer is not surprising
considering that cancer is a major global health problem. Cancer is the second most
common cause of death among adults in most developed counties, indicating a largely
unmet need for the development of novel therapies. Conventional cancer therapies are
usually hampered by their systemic toxicities, often leading to treatment discontinuation
and failure. Gene therapy with its ability to specifically target the tumour has a clear
advantageoverconventionaltherapies.Manycancertypeshavebeentargetedinbothpre
clinical and clinical settingswith gene therapy, including lung [Roth et al., 1996], breast
[Stewartetal., 1999],pancreatic [Chawlaetal., 2010], liver [Guanetal., 2011], colorectal




antiangiogenic gene therapy, oncolytic virotherapy, gene therapybased immune


















addition, the vector should not induce an immune response within the host, enabling
repeated, safe vector administrations without any adverse effects [Romano et al., 2000]
[Verma and Weitzman, 2005]. Sadly, none of the existing vectors match this ideal. At
present,bothviral,nonviralandcellbasedvectorsarebeingusedforthispurpose[Lawler
et al., 2006].Viral vectors are beingused in themajority of clinical trials andpreclinical
work. Adeno (23 %) and retrovirus vectors (20 %) are the most commonly used viral
vectorsinclinicaltrials.Vacciniavirus,poxvirus,AAV,HSVandlentivirusvectorsarethe
examples of other viral vectors in use. Plasmid transfection and lipofection are themost
commonnonviralgenedeliverymethodsinclinicaltrials.
Genedelivery into target tissue canbe achievedby twomethods. Direct invivogene
deliverymeansthatthegeneisdelivereddirectlyintothetargettissue,tumourcavityafter
surgical resection, or into the systemic circulation. In exvivo gene transfer, the gene
transductionisconductedoutsidethelivingorganism,intopreviouslyisolatedcells,which






transductionalor transcriptional targetingof thevector isnotrequired.Systemicdelivery
allows the vector to reach almost any part of the body. Hence, targeting of the vector
specifically to the tumour cells by transductional targeting or restricting the transgene
expression to tumour cells by transcriptional targeting is essential [Palmer et al., 2006].












Viralvectorsareconsideredas themosteffectiveofallgenedeliverymethods for invivo
genetransfer[Chioccaetal.,2003].ThecommonlyusedviralvectorsforMGgenetherapy
includeretroviruses,HSV[Shahetal.,2003],adenovirus[Wirthetal.,2009][Maattaetal.,
2009] andAAV virus [Mizuno et al., 1998]. In addition, baculovirus [Wang et al., 2006],
Newcastle Disease virus (NDV) [Csatary and Bakacs, 1999], poliovirus [Gromeier et al.,
2000],SemlikiForestvirus[Renetal.,2003],measlesvirus[Phuongetal.,2003],lentivirus
[Naldinietal.,1996a],reovirus[Wilcoxetal.,2001],andvacciniavirus[Gridleyetal.,1998]
have been used as vectors. In most of these vectors, the viral genome is genetically
modifiedtomakethemreplicationdefectiveandnonpathogenic,andtomakespaceforthe
transgene.However, in oncolytic viruses, the genome ismodified to provide itwith the
ability to replicate only within tumour cells that would lead to tumour destruction
[Hurtadoetal.,2005].Someofthenewviralvectorshavetheabilitytoreplicateonlyonce






Table 8: A summary of the general features of viral vectors in gene delivery 









No  70-100 4.7-30  Dividing and 
non-dividing 
cells  




SS RNA Yes 100-
150 
<10  Dividing and 
non-dividing 
cells 
Integrating Stable long 
term 








HSV DS DNA Yes  100-
200 
30-150  Dividing and 
non-dividing 
cells 
Episomal Transient but 
longer 
duration 
AAV-adeno-associated virus, DS=double stranded, HSV-herpes simplex virus, SS=single strand 
2.3.4.1.1Adenovirusvectors
Firstdiscoveredin1953,adenovirusesarepathogenictohumansaswellasmanyanimals.
The human adenovirus family (Adenoviridae) has more than 50 serotypes that have the
ability to infect both dividing and nondividing human cell types including cells of the
respiratory tract, eye, urinary bladder, gastrointestinal tract and liver resulting in mild
infections [Verma and Weitzman, 2005] [Douglas, 2007]. They have a linear double
strandedDNAgenomeof36kb[Chroboczeketal.,1992].Icosahedralviralparticles(vps)
are70100nminsize.Thecapsidofthenonenvelopedvirusismadeofhexons,pentons,
protein IX and fibre proteins that facilitate receptor attachment. The majority of the
adenovirus serotypes use the coxsackie and adenovirus receptor (CAR) to enter cells
[Bergelsonetal.,1997][Tomkoetal.,1997].OtherreceptorssuchasMHCclassI[Honget
al., 1997], heparan sulphate glycosaminoglycans [Dechecchi et al., 2000], vascular cell
adhesionmolecule1(VCAM1)[Chuetal.,2001]alsoplayaroleinthereceptormediated
endocytosis [Zhang and Bergelson, 2005] of the virus through clathrincoated vesicles
[Meier et al., 2002]. Internalisation is facilitated by the pentons interacting with cellular
integrinv5thatactasacoreceptor[Wickhametal.,1993].Thevirusisthentransported
into the endosomes [Glasgow et al., 2006] [Verma and Weitzman, 2005]. Subsequent
acidification of the endosomes results in disassembly of the viruses and release of the
capsid,whichdocksatthenuclearporecomplex,releasingtheviralDNAintothenucleus,
where it starts replicating in an episomalmanner without integration into host genome
[Glasgowetal.,2006][VermaandWeitzman,2005].
The ability to make the virus replicationdeficient was crucial in the development of
adenovirusvectors[Vanetal.,1984].Serotypesfiveandtwoaremostcommonlyusedas
gene therapyvectorsbutother serotypesandnonhumanviruseshavealsobeenused. In
the firstgeneration adenovirus vectors, the region encoding for early viral protein E1 is
replaced by the transgene making the vectors replication defective [Danthinne and
Imperiale, 2000]. By deleting the E1 gene, a transgene insertion capacity of 4.74.9 kb is
achieved [Bett et al., 1993], which is further increased upon 8.3 kb by deleting the non
essential region E3 [Bett et al., 1994] [Verma and Weitzman, 2005]. Secondgeneration
adenovirusvectorswerecreatedbydeletingE2andE4regionstocircumventtheproblem
ofhostcellularimmuneresponseagainsttheviralproteins[Armentanoetal.,1995][Wang
et al., 1995]. Cre/loxP system based sitespecific DNA excision of 25 kb of adenovirus
genome created highcapacity thirdgeneration vectors [Parks et al., 1996] [Lieber et al.,
1996] [Hardyetal.,1997].Asocalled“gutted”adenovirusvectorwasdesignedwhenall
viral sequences except for the inverted terminal repeats (ITRs) and cisacting packaging






transgene expression in both dividing and nondividing cells of many different tissues
including lung, skeletalmuscle, heart, liver, blood cells, vasculature andCNS [Kozarsky
andWilson, 1993] [Huard et al., 1995]. The systemic administration of the vector has a
predilection to liver, spleen, heart, lung and kidney irrespective of the CAR expression
status[Glasgowetal.,2006].Theycanbeproducedatveryhighconcentrationsof10121013
particles/ml[VermaandWeitzman,2005]andhavebeenusedinhumanstudiesatdosesup
to 3x1012 vps perml (vp/ml) [Barzon et al., 2006]. Dose escalating studies have revealed
toxicity with CNS symptoms, fever, leucocytosis, and hyponatremia with doses of 1012
vp/ml[Trasketal.,2000].Manystudieshavedemonstratedthatthetoxicitiestoadenoviral
vectorsaretransient,mildinflammatoryreactions,whicharewelltolerated[Barzonetal.,






LacZ marker gene [Puumalainen et al., 1998]. Some studies have demonstrated a
transductionefficacyof95100%aroundtheinjectionsitewithameanmaximumdistance
ofabout5mm[Langetal.,2003].
A significant proportion of the human population can possess preexisting antibodies
thatcould rapidly inactivate thesystemicallyadministeredadenoviralvectors [Nazirand
Metcalf, 2005]. Some serological surveys have shown this to be as high as 4060% for
serotypes1,2and5inchildren[VermaandWeitzman,2005].Vectorinjectionresultsinan
initial nonspecific host responsewith the release of the cytokines TNF, IL1 and IL6,
followedbyaspecificresponsedirectedagainsttheinfectedcellsmediatedbycytotoxicT
lymphocytes,monocytesandNKcells, andahumoral response throughactivatedBcells
and CD4+ Tlymphocytes giving rise to a major obstacle for the efficiency and a safety
concerns for the use of adenovirus vectors [Verma andWeitzman, 2005] [Driesse et al.,
2000]. This risk would be even greater with repeated vector administrations; making
efficacyofrepeatedgenetransferverylimited[Yangetal.,1994].Inspiteofthebrainbeing
consideredasanimmuneprivilegedregion,intracerebralinjectionofadenovirusvectors
is known to cause an immune reaction through a poorly understood mechanism
[Lowenstein,2002][Deweyetal.,1999].However, ifthevectorsareinjectedcarefullyinto
the brain parenchyma, avoiding the ventricles or systemic vasculature, as in the case of





thehost couldbe consideredasanadvantage in cancergene therapy, especially inbrain
[Kajiwaraetal.,1997].
VariableexpressionoftheCARreceptorcanlimittheuseofadenovirusvectorsinMG
gene therapy [Einfeld et al., 2001] [Mori et al., 1999].However, in spite of the lowCAR
expression byMGs [Lawler et al., 2006], most of themwere successfully transduced by












antibodies, antibody fragment chemical conjugates [Douglas et al., 1996] [Guet al., 1999]
[Dmitriev et al., 2000] [Kashentseva et al., 2002], cellselective ligands and direct
introductionofa targeting ligandonto the fibreknob,asamolecularbridgebetween the
vectorandthetargetcellsurfacereceptor,bypassingthenativereceptorandcreatingnovel
tropismwith the new receptors [Glasgowet al., 2006]. Pseudotypingwithdifferent fibre
proteins [Krasnykh et al., 1996], expression of chimeric fibre proteins and other capsid
proteins[Vigneetal.,2003],ligandincorporationintothefibreknob[Lamfersetal.,2002]
anddeknobbingof fibrecoupledwith ligandaddition,aresomeof theotherattemptsat
transductionaltargetingofadenovirusvectors[Glasgowetal.,2006].OverexpressedEGFR
inMG [Libermann et al., 1985]hasbeenused to target the adenovirusvectors to glioma
cells,capitalisingonthefactthatligandboundEGFRisinternalizedbyactivationofPI3K
dependent pathway [Li et al., 1998]. Bispecific antibody conjugates [Miller et al., 1998],
bispecificsinglechainantibodies[van,Vetal.,2002],chimericfusionmolecules[Dmitriev
et al., 2000] and bFGR2 [Wang et al., 2005] have been used successfully to retarget
adenoviralvectorstotheEGFR.Adenoviralvectorswiththeabilitytoreplicateonlyonce
withinthetargetcellswithouttheabilitytodisseminatehaveincreasedthetransgenecopy
number and expression within the transduced cells. This has been shown to improve
survival in a murine glioma model when compared to standard adenoviral vectors







termed detargeting. This can be achieved by genetic ablation of native receptorbinding
determinants,blockingbridginginteractionsorbyusingpolymercoated“stealth”vectors
toavoidtheseinteractions[Coughlanetal.,2010].Theimmunogenicityandtoxicityofthe
vector can be reduced by blocking the interaction with natural receptors [Palmer et al.,
2006], increasing the safety and bypass the preexisting antivector immunity, thus
increasingitsefficacy[VermaandWeitzman,2005].
2.3.4.1.2Lentivirusvectors
Lentiviruses belong to the Retroviridae family and are often derived from human
immunodeficiency virus1 (HIV1) [Goff, 2001]. Other nonHIVs have also been used as
gene therapy vectors. General features of lentivirus vectors are summarised in Table 8
[Naldini et al., 1996b]. The wildtype virus binds to the cell surface receptors such as
heparan sulphate proteoglycans (HSPG), CD4 and chemokine receptors and are
internalisedintoCD4cells,macrophagesandDCs.Thenucleoproteincomplexisreleased
into the cytoplasm [Freed and Mouland, 2006] where it is reversetranscribed into a
complementaryDNA (cDNA)by the reverse transcriptase complex. The resulting cDNA
incorporated preintegration complex enters the nucleus and integrates into the host
genome[AndersonandHope,2005].Lentivirusvectorsonlyhaveabout5%oftheoriginal
wildtype genome. They are considered as lowimmunogenic vectors. Usually the
lentivirus vectors are pseudotyped by vesicular stomatitis virus glycoproteinG (VSVG)
[Burnsetal.,1993].Pseudotyping increases the tropismaswellas the immunogenicityof
thevector [Baekelandtetal.,2003].Thevectorhas theability to transducequiescentcells
suchasneurones[CockrellandKafri,2007].Drawbacksoflentivirusvectorsarelowvector






al., 2009]. They have been used in several preclinical MG gene therapy experiments
[Naldini et al., 1996a] [SteinandDavidson, 2002] [Guoet al., 2011] [LopezOrnelas et al.,




AAV belongs to theParvoviridae family. These are nonenveloped, singlestrandedDNA
viruses,sized2025nmwithanicosahedralcapsid[Xieetal.,2002].Morethan10serotypes
ofthisvirushavebeenidentified[Morietal.,2004].AAV,withtheaidofcapsidproteins,




transgene insertion capacity of 4.5 kb and a tropism to muscle, lung, retina, neurons,









an immune responsewithin the host [Kok et al., 2005]. AAV vectors have been used in
many preclinical studies on brain cancer, with mixed success [Okada et al., 1996]
[Hadaczeketal.,2005][Hardingetal.,2006].
Herpes viruses are human pathogens belonging to Herpesviridae family consisting of
eightmembers[BradyandBernstein,2004].HSV1isalarge,enveloped,doublestranded
DNA virus, pathogenic to humans causing cytolytic replication inmucosal or epithelial
cells, with a neuronal predilection and the ability to induce latent infection due to the
persistenceoftheviralgenome[VermaandWeitzman,2005].TwotypesofHSVvectorsare




expression of viral proteins, they can be cytopathic and cytotoxic, and can induce an




andWeitzman, 2005]. HSVG207 andHSV1716 are conditionally replicatingHSVswith
specificgenemutationsandaselectiveabilitytoreplicateonlywithindividingcancercells,
leading to oncolysis [McKie et al., 1996] [Mineta et al., 1994]. Both of these viruses have
beentriedonMGinbothpreclinicalaswellasinclinicalstudies[Ramplingetal.,2000].
2.3.4.2Nonviralvectors
Due to their low toxicity, low immunogenicity, and lack of infectivity, nonviral gene
deliverymethodsareconsideredassafealternativesforviralvectorsthathavealongterm






Direct intralesional or systemic injections of naked/plasmidDNA are the simplest of
thesemethodsbuthavethedisadvantagesoflowtransductionefficacyinvivoandtherisk
of degradation by nucleases and phagocytes [Kawabata et al., 1995]. Calcium phosphate
precipitationfacilitatesthegenetransferbydisruptingtheelectrochemicalbarrierbetween
cellmembraneandtheDNA,butisnolongerverypopular[Wells,2004].Electroporation,
genegun, ultrasound and laser techniques can be used to increase the cell membrane
permeabilitytofacilitatetransductionbynaked/plasmidDNA[MehierHumbertandGuy,
2005]. The nonintegrating episomal nature of plasmid DNA with low transduction
efficiencyandtransientgeneexpression,havebeenlimitingfactorsencounteredwiththis
method.
In order to protect the plasmid DNA from endogenous degradation and to facilitate
entrythroughcellmembrane,DNAcanbepackedintoliposomesmadeoflipidbilayers,
polymers or micelles creating synthetic vectors [Yoshida and Mizuno, 2003]. Cationic
lipid/DNA complexes (lipoplex) [Felgner et al., 1987], cationic polymer/DNA complexes
(polyplex)[WuandWu,1987]andlipidpolymerhybridsystemshavealsobeendeveloped.
Lipoplexandpolyplexplasmidcomplexes[ThomasandKlibanov,2003]havesignificantly
improved transduction efficacy when compared to the traditional plasmids [Schatzlein,
2001].Monoclonal antibodies have been used successfully to target liposomes to glioma
cells[Zhangetal.,2004].
Attempts have been made to create plasmid DNA vectors capable of transgene
integrationandlongtermgeneexpressionusingtheSleepingBeautytransposableelement
withpositiveresultsinGBMpreclinicalmodels[Wuetal.,2007][Ohlfestetal.,2005].The
main disadvantage of thismethod is that these retrotransposons have a predilection to
integrateintoactivelytranscribedgenesleadingtopossibleproblemswithcellularfunction
[Hackett et al., 2005]. In another attempt, phiC31 integrase systemwasused to integrate
plasmid DNA into preferred locations in the mammalian genome for longterm gene
expression[Calos,2006].















develop as an alternative to viral gene delivery or to enhance viral gene delivery
[Herrlingeretal.,2000].
Nonviralgenedeliverymethodshavebeenusedin~25%ofregisteredclinicaltrialsby
January 2012 (http://www.abedia.com/wiley/vectors.php). Both naked/plasmid DNA and




last few decades has made MG an ideal candidate for novel therapeutic development.




infiltrative nature of MGs, preventing complete surgical resection, the inherent
radioresistance and limitations in the radiation dose to the brain, limited delivery of







vectors, inneuroblastomapatients. In thesameyear,Oldfieldetal. testedHSVtksuicide
gene therapyusing retrovirusvectorproducing cells (VPCs)with intravenous (i.v.)GCV
therapyinbraincancers[Oldfieldetal.,1993][Rametal.,1997].
ManygenetherapystrategiesareunderextensiveevaluationforMGtherapyatthepre
clinical and clinical trial levels. Table 9 summarises the gene therapy strategies under
developmentforMG.Thoughmostofthesemethodshavedemonstratedimmensesuccess
in invitro and preclinical level, rather few approaches have progressed up to phase III
clinical trials [PulkkanenandYlaHerttuala,2005] [Barzonetal., 2006]. Inmost instances,
gene therapy has been attempted as a monotherapy approach in both preclinical and
clinicaltrialswithonlyafewattemptsatcombiningdifferenttherapystrategies.

Table 9: Gene therapy strategies for MG 
Strategy Stage of 
development 
Reference 
Pro-drug activating suicide gene therapy Clinical trials  [Castro et al., 2011] 
Anti-angiogenic gene therapy Pre-clinical [Samaranayake et al., 2010] 
Oncolytic virotherapy Clinical trials [Castro et al., 2011] 
Gene therapy-based immune modulation Clinical trials [Castro et al., 2011] 
Correction of tumour genetic defects Clinical trials [Castro et al., 2011]  
Inhibition of tumour invasion Pre-clinical [King et al., 2005] [Castro et al., 2003] 
Induction of apoptosis Pre-clinical [King et al., 2005] [Castro et al., 2003]
Gene therapy to enhance chemo- and RT Pre-clinical [King et al., 2005] [Castro et al., 2003]
Myeloprotective gene therapy Clinical trials http://www.abedia.com/wiley/index.html  
Antisense and RNAi-based strategies Clinical trials http://www.abedia.com/wiley/index.html  





activating suicide gene therapy, which is also known as cytotoxic gene therapy, is to
introduceatransgeneencodingforanenzyme,thatiseitherabsentinmammaliancellsor
presentinaveryinactiveform,intothetumourcells,orintothesurgicalcavityofresected
tumours. Enzyme produced by the transduced cells will convert the subsequently
administered inactiveprodrug into itsactive form,evoking thedeathof cells expressing
thetherapeuticgene.Thephenomenonthatkillstheneighbouringnontransducedcellsis
termed the bystander effect [Freeman et al., 1993], which is fundamental for the
therapeutic success. It can result from the transfer of the active metabolite into the
neighbouring cells via gapjunctions [Elshami et al., 1996] [Mesnil et al., 1996], apoptotic
vesicles[Freemanetal.,1993]orthroughsimplediffusion[Huberetal.,1994].Activationof
theantitumourhostimmunesystembycellkillingalsocontributestothebystandereffect
[Barba et al., 1994]. The lipophilicity of the prodrug and the active metabolite also
influencethebystandereffect[Wilsonetal.,2002].Thebystandereffectcompensatesforthe










of the cellcycle with a good bystander effect [Denny, 2003]. Both the prodrug and the
active metabolite should have good biodistribution properties, and the prodrug or the
expressionofsuicidegeneitselfshouldnotbetoxictothecells.
Thisisawidelyusedgenetherapyapproachforthetreatmentofcancerinvolvedin144
registeredclinicaltrialscommonlyusingretrovirusandadenovirusvectors. It is themost
frequently employed gene therapy application for the treatment of MG with over 20
registeredclinicaltrialsbyJanuary2012(http://www.abedia.com/wiley).Multipleprodrug
activatingsuicidegenetherapystrategieshavebeendescribedintheliterature[Niculescu
Duvaz and Springer, 2005].HSVtk/GCV, cytosine deaminase (CDA)/5fluorocytosine (5
FC), cytochromeP450/cyclophosphamide (CPA),Escherichia coli (E.coli) purinenucleoside
phosphorylase (PNP)/6methylpurine2
deoxynucleoside, and carboxypeptidase G2
(CPG2)/methotrexatephenylalanine are some of the prodrug activation systems
evaluatedforMGtreatment[Kingetal.,2005].Apartfromthecommonlyusedretrovirus
vectors/VPC and adenovirus vectors [Pulkkanen and YlaHerttuala, 2005], HSV and






beenused todeliverprodrugconvertingenzymes [Barresi et al., 2003] [Uhletal., 2005],
andtoenhancethetransductionefficacyofviralvectors[Herrlingeretal.,2000].
Mostsuicidegenetherapystrategiesdependontheabilityofthesystemicallydelivered
prodrug to reach the target site, limiting the efficacy of this method. Nonspecific
activationof theprodrug inunintended tissuesand thediffusionof theactivedrug into
the systemic circulationmay lead to toxicities.Limitations in the transduction efficacyof
currently available vectors are amajor hurdle to overcome. Gene silencing can result in





pharmacokinetic and pharmacodynamics properties [Davies et al., 2005], enhancing the
bystandereffect, combinationwithstandardandnovel therapeutics [Boucheretal., 2000]
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CDA-cytosine deaminase, CMDA-4-benzoyl-L-glutamic acid CPA-cyclophosphamide, CPG2-
carboxypeptidase G2, dTTP-deoxy thymine triphosphate, FC-fluorocytosine, FU-fluorouracil, GCV-





suicide gene therapy with prodrug GCV approach is themost extensively studied and
widelyusedsuicidegenetherapyapproachforcancerincludingMG[PulkkanenandYla
Herttuala,2005].ItisbyfarthemostadvancedofallMGgenetherapystrategiesinclinical
trials to date having completed two multicentre randomised phase III clinical trials








intratumoural implantation of HSVtk producing VPCs in rodent models. In the initial
studies,amixtureofgliomacellandVPCswere inoculatedat thesametimefollowedby
GCV treatment [Culver et al., 1992],whereas in others, VPCswere inoculated oneweek
later [Ram et al., 1993]. Other studies showed tumour regression as well as improved
survival [Barbaetal.,1994]andsomeevendemonstratedcompletecure [Izquierdoetal.,






but later it was shown that adenovirus vectors have a better transduction efficacy than
retrovirusvectorsinhumanMG[Puumalainenetal.,1998].Theuseofadenovirusvector
mediatedHSVtkgenedeliveryhasresultedinregressionoftumourvolume[Chenetal.,
1994] [Maron et al., 1996] including complete responses [PerezCruet et al., 1994] and
increased survival [Vincent et al., 1996] [Tyynela et al., 2002] in MG animal models. In
comparative studies, using both types i.e. adenovirus vectors and retrovirus VPCs,
adenovirusvectorsshowedabetterresponse[Sandmairetal.,2000a]andthiswasfoundto
be curative when the transduction efficacy was high enough, [Sandmair et al., 2000b]
suggestingthatthelowtherapeuticefficacywithretroviralvectorscouldmainlybedueto
their low transductionefficacy [Sandmair etal., 1999].Toxicity studieshavenot revealed
anyseriousadverseeffectsexceptformildreactivegliosisattheinjectionsite,withtheuse
ofretrovirusvectors[Raffeletal.,1994]andadenovirusvectors[Langfordetal.,2009],as
well as with adenoviral vectors in nonhuman primates, suggesting that this is a safe





The HSVtk homodimer is capable of phosphorylating T, deoxycytidine,
deoxythymidylate and several pyrimidine and guanosine analogues into their
monophosphates.Theantiviraldrugs,acyclovirandGCV,canactassubstratesforHSVtk,
which has a 1000fold higher affinity for GCV compared to its mammalian counterpart
[Palmeretal., 2006].GCV isa syntheticacyclicanalogueofdeoxyguanosine,whichwas
developedintheearly1980s[Smithetal.,1982][Ashtonetal.,1982][Martinetal.,1983]for
thetreatmentandpreventionofCMVinfection.ThechemicalformulaofGCVisC9H13N5O4
with a molecular mass of 255g/mol and is a hydrophilic compound with poor
pharmacokinetic properties [Denny, 2003]. Oral bioavailability is poor, hence it is
administeredparenterally.Thedrughasarenalclearanceandaserumhalflifeof2.5to5
hours [Noble and Faulds, 1998]. Adverse effects of GCV include neutropenia,
thrombocytopenia,headache, convulsionsandcoma[FauldsandHeel,1990].GCVenters
the mammalian cells via nucleoside transporters [Buursma et al., 2004], where it is
phosphorylated into5’monophosphate (GCVMP)byHSVtkwithasubstrateKmof47M
[Field et al., 1983] (Figure 9). This is considered as the ratelimiting step of GCV
phosphorylation. Mammalian guanylate kinase and nucleoside diphosphokinase further
phosphorylatesGCVMPintoGCVdiphosphate(GCVDP)andGCVtriphosphate(GCVTP),
respectively [Cheng et al., 1983] [Boehme, 1984]. GCVTP competitively inhibits the
incorporation of deoxyguanosinetriphosphate (dGTP) into DNA. GCVTP is highly
cytotoxic due to its ability to incorporate into the nascent DNA strand causing DNA





is yet to be revealed. There are reports suggesting that cell death occurs by apoptosis
[Hameletal.,1996] [McMastersetal.,1998] inducedbydecliningBcl2 levels [Tomicicet
al., 2002] or phosphorylation of BclxL [Fischer et al., 2005b] and activating caspases
triggering themitochondrialapoptoticpathway[Glaseretal.,2001] [Tomicicetal.,2002],
independentofp53anddeathreceptors[Fischeretal.,2005b],whileothersclaimthatthere
is a p53dependent death receptormediated apoptosis [Beltinger et al., 1999]. Evidence
suggeststhatGCVcaninducechromosomalaberrationsandsisterchromatidexchange,an
indicationofapossibleinvolvementofHRDNADSBrepairpathways[Thustetal.,1996]





is cellcycledependent andaffectingmainlydividing cells.This is an advantage inbrain
cancer gene therapy when tumour cells are dividing amidst nondividing normal brain
cells.FourteendaytreatmentwithGCVhasbeenshowntokillHSVtktransducedglioma
cellsinpreclinicalstudies[Barbaetal.,1993].
Local and systemic immune responses contribute to the HSVtk/GCVmediated anti
tumoureffect[Barbaetal.,1994][Rainovetal.,2000]byenhancingthetumourinfiltration
of, CD4+ and CD8+ Tcells, NK cells andmacrophages. This was accompanied with an
increasedexpressionofcytokineIL12andFasligand(FasL),bythehost[PerezCruetetal.,







Figure 9: Principle of HSV-tk/GCV therapy including the bystander effect. Bcl-2 B-cell 
lymphoma-2, Bcl-XL-P-phosphorylated Bcl-XL, BER-base-excision repair, dGTP-deoxy guanosine 
triphosphate, DNA pol-DNA polymerase, DSB-double-stranded break, GCV-ganciclovir, GCVMP-
GCV-monophosphate, GCVDP-GCV-diphosphate, GCVTP-GCV-triphosphate, HR-homologous 
recombination, HSV-tk-Herpes simplex virus thymidine kinase, SSB-single strand break. Refer 
to the text for the relevant references. 

BystandereffectofHSVtk/GCV
The bystander effect plays an important role in HSVtk/GCVmediated cytotoxicity
[Freeman et al., 1993] even though the mechanism is not completely understood. Free
diffusion across cell membrane of GCVDP and GCVTP is unlikely due to the negative
charge of the molecules. The most widely acceptedmechanism is the diffusion of toxic
GCVTPviagapjunctionsinacelltocellcontactdependentmanner,toneighbouringnon
transduced cells, and thus triggering their apoptosis [Elshami et al., 1996] [Mesnil et al.,







regress the tumour both invitro and invivo [Sandmair et al., 2000b] [Culver et al., 1992]
[Freemanet al., 1993]. Inaddition, theeffect seems tobedependenton theMGcell type
[Burrowsetal.,2002][IshiiMoritaetal.,1997].Forexample,C6gliomasseemtobemore
sensitivetothetreatmentwhencomparedtohumangliomacell lines[Sturtzetal.,1997].
Evidencepoints toan inhibitionofHSVtk/GCVbystander effectby coadministrationof
dexamethasone, possibly due to a reduction of gapjunctionmediated intercellular
communication,inhibitionofgapjunctionsynthesisortosomekindofmodulationofthe
apoptotic cascade [Robe et al., 2005]. Other possible mechanisms responsible for the
bystandereffectcouldbethestimulationofthehostimmunesystemtoattackthetumour
[Colombo et al., 1995] [Kianmanesh et al., 1997], endothelial cell transduction leading to






gene therapy [Tyynela et al., 2002]. In clinical trials, multiple vector injections into the
tumourcavityhavebeenused[Immonenetal.,2004].CEDofvectorshasbeenattemptedto
increase the transduction efficacy [Hadaczek et al., 2005] and other improvements of the








withGCV,has improved thedeliveryofGCVacross theBBBwithenhanced therapeutic
efficacy[LeMayetal.,1998]andseveralotherprodrugshavebeentriedwithHSVtk.GCV
elaidic acid ester is more lipophilic than GCV and is converted to GCV by nonspecific
hydrolysis[Denny,2003].PencicloviriscloselyrelatedtoGCVwithlowlipophilicitybutit
islessgenotoxicthanGCVmakingitasaferalternative[Thustetal.,2000].Valgancicloviris
an orally available prodrug ofGCV.Acyclovir (ACV) is chemically related toGCV but
more lipophilic and less genotoxic. It is less potent than GCV and also has a lower
bystandereffect[Denny,2003].Therelativelymorelipophilicvalacyclovirisavalineester
ofACVandisadministeredorally[Denny,2003].
Attempts have beenmade to enhance the bystander effect ofHSVtk by combining it
with connexin 43 [Marconi et al., 2000] and connexin 30,which are gapjunction protein




Treatmentwith retinoidshasalsobeenable to increase thegapjunctionsby inductionof
connexinexpressionandthisaugmentedtheefficiencyofGCVinHSVtktransducedcell
lines[Parketal.,1997].
Inhibition of polyamine biosynthesis by difluoromethylornithine (DFMO) has been









The inherent heterogeneity of MG poses a formidable challenge to singleagent
therapeutics toachievea successfuldiseasecontroland in this respectgene therapydoes
not seem to be an exception. Combination of different therapies makes it possible to
capitaliseonthemultitudeofgeneticweaknessesinMGsandthiscanpreventordelaythe
occurrenceof resistance toeach individual therapeuticagent.However,mostof theearly
workwithgenetherapyevaluateditsefficacyasasingleagent.Demonstratingtheefficacy
asasingleagent is importantasaproofofconceptbutcombinationstrategieshavetobe




to enhance the host immune system against the tumours. This is logical because cellular
antigens released by HSVtk/GCV therapy can help stimulate the host antitumour
immunity.HSVtk/GCVgenetherapyhasbeencombinedsafelywithIL2inclinicaltrials
butthetherapeuticefficacyisyettobeproven[Colomboetal.,2005].Inpreclinicalstudies,




HSVtk/GCV has also been successfully combined with other suicide gene therapy
strategiessuchasCD/5FC[Aghietal.,1998],uracilphosphoribosyltransferase (UPRT)/5
FU[Desaknaietal.,2003],andcytochromeP450/CPA[Aghietal.,1999],p53[Huangetal.,
2007],antiangiogenic endostatin gene therapy [Pulkkanen et al., 2002], oncolytic viruses




the cytotoxicity [Nishihara et al., 1997]. Synergistic effects were observed when HSV
tk/GCVwascombinedwithchemotherapeuticagentssuchashydroxyurea[Boucheretal.,
2000], gemcitabine [Boucher and Shewach, 2005], 5FU [Wildner et al., 1999a], topotican
[Wildner et al., 1999b] and TMZ [Rainov et al., 2001]. The study of Rainov et al.
demonstrated synergism between HSVtk/GCV and TMZ but failed to provide a clear
mechanismforthissynergism.ItwasspeculatedthatinhibitionofDNApol	bythesuicide
genetherapycouldbeonereasonforsynergism[Rainovetal.,2001].Thereisaccumulating






safety ofMG gene therapy but in terms of efficacy they were unsuccessful [Palu et al.,
1999], except for the occasional longterm survivors [Ram et al., 1997] [Klatzmann et al.,
1998].Themainreasonforthefailurehasbeenattributedtothepoortransductionefficacy
ofVPCs[Rametal.,1997][Sandmairetal.,2000a].Puumalainenetal.in1998demonstrated
a lowtransductionefficacy (0.014.0%)ofVPCs [Puumalainenetal.,1998].Thephase III
trialpublishedbyRainovetal. failedtodetectanysurvivalbenefitusingretrovirusVPC
mediatedHSVtk/GCVgenetherapyascomparedtostandardcare[Rainov,2000].












months [Trask et al., 2000]. Eck et al. (2002) reported amedian time to progression of 3
months andaMSof 10months inMGpatients treated in aphase I studywithAdHSV
tk/GCVanddemonstratedthesafetyoftheprocedure[Maattaetal.,2009].IntheirphaseI
study;Germanoetal.reportedanaveragesurvivalof58.9weeksafterAdHSVtk/GCVgene
therapy in recurrent MG patients with the majority of patients having unchanged
neurologicalperformancescores[Germanoetal.,2003].AmedianPFSof2.3monthsandan
OSof4monthswerereportedbySmittetal.inaphaseItrialinrecurrentMGpatientswith
AdHSVtk/GCV. Vector doses up to 4x1011 vp/ml were well tolerated by the recipients
[Smittetal.,2003].
In 2004, Immonen et al. first published aphaseIIb randomised controlled clinical trial





group,multicentre clinical trial (ASPECT study/Ark Study 904) ), where the efficacy of
AdHSVtk/GCV,Sitimagenecerodenovec (Cerepro®)wascomparedagainststandardcare
inoperableMG [vanPuttenet al., 2010].Final resultshavenotyetbeenpublishedbuta




angiogenic therapy section. Antiangiogenic gene therapy has the potential to overcome
some of the disadvantages of systemic therapy. Gene therapy based targeting of anti
angiogenic agents into the tumours circumvents the systemic toxicities, permitting
attainmentofahighconcentrationofthetherapeuticcompoundinthetumourvicinityover
a desired period of time [Dell
Eva et al., 2002]. Once started on, it has been questioned
whether antiangiogenic therapy can ever be stopped safely [Zuniga et al., 2010], with
evidencesuggestingthatitwouldhavetobecontinuedforalongperiodoftime[Kirschet
al., 2000] placing enormous economic strain on the health care systems. As a onetime
therapeutic application, gene therapy could be more economical when compared to
classical pharmaceuticals [Morishita, 2004]. Due to local administration, antiangiogenic
genetherapycanovercomenaturalbarriersforconventionaldrugdeliverysuchastheBBB.
Thelowtoxicprofileofgenetherapymakes itapotentialcandidatetobecombinedwith




haveso farbeen limited to thepreclinicalphase.Antiangiogenicgene therapyhasbeen














antisense VEGF constructs [Saleh et al., 1996] and VEGF siRNA delivery [Niola et al.,
2006],andbyexpressingadominantnegativeVEGFR1mutant [Heidenreichetal.,2004]
andVEGFR2 [Machein et al., 1999]. Intratumoral injection of a plasmidvector encoding
VEGF siRNAreduced the tumourvascularitybut failed to stop tumourgrowth in aMG
xenograftmodel.However, retrovirusmediatedstable transductionof the samecell lines
withVEGFsiRNAandIL4genecompletelypreventedthegrowthoftumours[Niolaetal.,
2006].MGcells transfectedwith adominantnegativeHIF1 and siRNAagainstHIF1
[Gillespie et al., 2007] reduced invivo tumour growth and proliferation but not the
microvessel density suggesting that mechanisms other than antiangiogenesis are
responsiblefortheeffects, inspiteofthereductioninVEGFsecretion[Jensenetal.,2006]
[Fujiwara et al., 2007]. Inhibition of FGF2/FGFR2 signalling pathway by dominant









dominant negative homo/heterodimerisation with transmembrane VEGF receptors
[Barleonetal.,1997][Kendalletal.,1996].
Human sVEGFR1 is synthesized by alternative splicing of the VEGFR1 mRNA
[Thomas, 1996]orbyproteolyticprocessingof the transmembraneVEGFR [Olssonet al.,
2006].TheresultingsVEGFR1istruncatedontheCterminalsideofthesixthextracellular
IgGlike domain and contains a unique 31amino acid Cterminal residue [Kendall and
Thomas,1993][Thomas,1996].ThesVEGFR1retainsitshighaffinitybinding(Kdof210
pM)abilitytoVEGF[Kendalletal.,1994],whichisoneorderofmagnitudehigherthanthe








form of sVEGFR1 with the firstsix Iglike domains fused to Fc portion of human IgG















The therapeutic benefits of sVEGFRs are attributed to the inhibition of tumour
angiogenesis, growth, metastasis, ascites formation, and increases in survival and
apoptosis.AAVmediateddeliveryofsVEGFR1/2fusionproteingene(sVEGFR1/R2)in
murine colon carcinoma and melanoma models lead to an increase in the number of
activated CD4+ and CD8+ tumour infiltrating effector Tcells and activated DCs, while
reducing the numbers of regulatory Tcells. On the other hand, tumours modified to
overexpressVEGFhadahighernumberofregulatoryTcellsinthelymphocytepopulation






2002], oncolytic adenovirus [Zhang et al., 2005] and vaccinia virus vectors [Guse et al.,
2010]. Expression of sVEGFR1 was detectable for up to three weeks after adenovirus
mediatedgenedeliveryintoskeletalmuscle[Takayamaetal.,2000].







primary and the liver metastasis but not the lung metastasis, which responded to
intratracheal vector administration. In the same model, intratumoral gene therapy
suppressedthetumourgrowthinasubcutaneousmodel[Kongetal.,1998].
Severalstudiesdemonstratedtoxicitieswithi.v.administrationofadenovirusmediated
sVEGFR1 [Mahasreshti et al., 2003] [Mahasreshti et al., 2001] [Kuo et al., 2001]. These
includehaemorrhageandfocalnecrosisof liver,congestion in lungs,spleenandkidneys,





agents like endostatin [Graepler et al., 2005] and angiostatinendostatin fusionprotein
(statin AE) [Ohlfest et al., 2005] have shown synergy with sVEGFR1. In two studies,
sVEGFR1wassuccessfullycombinedwithanoncolyticadenovirus[Zhangetal.,2005]and
oncolytic vaccinia virus [Guse et al., 2010]. Two studies reported success with the
combinationofsVEGFR2and3inanovariancancermodel[Sallinenetal.,2009][Sopoet
al., 2012], while another study successfully combined sVEGFR1, 3 and soluble Tie2
receptor in the same cancer model [Sallinen et al., 2011]. AAVmediated delivery of
sVEGFR1/2 fusion protein gene (sVEGFR1/R2) demonstrated significant antitumour
efficacy inamurinegliomamodel,but tumourprogressionwasseenlatersuggestingthe
presenceofescapemechanisms[Hardingetal.,2006].




mechanisms include reduced tumour growth, tumour volume, angiogenesis, ascites
formationandmetastasis.AdenovirusmediatedsVEGFR2genetherapywasfarsuperior
in inhibiting tumourgrowth as compared to angiostatin, endostatin andneuropilin gene
therapies[Kuoetal.,2001].However,addingadenovirusesexpressingsolublePDGFRor




angiogenicpathways isonlyneededwhenone isnotblockedadequately [Kuhnertetal.,
2008].CombinationofadenovirusmediatedsVEGFR1,2and3inamouseovariancancer
model resulted in reduced tumour growth, less  vascularity and lower ascites formation





Genetic delivery of endogenous inhibitors of angiogenesis and cytokines has been
commonlyusedtopotentiateantiangiogenicpathwaysincancergenetherapy.Endostatin
is a byproduct of type XVIII collagen that inhibits VEGF and bFGF. Nonviral gene
deliverymethods[Chenetal.,1999]andviralvectors[Subramanianetal.,2005b]havebeen
triedinthetreatmentofseveralcancermodels[Bjerkvigetal.,2003][Pulkkanenetal.,2002]
with endostatin. Increased animal survival and apoptosis of cancer cells, and decreased
tumour growth and angiogenesis were reported as the main antitumour effects of
endostatin. Inhibition of tumourmetastasis andvessel cooptionhas beenobservedwith
endostatintherapy[Yoonetal.,1999][Subramanianetal.,2005b].Theabilityofendostatin
toinhibittumourdisseminationisattributedtoaparaendothelialactionduetoitsbinding
to integrin 51 [Yokoyama et al., 2007]. However, endostatin was not as effective in
humanxenograftmodelsasitwasinmurinecancermodels[Jinetal.,2001].Adenovirus
mediated systemic administration achieved endostatin concentrations between 936ng/ml
[Sauteretal.,2000]and1.34g/ml[Wenetal.,2001].Serumendostatinlevelspeakedthree
daysafterintratumouralgenetherapybutdeclinedtoalmosthalfbyday7[Lietal.,2004].
The effect of i.v. adenovirus vector administration was lost after sometime due to the
impactofantiadenoviralantibodies [Jinetal.,2001].Adverseeffectssuchasweightloss,
bleedinganddeathofanimalswereseenwithhighdosei.v.administrationofadenovirus
vectors [Wen et al., 2001].On the other hand, single i.m. administration ofAAVvectors
achievedasustainedsecretionofendostatinuptonineweeks[Subramanianetal.,2005b].
Exvivo transduction demonstrated that therapeutic efficacy persisted even when the
percentageoftransducedcellswasonly25%[Yoonetal.,1999].Apossiblesynergisticeffect




and migration, inducing cell apoptosis.  Stable transduction of liver cancer cells with
angiostatingenesuppressedthetumourgrowth[Schmidtetal.,2006]inmurinemodelsbut
failedtoinhibittumourangiogenesis,implicatingthatmultifactorialeffectsofgenetherapy
can contribute to the antitumour effects [Schmidt et al., 2006]. However, intratumoural
genetherapywassuccessfulinaMGmodel[Maetal.,2002].




even superior to the combinations [Scappaticci et al., 2001]. The further addition of
paclitaxel [Isayeva et al., 2007] and adenovirus encoding a soluble form of Tie2 gene
therapy[Raikwaretal.,2005]enhancedtheefficacyinsomestudies[Kimetal.,2004].
Intramuscular delivery of plasmid DNA encoding vasostatin (Nterminal domain of
calreticulin)gene inhibited tumourangiogenesis andgrowth, and increased survival and
tumourcellapoptosisintumourbearingmice[Xiaoetal.,2002].
Several cytokine gene therapy strategies such as IFN [Persano et al., 2009], IFN















Oncolytic HSV 1716 [Harrow et al., 2004] and G207 [Markert et al., 2009], replication
competent adenovirus: delta24RGD [GomezManzano et al., 2004] and ONYX015
[Bischoff et al., 1996] [Chiocca et al., 2004], NDVHUJ (OV001) [Freeman et al., 2006],
recombinantpolio/rhinovirus,measlesvirus[Phuongetal.,2003],reovirus[Forsythetal.,
2008] and retroviruses [Wang et al., 2003] are currently under development. Oncolytic
virotherapy have been successfully combined with CDA/5FC [Conrad et al., 2005],





The objective of this therapeutic approach is to boost the host immune system to
eradicatethetumour.Likemostothermalignancies,gliomasareabletosuppressthehost
immune system by secreting immunosuppressive factors such as TGF  [Platten et al.,
2000]andIL10,andbydecreasedexpressionofMHCmoleculesandincreasedexpression
ofFasL[Waziri,2010].Thepaucityofantigenpresentingcellsinthebrainparenchyma,the
immunologically privileged state of the brain and general impairment of host immune
functionarealsobelievedtocontribute [HussainandHeimberger,2005].With theaimof
enhancing cellmediated immunity, both adoptive and active (vaccine) immunotherapy
strategies have been attempted on glioma, with varying successes [Barzon et al., 2006]
[Lawler et al., 2006]. Autologous tumour cells/fibroblasts geneticallymodified to secrete
cytokinesIL2[Soboletal.,1995],IL4[Okadaetal.,2007]andGMCSF[Parneyetal.,2006]
have achieved some success inpreclinicalwork.Geneticdeliveryof cytokinegenes into
thetumourshasbeenattemptedwithIL2[LichtorandGlick,2003],IL4[Benedettietal.,
2000],IL12[Renetal.,2003],IFN[Tsugawaetal.,2004],IFN[Chioccaetal.,2008],IFN







intracellular signallingpathways [Ohgaki andKleihues, 2005b].Correction/compensation
of thesegeneticdefects bydelivering thewildtypegenevia gene therapy seems tobe a
logicalapproachforcancertherapy[RaoandJames,2004].Severalstudiesthatattemptedto
correct nonfunctional p53 [Lang et al., 1999] and its downstreampathway [Wang et al.,
2001] have demonstrated multiple antitumour effects in preclinical MG models and
limitedeffects inclinical trials [Langetal.,2003]. Inaddition,p53genetherapyincreased
chemo and radiosensitivity in tumours [Dorigo et al., 1998] [Badie et al., 1998]. Gene
therapybasedtargetingofdefectsinRBandcellcyclesregulationpathwayshasconferred













factors, and cytokines [Rao, 2003]. The genetic delivery of PTEN and tissue inhibitor of
metalloproteinase(TIMP)[Luetal.,2004b][Bakeretal.,2000],pigmentepitheliumderived








bound death receptors/ligands such as Fas/FasL and Apo2L/TNFrelated apoptosis
inducing ligand (TRAIL), regulate the apoptoticpathways.Manygene therapy strategies
includingsuicidegenetherapy,cytokinegenetherapyandp53genetherapyhavebeenable
to induce apoptosis in the MG cells. Gene therapy with FasL [Frei et al., 1998], TRAIL
[Ehteshametal.,2002],proapoptoticBim[Yamaguchietal.,2003]andBax [Arafatetal.,





The myelotoxicity of the chemotherapeutic agents is a major doselimiting factor in
cancerchemotherapyandisacommoncauseforprematureterminationoftreatmentand







Chemotherapy and RT are still the major therapeutic arms in oncology. Any novel
therapyinclinicaltrialswillhavetobecomparedatsomepointwiththeseapproachesto
prove their potential efficacy. Hence, the impact of the novel therapy on the efficacy of
chemotherapy and RTwill determine the final outcome. Several gene therapy strategies
havebeenshowntoenhancethechemoandradiosensitivityofMGs invitroand invivo.
Recent work has highlighted the fact that oncolytic adenovirus vectors enhance the
sensitivitytoTMZbysuppressingMGMTexpression[Alonsoetal.,2007]andtoirinotecan
by increasing topoisomerase1 expression [GomezManzano et al., 2006]. Gene therapy
based inhibition of cellcycle regulators [Ruan et al., 1999], proapoptotic gene therapy
[Arafatetal.,2003],p53genetherapy[Dorigoetal.,1998][Badieetal.,1998],PTENgene
therapy [Lawler et al., 2006], dominantnegative EGFR gene therapy [Lammering et al.,









AEDs, well tolerated by patients [Wolff et al., 2008]. Multiple mechanisms have been
proposed for its antiepileptic actions [Loscher, 2002]. It is an orally available drugwith




VPAmediated modulation has been implicated in tumour angiogenesis,
immunogenicity,invasion,metastasis,differentiation,proliferationandapoptosis[Gotfryd
etal.,2010].WiththediscoveryofitsHDACiaction,VPAhasreceivedanewleaseoflifein
pharmaceutical research. The organisation of DNA into nucleosomes is undertaken by
histoneproteinsdependingontheiracetylationstatus,whichisregulatedbyhistoneacetyl
transferase (HAT) and histone deacetylase (HDAC). Acetylation opens the chromatin
increasinggeneexpression.HDACandHATactivityisdysregulatedinGBM[Marksetal.,
2001].VPAcanhyperacetylatehistonesH3andH4andinhibitHDACactivity[Phieletal.,
2001] [Krameretal., 2003]andfurthermore,HDACi inhibits tumourgrowth,evokescell
cyclearrestatG1/S[Yeowetal.,2006],aswellasincreasingdifferentiation[Benitezetal.,





such as phosphorylation of intracellular signalling proteins may contribute the VPA
mediatedactionsinacelltypespecificmanner[Gotfrydetal.,2010].
SomeprotumourmechanismsofVPAhavealsobeenproposed.HDACiinvolvingVPA
throughPI3K/AKT [Mayo et al., 2003] and/orPKCmediated [Kimet al., 2003]pathways
transcriptionally activateNFB,which inhibits druginduced apoptosis by upregulating
p21[Burgessetal.,2001].ThereissomeevidencetosuggestthatVPAcanincreasetheHR
repairfrequency[Defoortetal.,2006]andcancercellmotility[Gotfrydetal.,2010].Some





chemotherapy and RT [Yin et al., 2007] [Chinnaiyan et al., 2005] via stimulation of
autophagy[Fuetal.,2010]incancercells,possiblybyimpairingDSBprocessing[Robertet
al., 2011].However, other studies have failed to demonstrate any synergy betweenVPA
and chemotherapy [Stander et al., 1998].There is evidence thatVPA in spiteofbeingan
HDACi does not increase MGMT expression [Sasai et al., 2007]. A recent study
demonstrated that VPA could sensitise MG cells to TMZ and radiation, and more
importantly, VPA did not antagonise the cytotoxicity of TMZ [vanNifterik et al., 2012].
Another study claimed that redox regulation could be a possible mechanism for the
synergismbetweenTMZandVPA[Chenetal.,2011b].Increasedcytotoxicitywasobserved
whenVPAwas combinedwithdoxorubicin [Catalano et al., 2006], etoposide [Das et al.,
2007], cisplatin, gemcitabine and adriamycin [ChavezBlanco et al., 2006]. Evaluation of
datafromEORTC/NCICphaseIII trialhasrevealedthatpatientswhoreceivedbothVPA











expression after adenovirusmediated gene transfer [Kothari et al., 2010]. Some HDACi
have increased the bystander effect of HSVtk/GCV by increasing gapjunction
communication[Ammerpohletal.,2004][Robeetal.,2004]byincreasinglevelsofconnexin






Systemic adverse effects are one of themajor drawbacks encountered in cancer therapy.
They are commonwithbothRTand chemotherapy, andoften limit the therapeuticdose
and frequency. Sometimes adverse effects can even prevent the completion of treatment
courses, contributing to the unfavourable outcome of cancer patients. The main aim of
targetedcancertherapyistolimitthetreatmenteffecttothetumoursandtherebytoreduce
systemic adverse effects and increase the therapeutic window. Furthermore, it may be
possible to reduce the required drug dosage, volume and the amount of drugs in the
systemiccirculation[GoodwinandMeares,2001].
Targetingcanbeachievedbyeitherdirecttargetingorpretargetingmethods[Paganelli
et al., 1990]. Direct targeting is a singlestep process where the therapeutic payload is
directly linked to a targeting moiety, which could be a mAb, peptide antigen, growth
factor,orcytokinethatwouldhaveahigheraffinitytowardsthetumourduetoexpression
of a specific target such as cell surface receptors. mAbs labelled with iodine 131 (131I)
tositumomab (Bexxar, Corixa & GlaxoSmithKline) and yttrium 90 (90Y) labelled
ibritumomabtiuxetan(Zevalin,BiogenIDEC)directedagainstCD20antigenareexamples
ofdirecttargetedtherapiesapprovedforthetreatmentofnonHodgkin’slymphoma.Sofar
no targeted therapy has been approved for MG but radionuclidelabelled mAbs and
growthfactorlabelledtoxinsareunderclinicaldevelopment[Lietal.,2010][Kunwaretal.,
2010] [Hockaday et al., 2005]. The toxicities due to these agents gaining access to the
circulationarestillaproblemalthoughthatcanbeovercomebylocoregionalapplicationof




Pretargeting is a multistep process involving sequential administration of targeting
constructsandfinallythetargetedtherapeuticpayload[Goodwinetal.,1986].Pretargeting
can be achieved by using bispecific mAbs (bsmAb) that can bind to a tumour specific
antigen.ThesebsmAbshaveaspecificbindingsiteforhaptenboundtargetedtherapeutics,
streptavidin or avidin conjugated antibodies that can trap biotinylated therapeutics,
biotinylatedantibodiesthatcancomplexwiththerapeuticsboundtoavidinorstreptavidin,
as well as DNA/oligonucleotide sequence conjugated antibodies that can bind
oligonucleotidelabelled therapeutics or enzyme conjugated antibodies that can activate
prodrugs [Goldenberg et al., 2006]. ThemAbs have to bemodified so that they can be
cleared rapidly from the circulation before administration of the targeted therapeutic in
order to prevent its binding in the circulation.Due to their smaller size (~100kD), rapid
clearance,hightissuepermeationanddiffusion,bsmAbsaremoresuitableforthepurpose.
The binding affinity of bsmAbbased pretargeting is much less (109M) compared to
avidin/biotinbasedsystems (1015M) [Goldenbergetal., 2006].Thegreatestobstacle faced




tumours, and the development of antibodies/peptides that are specific for that target.
Unfortunately,mostofthetumourtargetsidentifiedsofarisnotuniquetotumours.
2.3.7.2Avidinbiotintechnology
Avidin is a 66 kD tetrameric glycoprotein in chicken eggwhite that can bind one biotin
moleculeintoeachofitsidenticalmonomerswithextremelyhighaffinityi.e.Kdvaluesof
10131015M [Green, 1990]. The bacterial analogue to avidin, streptavidin is derived from
Streptomyces avidinii and it is also a tetrameric protein of 60 kD with similar binding
characteristicstobiotin.Avidinandstreptavidinhavea~60%sequencehomology,similar
secondary,tertiaryandquaternarystructures[Argaranaetal.,1986],andarestableagainst
heat, pH, denaturants and enzymes [Wilchek et al., 2006]. In spite of the apparent
similaritiesbetweenthem,therearesomecrucialdifferencesthatgivethesetwomolecules
distinct pharmacokinetic and biodistribution patterns [Schechter et al., 1990]. Due to its
highlysineandargininecontent,avidinispositivelychargedwithanisoelectricpoint(iP)
of~10.5andisheavilyglycosylated,leadingtothepossibilityofnonspecificbindinginto
tissues, rapid clearance from circulation and accumulation in liver [Sakahara and Saga,
1999].Hence, avidin is frequentlyused as a clearing agent to removebiotinylatedmAbs
from the circulation. On the other hand, streptavidin has an iP of ~58 and is not
glycosylated, which reduces both nonspecific binding and increases its serum halflife
[SakaharaandSaga,1999].Therefore,streptavidinhasabetterpermeationintothetumour.
Deglycosylationandneutralisationincreasetheserumhalflifeofavidin,whilebindingto




made to improve the utility of these proteins by chemical and genetic modifications
[Laitinenetal.,2006].






affecting their affinity to avidin/streptavidin [Sakahara and Saga, 1999]. The presence of
high amounts of biotinidase in human serum can affect the stability of biotinylated
substances[SakaharaandSaga,1999].Biotincanberadiolabelledwith90yttrium(90Y)anda
wide variety of radionuclides using diethylenetriamaniepentaacitic acid (DTPA),
ethylinediaminetetraaciticacid(EDTA)or2(pnitrobenzyl)1,4,7,10tetraazylododecane
N,N’, N’’, N’’’tetraacitic acid (DOTA) [Sakahara and Saga, 1999]. DOTA is superior to
DTPA in its suitability for biotinylation for therapeuticpurposesdue to its high stability
[Chinoletal.,1997].Ithasainvitrohumanserumstabilityforupto96hwith~85%invivo
clearance within 24h [Urbano et al., 2007]. 90Y has physical halflife of 2.7 days (64h)




Avidin/biotinbasedpretargeting systemscan involve several steps in the targetingof
the therapeutic payload. In twostep pretargeting systems, a biotinylated mAb with
specificity toa tumourantigen isadministered first, followedby the therapeuticpayload
boundtoavidinasthesecondstepafterallowingsufficienttimetoclearunboundantibody
fromthecirculation[Paganellietal.,1992].Avidin/streptavidinandbiotincanbeused in
the reverse manner in this method. Biotinidases in the serum can cleave biotinylated





circulation by liver for avidin and kidney for streptavidin [Goldenberg et al., 2006]. In
threestep pretargeting, the biotinylated tumour specific mAb is administered first




targeting is first toadministeravidinor streptavidinconjugated tumourspecificmAb. In
the second step, a clearing agent to remove the unbound avidin/streptavidin mAb
conjugates from circulation is given, followed by the biotinylated therapeutic payload
[Shen et al., 2005]. By increasing the number of steps, one can reduce offtarget adverse
effects.Numberofclearancestepscanbeincorporatedintothethreesteptargetingmethod
tofurtherreducetheunwantedsystemiceffects.Inthefoursteppretargetingmethod,the
biotinylatedmAb step is followedbyadministrationof avidin. Streptavidinwhich isnot
glycosylatedandhasabettertissuepenetrationandalongerserumhalflifethanavidinis
administered before the biotinylated therapeutic payload with the aim to increase the
possible binding sites for the therapeutic agent. In a fivestep pretargeting method,
biotinylatedalbuminisadministeredbetweenstreptavidinandthetherapeuticpayload,in
order to saturate the unbound streptavidin in the circulation. It is essential to have an
adequate time inbetween administrations to clear the unbound mAb, avidin and
streptavidin. Pretargeting provides a highly specific tissue targeting that reduces the
adverse effects by lowering the amount of drug/radiation in the circulation and other
tissues, thereby increasing the therapeutic index,ultimately leading to improvedefficacy.
The disadvantages of avidin/biotinbased pretargeting are the larger size of the mAb
construct (170220kD)withpoordiffusionandtissuepermeation, the immunogenicityof
streptavidin, the binding of avidin to various other tissues and uptake of biotinylated
therapeutic payload by untargeted tissues due to biotinylation leading to toxicities
[Goldenberg et al., 2006]. Locoregional pretargeted radioimmunotherapy with
biotinylated 90Y in combinationwith chemotherapy has been evaluated inGBMpatients
[Granaetal.,2002][Boiardietal.,2005].
The extremely high affinity of avidin/streptavidin towards biotin forms the basis of





Avidinbiotin technology has been exploited in various gene therapy applications.
Firstly,thissystemhasshownpromisingresultsinovercomingthemajorobstacleofgene
therapy; thepoor transductionefficacyof currentvectors.Thus, the transductionefficacy
canbeincreasedbytargetinggenetherapyvectorsintothedesiredsite.Pioneeringstudies
used streptavidin to bridge antibody against retroviral envelope protein and antibody
againstcellsurfaceantigen[Rouxetal.,1989][EtienneJulanetal.,1992].Theprincipleof
present avidinbiotin based vector targeting is based on coating the vector surface with
either biotin or avidin/streptavidin by chemical or metabolic techniques. Chemical





























cell surface after local gene transfer using Semliki Forest virus vectors. The monomeric
version of the fusionproteinhas an affinity ofKd 2 x 108M for biotin.After local gene
transfer into orthotopic rat MGs using the same vector, the construct was capable of
binding locally and systemically (intraarterially) administered biotinylated molecules
[Lehtolainen et al., 2003]. This construct utilizes a twostep process for targeted therapy.
TheprincipleofLDLRavidinfusionproteingenetherapyispresentedinFigure10.

Figure 10: Principle of LDLR-avidin fusion protein gene therapy-based targeted therapy. LDLR-
avidin fusion protein is expressed on the cell surface after lentivirus-mediated local gene 
transfer. Systemically administered biotinylated yttrium binds to avidin with high affinity and is 
internalised. B-biotin, LDLR-low-density lipoprotein, 90Y-90yttrium 

A recent study demonstrated longterm expression of this fusionprotein gene after
lentivirusmediatedlocalgenetransferinanorthotopicratMGmodelanditsabilitytobind
biotinylated compounds invitro. The study also revealed the development of antibodies









2.4 ANIMAL MODELS FOR MALIGNANT GLIOMA STUDIES 
Experimental tumourmodels arevital for studying tumorigenesis, basic tumourbiology,
andtoevaluatenewpreventive,diagnosticandtherapeuticstrategiesforcancer[Workman
et al., 2010] [BulnesSesmaet al., 2006].Historically, tumourswere created in animalsby
administrationofchemicalcarcinogensorbyinfectingtheanimalswithoncogenicviruses.
Thesemethodsaretediousandhamperedbythelongwaitingtimes,unpredictabletumour
incidence, and the lack of reproducibility [Barth and Kaur, 2009], even though they do




the original animal strain; hence they do not evoke significant immune responses in the
host,havingsomeresemblancetotheusuallyimmunosuppressivehumantumours[Barth,
1998].Therearedrawbacksof thismethod, i.e. the tumourcellsareofnonhumanorigin
andthustheresultsobtainedcannotbedirectlyextrapolatedintohumancancersandthe
biological behaviour of these tumours may not exactly resemble those encountered in
human tumours.Moreover, since a largenumber of cells have to be injected to generate
tumoursbythismethod,fromapointofviewofhumantumorigenesis,theydonottotally
resemblethemalignancyprocessinhumans.However,syngeneictumourmodelsareeasy





this technique is that tumours are of human origin. However, the types of immune
deficiencies in theseanimalsdonotresemble those foundinhumanswithcancer.Hence,
these models are not suitable for the evaluation of the host immune response to the
growing tumours. Furthermore, due to the same reason, the growth kinetics,
vascularisation,invasivenessandmetastaticpatternsofthesetumoursmaynotcompletely
resembletheirhumancounterparts[Workmanetal.,2010][Candolfietal.,2007].Another
pointofconcern is that longtermpassagingof tumourcell linesmeans that thecell lines
will lose some of the original features and may acquire novel molecular genetic
characteristics [Workmanetal.,2010].Thiscanbeavoidedbyusing lowpassagenumber
cell lines.Anotherway to circumvent thisproblem is touse tumourcell lines from fresh
patient samples directly or after passaging in the relevant animal model a few times.
Tumoursthuscreatedtendtoresembletheoriginalhumantumoursfarmorethantheother









One can divide the experimental tumours on the basis of tumour location into two
groups. Orthotopic tumours are tumours located in the natural anatomical location, as
opposedtoheterotopictumourswhicharelocatedelsewherethanthenaturallocation,such
as subcutaneous tumours of internal organ malignancies. There is a growing body of
evidencesuggestingthatthemicroenvironmentofthetumoursplaysacriticalroleintheir





respond to therapies in the same way as their intracranial counterparts. However, the
subcutaneousxenografttumoursareconvenienttocreateandeasytofollowup.
Rats and mice are the most widely used species to create brain tumour models in
experimentalstudies [Petersonetal.,1994].Since themid1970s,severalratbrain tumour
modelshavebeendescribedandcharacterised[RamadanandWechsler,1975][Ishidaetal.,
1975].Apartfromtherodentmodels,cat,dog,rabbitandnonhumanprimatebraintumour










p53, neu/erbB2 andRaspathways, and thus resemblehumanMGs [BulnesSesma et al.,
2006].Thegeneralconsensusforwhichfeaturesavalidbraintumourmodelshouldcontain
areas follows;glial celloriginof the tumour,ability togrow invitro asacontinuouscell
line andpropagate invivo by serial transplantation,predictable and reproduciblegrowth
pattern,gliomalikecharacteristicswithinthebrain,sufficientsurvivaltimefortherapeutic
intervention, nonimmunogenic or weakly immunogenic in the syngeneic host,








BDIX rats with almost 100 % tumour take [Visted et al., 2000], and do not induce
immunological reactions in the host thus mimicking human gliomas [Laerum and
Rajewsky,1975][Laerumetal.,1977]andcontainamixtureofmultipolarglialikecellsand
flattened cells with fewer and shorter cytoplasmic processes and occasional giant cells
[Laerumetal.,1977].BT4CcellsproducehighamountsoftypeIVcollagenandfibronectin
and can have a high turnover of type I collagen depending on the growth conditions
[Bjerkvigetal.,1989].Moreover,thesetumoursarehighlycellularwithpleomorphicnuclei,
a sarcomatousgrowthpattern,possessingnumerousmitotic figures, scatteredgiant cells,
irregular and dilated blood vessels, areas of proliferation, a propensity for invasion into
surroundingnormalbrainparenchymaalongperivasculartracts,occasionalsatellitelesions
(tumour cell nests) in the brain parenchyma, neovascularisation, especially in the
periphery with frequent microhaemorrhages and occasional scattered necrosis. On the
other hand, the incidence of central necrosis is rare [Stuhr et al., 2007] [Barth andKaur,
2009].Onestudyhasshownthat98%of the tumoursdevelopedusingthismethod,were
neurogenic inorigin resemblingODGs, astrocytomas,mixedgliomas, anaplasticgliomas,




cells that were derived after repeated invivo passaging [Mella et al., 1990] form more











regression [Beutler et al., 1999]. C6 gliomas have mutant p16/CDKN2A/Ink4a locus but
wildtype p53 and overexpress PDGF, IGF1, EGFR and Erb3/Her3 genes [Barth and
Kaur,2009].Weaklyimmunogenic,F98(ATCC#CRL2397)gliomashaveaveryinfiltrative
growth patternwithmicrosatellites. These glioma cellswere created in a similarway as






immunogenic in the syngeneic host, the RG2 (D74) (ATCC#CRL2433) glioma model is





use for glioma studies. SMA497 and SMA560 glioma cell lines have been characterised
from an inbred VM/Dk mouse strain, which spontaneously developed astrocytomas
[Serano et al., 1980] and they have been used in preclinical gene therapy experiments.
GL26gliomasinC57BL/6micearesyngeneic[Candolfietal.,2007].Thegliomamodel4C8
isalsosyngeneicinB6D2F1mice,andhasbeenusedingliomastudies[Weineretal.,1999].
Glioma xenograft models produced by subcutaneous tumour cell implantation in
immunodeficientathymicornudemice,althoughwidelyusedinresearch,seemtodisplay
a significantanimal toanimalvariation in their tumourmorphology limiting theiruse in
research[Jonesetal.,1981].
2.5 ETHICAL CONSIDERATIONS IN CANCER GENE THERAPY  
Publicdiscussionsontheethicalissuesconcerninghumangenetherapystartedmanyyears
before the commencement of proper gene therapy clinical trials [Anderson and Fletcher,
1980], especially following the Cline experiment, where Cline and colleagues
unsuccessfully attempted to treat thalassaemia by reinfusing bonemarrow cells, invitro
transfected with the human globin gene [Friedmann, 1992]. Deliberate genetic
manipulationofthehumanbeingsevenfortherapeuticpurposesraisesdifficultethicaland
public policy problems i.e. trying to balance the improvement of care for some serious
medicalconditionsononehandwiththepossibleadverseimpactontheenvironmentand
human genome on the other [Anderson, 1998]. Continued public discussion, technical
advances and clarification of the ethical differences between somatic gene therapy and
germ line genetic modification paved the way for somatic gene therapy clinical trials
[Friedmann,1992].











al., 2005]. Preventive, diagnostic and therapeutic geneticmanipulation of somatic cells is
permitted based on these directives and laws, but germ line geneticmanipulation is not
allowed. Approval by the institutional and local ethical committees has to be obtained
before thecommencementofgene therapyclinical trialsandalso forpreclinical research
work. Gene therapy products have to be manufactured under “good manufacturing
practices” (GMP) conditions for human use. Another point of concern is the use of
genetically modified microorganisms as gene therapy vectors and the possible
consequencesofaccidentalreleaseofthesevectorsintotheenvironment.However,proper
risk assessments and implementation of appropriate risk reduction methods have
addressed this issue to a great extent. Another issue that needs to be addressed is the
discrepancybetweenthepotentialofgenetherapyandsocialexpectationsofgenetherapy.
Overenthusiastic interpretations of gene therapy successes may be contributing to this
difference in perception; raising the question of how critical should one be when
interpretinggenetherapysuccesses.
Gene therapy forbraincancer targets somatic tumourcellsanddoesnot involvegerm
line cells. By virtue of its action, all the cells that are transducedwith the new gene in
suicidegenetherapywillbeeliminatedbytheactivatedprodrugiftheyattempttodivide,
thuspreventingthepossibilityoftransmittingthetransgeneintosubsequentgenerations.
Thepossibilityof transducingunwantedcells, the riskof insertionalmutagenesiswith
theuseof integratingvectors, theriskofhavinginfectiverecombinanthelpervirusesand
thepossibleimmunereactionsagainstthevectorstrainsaresomeofthefactorslimitingthe
widespread use of human gene therapy that need to be addressed. The death of Jesse
Gelsinger due to a systemic inflammatory response, following an adenovirusmediated
genetherapyinaclinicaltrial[Raperetal.,2003][Lehrman,1999]andthedevelopmentof





















1. To evaluate the preclinical feasibility and efficacy of combining adenovirus
mediatedHSVtk/GCV suicide gene therapywith adenovirusmediated sVEGFR1
antiangiogenicgenetherapyforthetreatmentofmalignantglioma.

2. To unravel the underlying mechanisms of synergism when adenovirusmediated
HSVtk/GCV suicide gene therapy is combined with the chemotherapeutic agent,
TMZ, inMG therapy and todelineate theoptimal treatmentprotocol tomaximise
thesynergisticeffect.

3. To determine the effects of adding VPA to adenovirusmediated HSVtk/GCV
suicidegenetherapyandTMZcombinationinthetreatmentofmalignantglioma.

4. To evaluate the invivo efficacy of lentivirusmediated LDLRavidin fusion protein













All adenovirus vectors used were replication deficient, first generation E1E3 deleted,
derived from serotype 5 adenoviruses carrying either sVEGFR1 (15)Ig (AdsVEGFR1),
HSVtk (Gene Bank V00470) (AdHSVtk) or LacZ (AdLacZ) cDNA, driven by a CMV
promoter. The production of adenovirus vector encoding cDNA for the first five
immunoglobulinlike domains of human VEGFR1 fused inframe with the sequence
encodingforFcportionofhumanIgG(AdsVEGFR1)wasachievedbycloningtheVEGFR
1 (15)Ig expression cassette into the EcoRV site of pAdCMV plasmid [Bhardwaj et al.,
2005]. The functional titre of AdsVEGFR1 was 2.7 x 1010 pfu/ml. Adenoviruses were
manufactured in HEK293 cells [Graham et al., 1977] and purified by density gradient
centrifugation [Sandmairetal., 2000a] [Immonenetal., 2004].AdHSVtk (Cerepro®)was
suppliedbyArkTherapeuticsPLC.ThetitreofAdHSVtkvectorstockusedinthisstudy
was 1.5 x 1012 vp/ml. Adenovirus vector carrying the LacZ markergene used for gene
transfercontrolshadanOD260titerof3.1x1012vp/ml[Puumalainenetal.,1998].
LentivirusvectorsencodingforLDLRavidinfusiongene(Lodavin®,ArkTherapeutics
PLC) [Lehtolainen et al., 2003] were produced by cloning into a third generation self





Norway. HumanMG cell lines T98G (ATCC, CRL1690) and U87MG (ATCC, HTB14)
werepurchasedfromAmericanTypeCultureCollection(ATCC).AdherentMGcellswere
grown at 37 C in the presence of 5%CO2 in highglucoseDulbecco´smodified Eagle’s
medium(DMEM) (BT4CandU87MG)or  inminimumessentialmedium(MEM) (T98G),





mice were purchased from Taconic, Denmark. Animals were housed at the National
LaboratoryAnimalCentre,UniversityofEasternFinland’sSnellmaniaanimalfacilities.A
twelvehourperiodoflightperdaywithaconstanttemperatureof24°Cwasmaintainedat
the housing facility and food and water were provided ad libitum. Animals were
quarantinedfor5daysbeforeexperimentalprocedures.
4.1.4Pharmaceuticalcompounds
GCV (Cymevene® 500 mg, Roche, Finland) was diluted in 10 ml of distilled water for
injection to achieve a 50 mg/ml stock solution. TMZ (Temodar®/Temodal®, Schering
PloughMerck),100mgcapsulewasdissolvedin10%dimethylsulphoxide(DMSO)/0.9%
saline solutions daily before the injections. VPA solution (Deprakine 200mg/ml) was
purchasedfromSanofiWinthropIndustrieAmbarés,France.90Yttrium(90Y)waspurchased










Subconfluent BT4C cells were transduced with AdsVEGFR1 vector at multiplicity of
infection(MOI)0,0.1,1,5,10and25toassesstheeffectofthevectorandVEGFinhibition
ontheviabilityandproliferationofBT4Ccells.Cellviabilitywasmeasured24,48,72,96,
120 and 144h after transduction using an 3(4,5dimethylthiazol2yl)5(3
carboxymethoxyphenyl)2(4sulfophenyl)2Htetrazolium(MTS)assay(PromegaCellTiter
96® AQueous One Solution Cell Proliferation Assay kit) according to the manufacturer’s
instructions.Absorbancewasdetectedat490nmwithaMicroplatereader.
Todetermine the invitro synergybetweenAdHSVtk/GCVandTMZ, 2500BT4C cells



















orday14.CellviabilitywasmeasuredbyMTSassay4daysafter the last treatment.The
findings were confirmed by crystal violate staining done on 6well plates after plating
10000 BT4C cells per well and following the same protocol as used in the microscopic
examinationexcept thatTMZtherapywasgivenatdoses1,10and100mol/Londay9.




the fraction of cell survival after treatment with drug1 and drug2, respectively. The



















tk and/or AdsVEGFR1 at MOIs 0 and 25, was measured 1 week after transduction by
enzymelinked immunosorbant assays (ELISAs) specific for rat VEGF (R&D Systems,
Germany) and human sVEGFR1 (R&D Systems, Germany), according to the
manufacturer’s instructions.The conditionedmedia (CM)were collected after 24h serum
starvation and stored at 70°C until the ELISAs were performed. The objective was to





10 dilutions of the CM from BT4C cells transduced with AdsVEGFR1, AdHSVtk, the
combinationandthecontrolcellscollectedpreviously,withtheoptimisedgrowthmedium
providedbythemanufacturer.Digitalimagesof10xmagnificationwereobtainedusingan
inverted phase microscope on day 15. Tubular formations were quantified in a blinded
mannerusingCellFimagingsoftware(OlympusSoftImagingSolutions).
4.2.1.4Cellmigrationassays
The invasivenessofBT4Ccells, grown in 1:10 and1:1dilutionsof the fourCMcollected
before and serumfree media (SFM), or transduced 5 days before with MOI 5 of
AdsVEGFR1,AdHSVtkandthecombination(MOI5+5)growinginSFM,wasmeasured
using QCM™ 96Well Cell Invasion Assay (Millipore, Germany) according to the
manufacturer’s instructions.The invasionofnontransducedBT4Ccellsgrowing inSFM,
intoachambercontainingchemoattractant(mediawith10%FBS)wasthepositivecontrol,








days4and6.The first samples forRTPCRwere collectedonday5 (1dayafter starting
treatment)and the secondsamplesonday8 (5daysafter starting treatment).TotalRNA
wasextractedfromtreatedcellsbyTriReagent(Invitrogen)accordingtothemanufacturer
s
protocol, its purity was confirmed and concentration measured by spectrophotometer
(Nanorop ND1000). RNA was reverse transcribed to cDNA by MMuLV reverse
transcriptase(MBIFermentas).TargetgenemRNAlevelsweremeasuredbyrealtimePCR
(StepOnePlus RealTime PCR system, Applied Biosystems) using specific Taqman® gene






Cultured BT4C cellswere lysed and protein concentrationsmeasured by the BCA assay
(Thermo Scientific, Rockford, IL, USA). About 2030 g of total proteins were run on a
polyacrylamidegelelectrophoresisandtransferredontonitrocellulosemembrane.Blocked
blotswere incubatedwithaprimaryMGMTantibody (MT3.1SantaCruzBiotechnology)
followed by the corresponding secondary antibody (Biotinylated antimouse IgGHRP















Thepresenceof intracranial tumourswasverifiedonposttumour implantation (p.i.)day
12 or 13 in the adenovirus studies and on p.i. day 14 in the lentivirus study, by MRI.
Anaesthesiawasinducedwith5%isofluraneinamixtureof70%:30%N2O:O2,andwas
maintained at 1.5 % isoflurane. MRIs were conducted using a 4.7T small animal MRI
scanner (Magnex Scientific Ltd, Abington, UK) interfaced to a VarianUnity Inova (Palo
Alto,CA,USA)console.Noncontrastenhanced,T2weightedspinechosequencewithan
echo time of 0.08 seconds and repetition time of 2.5 seconds was used to generate 17
coronalimagesof1mmthicknesswithnogapbetweenslicestocoverthetumourareain
theratbrain.Imageswerefrom256x256matriceswithafieldofviewof4.0x4.0cm.Total
tumour volume was calculated by delineating the tumour area in all the image slices,
processedandanalysedwithMatlabversion7.1b (MathWorks Inc.USA)usingpremade
macros. FollowupMRIswere done for the adenovirusmediated studies on p.i. days 28
and42.
4.2.2.3Invivogenetransfers
Table 11 summarises the study protocol for the sVEGFR1study.On p.i. days 14 and 15
intratumoural gene transfers were conducted using the multiplesite vector injection
technique.Dependingon the studygroup (Table 11), 15lofAdHSVtk and/or 10lof





Tables 12 and 13 summarise the study protocol for AdHSVtk/GCV and TMZ, and
AdHSVtk/GCV with TMZ and VPA studies, respectively. All gene transfers were
conducted usingmultiplesite vector injection technique on p.i. days 14 and 15. A total











Table 11: Study Protocol for the AdHSV-tk/GCV and AdsVEGFR-1 Study 
Study Groups n 
Protocol (in days from tumour implantation) 
MRI Gene Transfer GCV 
Control-survival 13 13 - - 
AdsVEGFR-1-survival 9 13 14-15 - 
AdHSV-tk/GCV-survival 19 13 14-15 19-32 
Combination-survival 8 13 14-15 19-32 
Control-histology 7 13 - - 
AdsVEGFR-1-histology 4 13 14-15 - 
AdHSV-tk/GCV-histology 3 13 14-15 19-32 
Combination-histology 3 13 14-15 19-32 
n = number of animals 
 





Protocol (in days from tumour implantation) 
MRI Gene 
Transfer 
Gap GCV Gap TMZ 
AdLacZ 3 12 14-15 - - - - 
Control 9 12 - - - - - 
TMZ 10 12 - - - - 19-23 
AdHSV-tk/GCV 19 12 14-15 16-18 19-25 - - 
AdHSV-tk/GCV+TMZ (a) 11 12 14-15 16-18 19-25 26-29 30-34 
AdHSV-tk/GCV+TMZ (b) 7 13 14-15 - 16-22 - 23-27 
n = number of animals  
 





Protocol (in days from tumour implantation) 
MRI VPA Gene 
Transfers 
GCV VPA TMZ 
Control 11 12 - - - - - 
VPA 6 13 14-15 - - 19-32 - 
TMZ+VPA 7 13 14-15 - - 19-32 28-32 
AdHSV-tk/GCV 10 13 - 14-15 19-32 - - 
AdHSV-tk/GCV+VPA 10 13 14-15 14-15 19-32 19-32 - 
AdHSV-tk/GCV+TMZ 7 13 - 14-15 19-32 - 28-32 
AdHSV-tk/GCV+TMZ+VPA 9 13 14-15 14-15 19-32 19-32 28-32 
















(in days from tumour implantation) 
MRI Gene Transfers Bt-90Y-DOTA 
Control 8 14 - - 
Bt-90Y-DOTA 8 14 - 24-25 
Lenti-LDLR-avidin and Bt-90Y-DOTA 8 14 17-18 24-25 
Lenti-LDLR-avidin-histology 3 14 17-18 - 
n = number of animals 
4.2.2.4Pharmacologicaltherapy





asan i.p. injectiononceadayon5 consecutivedays.Thedoseand thedurationofTMZ
treatment were determined based on values in the literature [Friedman et al., 1995]
[Newlandsetal.,1997].ThetreatmentprotocolforVPAstudyissummarisedinTable13.
I.e. GCV and TMZ doses were as above. VPA (Deprakine 200mg/ml) was injected as
subcutaneous(sc)injectionsatadoseof200mg/kgtwiceadayfortheindicateddurations






the survival study for 50 days after tumour implantation. In the other three studies the
animals were followedup until the criteria for euthanasia were met. The animals were
observeddailyandbodyweightmeasuredregularly,andtheyweresacrificedwithCO2if




the whole brain were fixed in 4 % PFA at 4 C overnight and then changed into 15 %
sucrose solution having a pH of 7.4 at 4 C. Sampleswere processed and embedded in
paraffinblocks,andweresectionedinto5mthickslices.IntheAdHSVtk/GCVandTMZ
study theAdLacZ transducedanimalswere sacrificed 5days after gene transfer and the
brainsfrozeninisopentaneandstoredat70C.Frozenbrainswereembeddeddirectlyinto




Serum samples were collected from the animals after the completion of therapy from
sVEGFR1studyandAdHSVtk/GCVandTMZstudy,andanalysedforbilirubin,alkaline
phosphatase(AFOS),alanineaminotransferase(ALT)andcreatinineatKuopioUniversity
Hospital laboratory. In the AdHSVtk/GCV and TMZ study, blood samples were also
collectedforfullbloodcount(FBC)analyses.FromthesamesamplesCD3,CD4andCD8




leucocyte antibodies (APCMouse antiratCD3,PEMouse antiratCD4andFITCMouse
AntiRatCD8,BDBiosciences).
4.2.2.7Histologyandimmunohistochemistry
Randomly selected paraffin embedded tumour sections from the sVEGFR1 histology
animals were stained with haematoxylin and eosin for general tumour morphology.
Immunohistochemical stainings were done using antirat primary antibodies for CD34
(AF4117R&DSystems1/100),ratVEGF(ab1316AbCam1/200),humansVEGFR1(ab9540
AbCam1/100), CD68 (MCA341RAbDSerotec1/100), CD8 (MCA48RAbDSerotec1/50),
CD4 (MCA55RAbDSerotec1/50) and CD25 (MCA273RAbDSerotec1/50). Kidney, liver
and spleen samples were chosen as positive controls. Secondary antibodies were
biotinylatedhorseantimouseIgGorgoatantirabbitIgG(VectorLaboratories,Burlingame,
CA,USA).VectastainABCkit (VectorLaboratories) andDABPlus (ZymedLaboratories,
SanFrancisco,CA,USA)wereused to form the colourprecipitate.Counter stainingwas
donewithhaematoxylin(MerckKGaA).StainingsforapoptosisweredoneusingApoTag®
apoptosis detection kit (Chemicon International) according to the manufacturer’s







Brain sections fromLDLRavidin fusionproteingene therapy studywere stainedwith
goat antiavidin primary antibody (Vector Laboratories, Burlingame, CA, USA1/250) as
describedbefore[Lehtolainenetal.,2002a]inordertodeterminethetransgeneexpression.
4.2.2.8BT4Cratmalignantgliomanudemicestudy
In the experimentdesigned todetermine theduration of therapeutic efficacy ofAdHSV
tk/GCVandAdsVEGFR1genetherapycombinationinreducingtumourgrowthrate,male
BALB/cAnudemice(Taconic,Denmark)at46weeks(n=11)were injectedwith105BT4C









Resultswere analysedwithGraphPad PrismVersion 5.01 statistical software (GraphPad
Software Inc.USA).Survivaldata analysesweredoneusingKaplanMeier survivalplots














5.1 SUICIDE AND ANTI-ANGIOGENIC GENE THERAPY 
5.1.1ViabilityofBT4CcellsafterAdsVEGFR1genetransfer
TheresultsrevealthattransductionwithAdsVEGFR1didnotaffecttheviabilityorgrowth
patternofBT4Ccellsoverawide rangeofMOIs (0.125)up to6daysafter transduction
(Figure11).Maximumgeneexpressionbyadenovirusvectorswasachieved45daysafter
genetransfer.Hence,lackofgrowthinhibitionevenafter6daysindicatesthatthevectorat
theseMOIs was not toxic to the cells and the degree to which VEGF was inhibited by
sVEGFR1 did not affect the growth pattern of BT4C rat MG cells. Generally MGs are
considered highly vascular tumours with high VEGF expression [Plate et al., 1992].
PreviousworkinBT4CratMGmodelhasdescribedhighexpressionofVEGFbythesecells




Figure 11: Cell viability measured over time by absorbance at 490nm using an MTS assay after 
transducing BT4C cells with different MOIs (0, 0.1, 1, 5, 10 and 25) of AdsVEGFR-1 vector. 
AdsVEGFR-1 had no significant impact on the viability of BT4C cells within the range of MOIs 
tested. 
5.1.2ExpressionofsolubleVEGFR1aftergenetransfer
TransductionofBT4C cellswithAdsVEGFR1 alone and in combinationwithAdHSVtk
led to the production of human sVEGFR1 at almost equal concentrations of >700pg/ml.
Simultaneoustransductionbytwodifferentvectorsdidnothaveanysignificantimpacton
theproductionofthetransgeneconstruct.Thisinvitrodatasupportsthesimultaneousgene
transfermethodology applied in the invivo experiment to be effective in expressing the
transgeneconstructswithoutinterferingwitheachother(Figure12A).ItisknownthatMG
producehighamountsofsVEGFR1buttheVEGF/sVEGFR1ratioisincreasedtippingthe
balance towards an angiogenic phenotype [Plate et al., 1994] [Lamszus et al., 2003]. The
transgene construct used in the study was from the human sVEGFR1 and the ELISA





Figure 12: Transduction of BT4C cells simultaneously with 2 different vectors had no effect on 
the production of sVEGFR-1 since almost equal concentrations were produced by AdsVEGFR-1 
transduced cells and combination transduced cells (A). Secretion of VEGF and sVEGFR-1 by 
BT4C cells after gene transfer with AdHSV-tk, AdsVEGFR-1 or the combination of the two 
vectors. No significant impact on VEGF secretion by the gene transfers can be demonstrated 
(B). Error bars indicate standard error of the mean (SEM). 
5.1.3EffectofhumansVEGFR1onVEGFproduction
Inaccordancewiththeliterature[BarthandKaur,2009],BT4CratMGcellsproducedVEGF






used in this study is specific to the rat VEGF164 isoform. It was not clear whether this
antibodymaystilldetectsVEGFR1boundVEGF,whichcouldexplain thenonreduction
ofVEGF levels afterAdsVEGFR1gene therapy in spiteofproducing sVEGFR1.On the
otherhand,inMGs,VEGFexpressionfarexceedsthatofsVEGFR1[Lamszusetal.,2003].
Increasing the sVEGFR1 production in the tumours by gene therapy helps to shift this
balance in favour of antiangiogenesis, even though the VEGF levels are not reduced
remarkably.TheaffinityofthehumansVEGFR1towardsratVEGFdoesnotseemtobea














AdsVEGFR1 and the combination groups, were significantly (p<0.05) less than the
respectivecontrolgroups.RepresentativeimagesfromeachgrouparepresentedinFigure




suppressing VEGFmediated angiogenesis when transduced either on its own or in
combinationwithAdHSVtkintoBT4Ccells.

Figure 13: Quantifications of tubule formation assay under different CM, indicating the area 
covered by tubules (A), total tube length (B), total tubes (C) and total branch points (D). All the 
parameters demonstrate a similar trend towards lower values in the groups having sVEGFR-1. * 
= p value <0.05. ns = no statistical significance. Error bars are SEM. 
 
Figure 14: (A) Representative images of tubule formation assay from the control (A), 
AdsVEGFR-1 (B), AdHSV-tk (C) and the combination (D) groups are presented. Magnification 
10x. 
5.1.5TheeffectofgenetransferonBT4Ccellmigration
Evidence suggests that treatment ofMGswith antiangiogenic therapies can increase the






generally increased the invasiveness of BT4C cells in all groups. There was no obvious
differential increase among the groups or between any of the groups with the positive
controlgroup.Onepossibilityforthisobservationcouldbethegeneraldepletionofgrowth
factors and nutrients in the CM promoting the invasiveness of the cells towards the
chemoattractant.However,additionofAdsVEGFR1CM(1:10)significantlyincreasedthe
invasivenessascomparedtothenegativecontrolgroup(Figure15A).Priortransductionof






SFM towards the chemoattractant was diminished to the level of negative control by
diluting thechemoattractant1:1with theCMfromcontrol,AdsVEGFR1,AdHSVtkand
combinationgroups(Figure15D).Therewasnosignificantdifferentialsuppressionofthe
invasiveness among the groups confirming the previous findings that themigrationwas
beingaffectedmorebythegeneralisedlossofgrowthfactorsandnutrients.However,the
inhibition byAdHSVtk CMwas significant as compared to the positive control (Figure
15D).
The results point to a possible increase in the invasiveness of BT4C cells after
transductionwith adenovirus vectors or secondary to transgene expression by the cells.
However,theeffectoftheindividualtransgeneproductintheCMoncellmigrationcould
not be evaluated properly due to the potentially superior effect of growth factor and




Figure 15: Migration ability of BT4C cells cultured in SFM supplemented 10:1 (A) and 1:1 (B) 
with CM collected after transduction with AdHSV-tk, AdsVEGFR-1 or the combination compared 
to the CM from non-transduced cells. No differential increases in the invasiveness were 




control group. Transduction of BT4C cells with the two vectors or the vector combination 
increased the invasiveness of the cells with a statistically significant increase between the 
negative control and AdsVEGFR-1 group (C). Migration of BT4C cells towards the 
chemoattractant supplemented with 1:1 CM was impaired in general in all groups to the level of 
negative control (D). * = p value <0.05. Error bars are SEM. 
5.1.6Theimpactofgenetherapycombinationontumourvolume
Therewasno significantdifference inmean tumourvolumesbetween the groups before
starting treatment on 13d (data not shown).MRI on 28d p.i. revealed thatAdsVEGFR1
gene therapy had no effect in controlling tumour growth in this aggressive MGmodel
(Figure 16A). AdHSVtk/GCV and the combination groups displayed significantly lower
(p<0.001)mean tumourvolumescompared to controlandAdsVEGFR1onlygroups,but
notcomparedtoeachother,suggestingthattheadditionofAdsVEGFR1didnotconfera






combination groups were not significantly different (Figure 16B). It is surprising that
animals in the combination group lived significantly longer (data presented below)
compared to theAdHSVtk/GCVgroup that had a smallermean tumour volume onp.i.
42d. Similar results have been reported in the literature with the use of antiangiogenic
therapies[Jahnkeetal.,2009],highlightingthepossibilitythatindirectmechanismssuchas
reduction in peritumoural oedemamay be contributing to the therapeutic efficacy. This
study did not use MRI techniques to detect changes in tumour perfusion and oedema
whichwouldhavebeenusefulininterpretingtheresults.
Figure 16: Mean tumour volumes measured by MRI on p.i. 28d (A) and 42d (B). *** and ¤¤¤ 
denote significances (p<0.001) compared to control and AdsVEGFR-1 groups, respectively. No 
survivors in control and AdsVEGFR-1 groups by p.i. 42d. Error bars are SEM. 
5.1.7Theimpactofgenetherapycombinationonsurvival
AdsVEGFR1 alone was unable to improve the survival of tumour bearing rats (Figure
17A). In fact, compared to control group, theMSwas reduced by 13.5% in this group.
AdHSVtk/GCV increased the MS by ~11 % and by 28 % compared to control and
AdsVEGFR1groups,respectively.ThecombinationofAdHSVtk/GCVandAdsVEGFR1
wasabletoincreasetheMSby27%and~47%comparedtothecontrolandAdsVEGFR1




wasa~15%increase.Survival in thecombinationgroupwassignificantlybetter (p<0.01)
comparedtocontrol(hazardratio0.24(0.080.7))andAdsVEGFR1groups(hazardratio0.2
(0.060.68) (Figure 17D and E). These findings indicate a 76 % and 80% risk reduction,
respectively.However,inspiteofhavingabettertrendtowardssurvival,thedifferencedid
not reach statistical significance as compared to AdHSVtk/GCV group (Figure 17F).
AdHSVtk/GCVincreasedthesurvivalsignificantlycomparedtothecontrolgroup(Figure
17B) (p<0.05) butnot compared to theAdsVEGFR1group (Figure 17C). Furthermore, at
theprimaryendpointof50dp.i.,thecombinationgrouphad50%oftheanimalsstillalive
as opposed to 16 % in AdHSVtk/GCV group, further emphasising that combination is
superiortoAdHSVtk/GCValoneinenhancingsurvivalinthismodel.Neithercontrolnor
AdsVEGFR1groupshadanyanimalssurvivingatthistime(Table15).
Figure 17: Kaplan-Meier survival plots comparing the survival of the control group with 
AdsVEGFR-1 (A), AdHSV-tk/GCV (B) and the combination group (D), AdsVEGFR-1 group with 




combination group (F). Data was censored at the primary end-point (50d p.i.) and plotted on 
separate figures to improve the readability of the results. * and ** indicate p values <0.05 and 
<0.01, respectively. 














Control 13 37 - 15.6 0 
AdsVEGFR-1 9 32 13.5* - 0 
AdHSV-tk/GCV 19 41 10.5 28.1 16 
Combination 8 47 27.0 46.8 50 
n= number of animals, * percentage decrease from control 
 
Theoverall resultsof the invivoexperiments indicate that thecombinationofAdHSV
tk/GCV andAdsVEGFR1 is feasible in an orthotopic syngeneicMGmodel and that the
combinationachievesabettertherapeuticoutcomecomparedtotheindividualtherapy.In
spiteofhavinglargertumourvolumesatthelastimagingtheanimalsinthecombination
groupfaredbetter than those in theothergroups. In intracranial tumourmodelsanimals
oftenhave tobe sacrificeddue topoorphysicalwellbeingat leastpartlydue to elevated
ICP, obstruction of the ventricular system, peritumoural oedema and pressure effects.
Several clinical studies have demonstrated a reduction in the peritumoural oedema in
patientsafterantiangiogenictherapythatmayhavecontributedtothegeneralwellbeingof






displayany significantdifferencesamong thegroups (Figure18BandC).However,ALT




Figure 18: Serum clinical chemistry analyses of alanine aminotransferase (ALT) (A), alkaline 




indicated with horizontal lines and the error bars indicate SEM. ns = no significance. * = 
p<0.05, ¤¤ = p<0.01, and ¤¤¤ = p<0.001. 
 
TheALTlevelswerewithintheupperlimitsofnormalityintheAdHSVtk/GCVgroups.
Transient elevation of ALT levels has been reported with AdHSVtk/GCV suicide gene
therapy[Immonenetal.,2004](Figure18A).Therenalfunctiontest,serumcreatinine,was
within thenormal range inAdsVEGFR1andcombinationgroupsandbelow thenormal
rangeinthecontrolandAdHSVtk/GCVgroups.Thedifferencesweresignificant(p<0.05)
inAdsVEGFR1andcombinationgroupscomparedtoAdHSVtk/GCVgroup(Figure18D).
Previous studies have reported adverse effects such as liver and renal toxicities with
systemic administration of adenovirusmediated sVEGFR1 [Mahasreshti et al., 2003]
[Mahasreshti et al., 2001] [Kuo et al., 2001], but notwith local gene transfer.Our results
supportthefactthatAdsVEGFR1genetherapyissafewithlocalgenedelivery.
5.1.9Immunohistochemistry
Asexpected,human sVEGFR1expressionwas limited toAdsVEGFR1andcombination




CD34). The sVEGFR1 exerts its therapeutic effect mainly through inhibition of tumour
angiogenesissecondarytosequestrationofVEGF[Barleonetal.,1997][CebeSuarezetal.,
2006] [Kendall et al., 1996] [Thomas, 1996]. AdHSVtk/GCV can also kill dividing
endothelialcellsandhaveantiangiogenicproperties[Rametal.,1994][Floethetal.,2001].
Quantification of the angiogenesis confirmed that there was no difference in the mean
capillarynumber(Figure19A)anddensity(Figure19B)betweenthegroups.Inthisstudy,
contrary to the popular belief, inhibition of angiogenesis was not a major antitumour
mechanism. Even thoughMGs secrete high amounts of VEGF, several other angiogenic
mediatorshavebeendescribed,thatmaywellhavecontributedtothetumourangiogenesis
[Jain et al., 2007] [Fischer et al., 2005a] [Furnari et al., 2007]. Furthermore, several







Figure 19: Quantification of tumour angiogenesis from CD34 stainings. The mean capillary 
number (A) and the mean capillary density (B) did not show any significant difference among 






Figure 20: Immunohistochemical stainings for human sVEGFR-1, rat VEGF, angiogenesis by 
CD34, tumour infiltrating macrophages/microglia by CD68, tumour infiltrating cytotoxic T-
lymphocytes by CD8 and apoptosis by ApoTag® staining in control (A), AdsVEGFR-1 (B), 





an immune responseagainst thevirusvectors thatwouldevokeanantitumour immune
responseisapossibility.Thus,thetumoursectionswerestainedforCD68,CD8,CD4and
CD25expressingcellsbutnoexpressionofCD4orCD25wasobserved(datanotshown).




is amarker of theM2 phenotype [Murdoch et al., 2008]. However, recent evaluation of
humanMGsamples suggests thatCD68 is also expressedbybothmicroglia and tumour
cells.Furthermore,thehighCD68positivitywasassociatedwithahighermalignancygrade
and poor survival [Strojnik et al., 2009]. Multiple protumour mechanisms have been
attributed to TAMs [Naganuma et al., 1996] [Letterio and Roberts, 1998] [Watters et al.,
2005].Onclose inspection, it isclear thata specificareaaroundthegene transferneedle
trackinAdsVEGFR1andcombinationgroupswasdevoidofCD68+cells(Figure20,CD68;
BandD)asopposedtodiffuseuniformTAMinfiltrationinthecontrolandAdHSVtk/GCV






2009]. All groups had some CD8+ Tlymphocyte infiltration (Figure 20, CD8) and as
describedpreviously,theAdHSVtk/GCVtreatedgroupsseemtohaveahighernumberof
CD8+ cells (Figure 20, CD8; C and D) [PerezCruet et al., 1994] [Aguilar et al., 2011].




transfer (3 days after starting GCV) on p.i. 25d, when adenovirus vectormediated gene
expression was at its highest. Mean tumour volumes were significantly lower (p<0.05)
comparedto thecontrolsbetweenp.i.2832d(Figure21). In thetreatmentgroup, tumour






Figure 21: Comparison of mean tumour volumes of control and combination gene therapy 
groups at gene transfer (21d), during (23-28d) and after (30-39d) GCV therapy. * indicate 








al., 2005] [Harding et al., 2006] [Goldman et al., 1998]. The high vascularity of MGs
theoreticallymakesthemhighlyamenabletoantiangiogenictherapy.Withtheapprovalof
BV,antiangiogenictherapieshaveenteredtheMGtherapeuticarena.However,previously










and to examine the putative antitumour mechanisms in operation. One possible
mechanismfor thebetter therapeuticoutcomeof thiscombinationcouldbe the increased
GCVdelivery into the tumour due to vascular normalisation by antiangiogenic therapy
and the reduced peritumoural oedema and ICP improving the generalwellbeing of the
animals.However, the sVEGFR1gene therapydidnotdemonstrate any significant anti
angiogenic effects in spite of enhancing the efficacy of AdHSVtk/GCV suicide gene
therapy. The study was not intended to differentiate between whether there was no
inhibition of angiogenesis from the beginning or whether resistance mechanisms
subsequentlymaskedtheeffectlater.AsasingletherapyAdsVEGFR1didnotconferany




p.i. 1213d, itwasnot possible toundertake earlier commencement of the therapy.Early
treatmentbyantiangiogenictherapymayhaveledtoadifferentoutcome.Theunderlying
reasons for the better therapeutic effect needs further evaluation and the optimal
therapeutic protocol, which would maximise the beneficial effect, remains to be
determined. AdsVEGFR1 as an antiangiogenic agent has some advantages over the
currently approvedBV. Being a parenteral therapy, BVhas the disadvantage of evoking
systemicadverseeffects.Ontheotherhand,tumourdirectedAdsVEGFR1antiangiogenic
therapydoesnotcarrythisrisk.Furthermore,BVhasfailedtoconferanOSbenefittothe
MG patients [Gerstner and Batchelor, 2012], whereas the present findings suggest that
AdsVEGFR1 in combination with cytotoxic therapies may enhance survival. The major
limitation in combination gene therapy strategies, especially in the brain, is the limited
vector volume that can be injected into the tumours. The development of concentrated
vectorsandvectorsexpressingmultipletransgeneconstructscouldbeonewayforwardto
improvetherapeuticeffects.
5.2 SUICIDE GENE THERAPY AND TEMOZOLOMIDE STUDY 
5.2.1SynergismbetweenAdHSVtk/GCVandTMZinBT4Ccells
The cytotoxicity was markedly enhanced when AdHSVtk/GCV was simultaneously
combined with TMZ in BT4C cells (Figure 22). TMZ alone, even at therapeutic plasma
concentrationsof100mol/L[Ostermannetal.,2004],wasnotveryefficientinkillingBT4C




AdHSVtk/GCV. However, at 100 mol/L TMZ shows a clear dose response with
increasingMOIsofAdHSVtk/GCV.Thecellviabilityinthisgroupwaslessthanthatofthe
correspondingAdHSVtk/GCVonlygroups,indicatingapossiblesynergisticoranadditive
effectof thecombination. Interestingly,TMZat10mol/L. in combinationwithAdHSV
tk/GCVatMOI10,showedmuchbettercytotoxicitythanthe100mol/Lconcentrationof
TMZ on its own. The results confirm the hypothesis that, the therapeutic efficacy is
markedlyenhancedbysimultaneouslycombiningAdHSV/tk/GCVwithTMZ.Theability




mol/L TMZ demonstrated a marked synergistic cytotoxic effect with all 3 MOIs of
AdHSVtk/GCV. This finding is important because TMZ is the standard care of
chemotherapy for GBM and AdHSVtk/GCV is under clinical evaluation for the same
condition.

Figure 22: BT4C cell viability after combining MOIs 1, 5 and 10 of AdHSV-tk and 1 μg/ml GCV 
with 10 and 100 μmol/L of TMZ. The triplicate values were normalized to the average of 
untreated cells. The significances compared to MOI 0, MOI 1 and MOI 5 are indicated in *, ¤ 
and #, respectively. P values <0.05, <0.01 and <0.001 are indicated as */¤/#, **/¤¤/## and 
***/¤¤¤/###, respectively. The viability of BT4C cells was significantly reduced by adding TMZ 
to AdHSV-tk/GCV, even at a low concentration of 10 μmol/L. Error bars indicate SEM. 
Table 16: Evaluation of the synergism between simultaneous combination of AdHSV-tk/GCV and 
TMZ in BT4C cells by fractional product method of Webb 
Viability with  
AdHSV-tk/GCV 
Viability with TMZ Predicted  
viability 
Observed viability  
MOI 1 Dose 2 12 Combination 12 
1 0.924 10 0.944 0.872 MOI-1+10 0.894 
1 0.924 100 0.721 0.666 MOI-1+100 0.577 
5 0.830 10 0.944 0.783 MOI-5+10 0.865 
5 0.830 100 0.721 0.599 MOI-5+100 0.449 
10 0.599 10 0.944 0.565 MOI-10+10 0.543 
10 0.599 100 0,721 0.432 MOI-10+100 0.252 






the MGMT nonexpressing cell line U87MG [Blough et al., 2011] were evaluated. The
expression ofMGMTbyMG confers a primary resistance tomethylating agents such as




in this interaction (Table 18). The TMZ dose of 100 mol/L was chosen because it is a
physiologicallyachievabledose[Ostermannetal.,2004]thathadshownsynergyinBT4C
cells.Previousworkhas shown thatT98Gcells arenotvery sensitive toAdHSVtk/GCV




Results frommicroscopic examination of T98G andU87MG cells 4 days after the last
treatment are shown in Figure 24. The results highlight the lack of efficacy of TMZ in




Figure 23: T98G (A) and U87MG (B) cell viability measured by luminescence assay after 
combining MOIs 5 and 20 of AdHSV-tk/GCV and GCV at doses of 1 or 10μg/ml with 100 μmol/L 
of TMZ. The triplicate values were normalized to the average of untreated cells. Significances 
compared to the control, MOI5-GCV1 and MOI5-GCV10 groups are indicated by */***, 
¤/¤¤/¤¤¤ and #/##, respectively.  P values <0.05, <0.01 and <0.001 are indicated as */¤/#, 
**/¤¤/## and ***/¤¤¤/###, respectively. Error bars are SEM. 
 
Table 17: Evaluation of the synergism between simultaneous administration of AdHSV-tk/GCV 
and TMZ in MGMT positive T98G human MG cells 
Viability with 
AdHSV-tk/GCV 





MOI/GCV 1 Dose 2* 12 Combination 12 
MOI-5/GCV-1 1.073 100 1.129 1.211 MOI-5/GCV-1+TMZ 1.312 
MOI-5/GCV-10 0.995 100 1.129 1.124 MOI-5/GCV-10+TMZ 1.154 
MOI-20/GCV-1 0.771 100 1.129 0.871 MOI-20/GCV-1+TMZ 0.908 
MOI-20/GCV-10 0.664 100 1.129 0.750 MOI-20/GCV-10+TMZ 0.775 





Table 18: Evaluation of the synergism between simultaneous administration of AdHSV-tk/GCV 
and TMZ in MGMT negative U87MG human MG cells 
Viability with  
AdHSV-tk/GCV 





MOI/GCV 1 Dose 2 12 Combination 12 
MOI-5/GCV-1 0.211 100 0.753 0.159 MOI-5/GCV-1+TMZ 0.117 
MOI-5/GCV-10 0.072 100 0.753 0.053 MOI-5/GCV-10+TMZ 0.038 
MOI-20/GCV-1 0.247 100 0.753 0.186 MOI-20/GCV-1+TMZ 0.189 
MOI-20/GCV-10 0.033 100 0.753 0.025 MOI-20/GCV-10+TMZ 0.015 
GCV doses of 1 and 10 μg/ml with TMZ dose of 100 μmol/L. Points of synergism are shown in bold. 

Figure 24: Microscopic examination of U87MG and T98G cells on day 10, after being transduced 








MGMT negativeMG cells demonstratedmarked synergismwhen treated with AdHSV
tk/GCV and TMZ. Expression of MGMT byMG cells confers primary resistance to the
alkylatingchemotherapeuticagentssuchasTMZ[Kainaetal.,2007].TheMGMTstatusof
BT4C cells was evaluated by Western blot and RTPCR but no protein or RNA
amplificationwas observed, respectively (data not shown), in spite of the cell line being






after starting GCV therapy. When administered alone, TMZ evoked only a marginal
cytotoxicity in BT4C cells at 100 mol/L dose, whereas 10 mol/L dose was totally
ineffective (Figure 25A and Table 19).However, both doses of TMZ induced synergistic
cytotoxicity with increasingMOIs of AdHSVtk/GCVwhen added 5 days after the first
dose ofGCV (Table 19), even though TMZ alone caused only amarginal cytotoxicity in
BT4C cells. When TMZ was added 10 days after starting GCV, it was still able to







20). These findings indicates that the synergistic effect can still be achieved by
administering TMZ even 10 days after starting GCV therapy. However, the synergism
observedbetweenAdHSVtk/GCVandTMZisprotocoldependentandmayevenbelostif
administrationofTMZisdelayedfortoolong.
The crystal violet stainings, which were done with the same experimental protocol,
whereTMZwasadded5daysafterstartingAdHSVtk/GCV,confirmsthattherehadbeen
a profound synergistic effect between these two combinations with even a 5 day gap
between the therapies (Figure26).TMZat100mol/Lhadamarginal cytotoxiceffecton
BT4Ccells,whereasAdHSVtk/GCVwasmuchmoreefficientinkillingthecells.

Figure 25: BT4C cell viability after combining with 10 or 100 μmol/L of TMZ at 5 (A) and 10 
days (B) after starting GCV at 1 μg/ml following transduction with AdHSV-tk at MOIs 30, 50 and 
75. The triplicate values were normalized to the average of untreated cells. All MOIs had *** 
significance (p<0.001) compared to the controls. Significances compared to the control and 
MOI30-GCV groups are indicated by *** and ¤/¤¤/¤¤¤, respectively. P values <0.05, <0.01 and 
<0.001 are indicated as */¤, **/¤¤ and ***/¤¤¤, respectively. Error bars are SEM. 
 




Viability with TMZ Predicted 
viability 
Observed viability 
MOI 1 Dose 2 12 Combination 12 
30 0.325 10 1.038* 0.337 MO1-30+10 0.258 
30 0.325 100 0.950 0.309 MOI-30+100 0.224 
50 0.154 10 1.038* 0.160 MOI-50+10 0.127 
50 0.154 100 0.950 0.147 MOI-50+100 0.119 
75 0.124 10 1.038* 0.128 MOI-75+10 0.098 
75 0.124 100 0.950 0.117 MOI-75+100 0.097 
Points of synergism are indicated in bold. * The fractional survival with TMZ 10 μmol/L alone is more than 








Viability with TMZ Predicted 
viability 
Observed viability 
MOI 1 Dose 2 12 Combination 12 
30 0.160 10 1.064* 0.170 MO1-30+10 0.152 
30 0.160 100 1.012* 0.162 MOI-30+100 0.154 
50 0.117 10 1.064* 0.125 MOI-50+10 0.117 
50 0.117 100 1.012* 0.119 MOI-50+100 0.115 
75 0.150 10 1.064* 0.160 MOI-75+10 0.115 
75 0.150 100 1.012* 0.152 MOI-75+100 0.137 
Points of synergism are indicated in bold. * The fractional survival with TMZ alone is more than one 
indicating lack of cytotoxicity. 

Figure 26: The crystal violet staining conducted 4 days after TMZ therapy of BT4C cells treated 
with AdHSV-tk (MOI 5)/GCV (1 μg/ml) on day 4 and 6 and TMZ (1, 10 and 100 μmol/L) on day 
9.  
 
Previous work by Rainov et al. has detected invitro synergism between these two
therapies when they are combined simultaneously [Rainov et al., 2001]. This study
demonstrated that the synergism between AdHSVtk/GCV and TMZ was protocol
dependentandmostlikelytobelostiftheTMZadministrationweretobedelayedbeyond
10daysafterGCVtherapy.Thissuggeststherecouldbeaspecifictherapeuticwindowfor
the synergism between these two therapies. What was even more interesting was that
treatment with AdHSVtk/GCV sensitised both human and rat MG cells to TMZ in a
MGMT status and protocoldependentmanner. The use of fractional productmethod to
evaluate synergism is validonly inpure,mutuallynonexclusive conditions,whendose
effectrelationshipsareoffirstorderkinetics.Inotherwords,synergismcalculatedbythis
methodmaynot be consistentwith the classical isobologrammethod, since it only takes







The mechanism behind the synergistic effects of TMZ and AdHSVtk/GCV was further














Figure 27: Relative mRNA expression of MLH1 (A) and MSH2 (B) MMR proteins by BT4C cells 
measured by RT-PCR. *** indicates a significant (p<0.001) increase compared to the control 








notbeen reportedbefore.This is the first reportofupregulationofMMRpathwaygene
expression after AdHSVtk/GCV therapy and is being proposed as the mechanism by
which AdHSVtk/GCV enhances the cytotoxicity of TMZ administered within the
therapeuticwindow.ThestudybyRainovetal.demonstratedasynergismbetweenHSV





theMMR pathway upregulation, which occurs a few days after starting GCV therapy.
AdHSVtk/GCVmediatedenhancementof thecytotoxicityofTMZisuniquebecausethis
enhancement is limited to the tumour, where the gene therapy is effective. Hence,
theoretically this would not increase the adverse effects of TMZ, and in this way could




gene therapy can enhance theMMR pathways is intriguing and may have farreaching
consequences. Apart from TMZ, MMR dysfunction is associated with an increased
resistancetothemanycytotoxicagentse.g.DNAmonofunctionalalkylatingagents,suchas
procarbazine and dacarbazine, [Branch et al., 1993] [Koi et al., 1994] [Goldmacher et al.,
1986][Cejkaetal.,2003],platinumanaloguescisplatinandcarboplatin[Papoulietal.,2004]
[Branchetal.,2000],antimetabolites,suchas6TG[Aquilinaetal.,1989][Swannetal.,1996]
[Aquilina et al., 1993] and 6MCP, and fluoropyrimidines 5FU and fluorodeoxyuridine
[Kinsella, 2009]. Whether AdHSVtk/GCV can enhance the cytotoxicity of these
chemotherapeutics needs to be fully evaluated. Furthermore, loss of MMR function has








therapy leads to repair of the DNA damage evoked by suicide gene therapy. The
incorporationofGCVtriphosphate intoDNAisknowntocauseGCtoTAtransversions,
errors inDNAreplicationandanincreasedmutationfrequencythatcancontributetothe
activation of theMMRpathway. It is alsopossible that thegenerationofGCVTP,which
competes with dGTP for the incorporation into DNA, could lead to misincorporations
resulting in the activation of the MMR pathway [Martomo and Mathews, 2002;Kunz,
1982;Bebeneketal.,1992].
5.2.5Theeffectoftherapycombinationontumourvolume
Next itwasdecided todeterminewhether itwouldbepossible toextrapolate the invitro
resultsintoaninvivoexperimentalMGsituation.Theotheraimofthestudywastomimic
the treatment protocol in the phase III clinical trialswhere TMZ had been administered
afteravariablegapaftercompletingGCVtherapy(PressreleasebyArkTherapeuticsPLC
18/12/2009).OrthotopicBT4CratMGs in immunocompetentBDIXratswaschosenas the
animalmodel due to previous experience [Tyynela et al., 2002]. The LacZ gene transfer
using the same technique demonstrated transduction of the tumours by the adenovirus
vectors (datanot shown).TheMSofuntreated animals in thismodel is around35days.
MRIconfirmationofthetumourpresenceispossibleonlyaroundp.i.day12or13.Hence,





The therapeutic efficacy was determined noninvasively by MRI by calculating the




(Figure 28A), confirming theuniformity of the findings.On theotherhand, combination
groupBthathadcompletedbothGCVandTMZtherapies,hadasignificantlylowermean
tumour volume as compared to control (p<0.001), TMZ (p<0.001) and AdHSVtk/GCV
(p<0.05) groups (Figure 28A). Combination groupA had a significantly (p<0.05) lower
meantumourvolumecomparedtocontrolandTMZgroups(Figure28A).Thedifference
betweenthecombinationgroupsAandBdidnotreachstatisticalsignificanceinspiteofthe







Table 21: The mean tumour volumes on days 28 and 42 after tumour implantation 
 
MRI 
Mean Tumour Volumes (mm3)+/- SEM for the study groups 
Control TMZ AdHSV-tk/GCV Combination-A Combination-B 
Day 28 102.3 +/- 17.9 107.2 +/-10.6 66.5 +/- 11.4 44.6 +/- 10.2 8.3 +/- 1.8 
Day 42 428.0 +/- 180.7 370.0* 294.5 +/- 59.2 120.4 +/- 37.6 8.5 +/- 0.7 
* Only one surviving animal 

Figure 28: Mean tumour volumes measured by MRI on p.i. 28d (A) and 42d (B). By day 28 
combination group-B had a significantly lower mean tumour volume compared to the control 
*** (p<0.001), TMZ ¤¤¤ (p<0.001) and AdHSV-tk/GCV * (p<0.05) groups. Combination 
group-A had a significantly (p<0.05) lower mean tumour volume as compared to the control (*) 
and TMZ (¤) groups (A). Still at day 42 the mean tumour volumes of the combination groups-A 
(*) (p<0.05) and -B (**) (p<0.01) were significantly lower compared to the AdHSV-tk/GCV 
group (B). Error bars are SEM. 
 
Themean tumour volumes in the control group increased >30 fold between first and
secondMRIsand inTMZgroup the increasewas>15 fold.During the sameperiod, the
meantumourvolumesofbothAdHSVtk/GCVgroupandcombinationAgroupincreased
>8fold.However,incombinationBgroup,whichcompletedbothGCVandTMZtherapies
during this period, the increase in mean tumour volume was only 79% (i.e. <1 fold).
BetweenthesecondandthirdMRIs,themeantumourvolumeincreaseinthisgroupwas
less than 2 %, suggesting that this protocol was able to maintain stable disease for a
prolonged period. The efficacy of AdHSVtk/GCV group cannot be compared to the
previousstudiesduetotheshorterdurationofGCVtherapy.Theresultssuggestaninvivo




data in Table 22. A significant survival enhancement was seen in the combinationA
(p<0.01)andcombinationB(p<0.001)groupsascomparedtothecontrol(Figure29CandD)
and TMZ alone (Figure 29F and G) groups. CombinationB also achieved a significant
survivalbenefit(p<0.05)comparedtotheAdHSVtk/GCVgroup(Figure29J).Noneofthe
othercomparisonsreachedstatisticalsignificance.NeitherTMZnorAdHSVtk/GCValone
was able to enhance survival compared to controls. In spite of having a better trend for





Figure 29: Kaplan-Meier survival plots comparing the control group with TMZ (A), AdHSV-




combination-A (F) and combination-B (G), AdHSV-tk/GCV group with combination-A (H) and 
combination-B (J), and combination-A with combination-B (K). The results are shown in 
separate graphs to improve readability. P values <0.05, <0.01 and <0.001 are indicated by *, 
** and *** respectively.  
 




Control TMZ AdHSV-tk/GCV Combination-A Combination-B 
Median 35 36 35 42 52 
Mean+/-SEM 35.4+/-2.4 35+/-1.5 37.8+/-2.4 44.7+/-2.9 54.6+/-4.5 
AdHSV-tk/GCV-adenovirus-mediated herpes simplex virus thymidine kinase and ganciclovir, SEM-standard 




groups, respectively. In spite of the combinationB group having aMSmore than 20%
comparedtothecombinationAgroup,thedifferencedidnotreachstatisticalsignificance.
However, theresultsonceagainconfirmthe findingsof the tumourvolumesand invitro






inallgroups (Figure30).Allgroups that receivedTMZhad leukocytopenia (Figure30A)
and thrombocytopenia (Figure 30B). In the combinationB group, the values seem to be
smaller compared to combinationA group, even though not statistically significant.
Interestingly,AdHSVtk/GCV therapy alonedid not show this adverse effect. Red blood
cell (RBC) and haemoglobin counts were within normal limits in all groups (data not
shown). The FACS analysis (Figure 31) of the Tcell populations for CD3 (general T
lymphocyte marker), CD4 (Thelper cell marker) and CD8 (cytotoxic Tcell marker)
revealeda significant (p<0.05) reduction in thenumberofCD3+cells in theTMZ treated
group(Figure31A).AdHSVtk/GCValonedidnotexertthisadverseeffect.TheCD4:CD3




Figure 30: The white blood cell counts (WBC) (A) and platelet counts (B) after treatment in 
each group. Significances compared to control and AdHSV-tk/GCV groups are indicated by */** 




All groups that received TMZ had lower values compared to those that did not receive TMZ. 
Error bars are SEM. 

Figure 31: The proportion of CD3+ cells out of the lymphocyte cell population (A), CD4:CD3 
population ratio (B) and CD8:CD3 population ratio (C) in different treatment groups. 
Significances compared to the control and AdHSV-tk/GCV groups are indicated by */** and 
¤/¤¤, respectively. P values <0.05 and 0.01 are indicated by */¤ and **/¤¤, respectively. Error 
bars are SEM. 
 
Figure 32: Serum clinical chemistry analyses for bilirubin (A), ALT (B), AFOS (C) and creatinine 
(D). Significances compared to the control and AdHSV-tk/GCV groups are indicated by * and 





group.However, someof thesevalueswerebelowthenormal limits for rats.A transient







benecessary toobtaina trueperspectiveof themyelotoxicitieswhenadministeringTMZ
andGCVsimultaneouslyorclosetoeachother.






adosedependentmanner.Thedifferences in theBT4Ccellviabilityof thecontrolgroup
(GCVTMZ),whencomparedtoGCVTMZ+andGCV+TMZ+groupsinallVPAdosesin
bothnontransducedandtransducedcells,andcomparedtoGCV+TMZgroupinVPA0.5
and1mmoldoses in transduced cells,were statistically significant (p<0.05) (Figure 33B).
The combination of TMZ with GCV in nontransduced cells did not increase the
cytotoxicity further (Figure33A), suggesting that the synergistic effectwasdependenton
both AdHSVtk and GCV. The VPA dose between 0.5 and 1.0 mmol is close to the
therapeutically achievable doses when VPA is used as an AED [Chen et al., 2011b]
[Catalano et al., 2006]where the therapeutic enhancementsweremore pronounced. The
enhancement of the cytotoxicity of AdHSVtk/GCV and AdHSVtk/GCV and TMZ
combination by VPA was more marked than the enhancement in TMZ (Figure 33B).
PossiblemechanismsforthebetterefficacycouldbetheVPAmediatedincreaseintheCAR
receptor expression and enhanced adenovirusmediated gene expression, as reported
before[Goldsmithetal.,2007][Kotharietal.,2010].InadditionitisreportedthatVPAcan
also increase thebystandereffectofHSVtk/GCVtherapyby increasingtheexpressionof
gapjunctions[Ammerpohletal.,2004][Robeetal.,2004][Asklundetal.,2004].

Figure 33: Viability of BT4C cells non-transduced (A) and transduced with AdHSV-tk (B) with 
GCV and TMZ at different VPA concentrations. The triplicate values were normalized to the 
average of untreated cells. Significances compared to the GCV-TMZ- group are indicated by 
*/**/***. P values <0.05, <0.01 and <0.001 are indicated by *, ** and ***, respectively. 






Invivo evaluation of the impact of addition of VPA into AdHSVtk/GCV and TMZ
combinationintheBT4CratMGmodelfailedtodemonstrateanyreductioninthetumour
growth rate (Figure 34). VPA failed to reduce the tumour growth rate alone or in
combinationwithTMZ,AdHSVtk/GCVorAdHSVtk/GCV+TMZ.Byday28(Figure34A)
noneoftheAdHSVtk/GCVandTMZcombinationgroupshadreceivedTMZyet.Hence,
the impact on the tumour volumes is purely due to AdHSVtk/GCV. There were no
significant differences in the mean tumour volumes among these groups, again
emphasising theuniformityof the findings.However, the twogroups that receivedVPA
did seem to have slightly highermean tumour volumes compared to those that did not
receiveVPA (Figure34A).Byday42 thegroups that receivedAdHSVtk/GCVandTMZ
had lowermean tumour volumes compared to theAdHSVtk/GCV groups even though
this was not statistically significant. However, the differences were significant when
compared to the AdHSVtk/GCV+VPA group (Figure 34B). There were no animals





Figure 34: Mean tumour volumes on days 28 (A) and 42 (B) after tumour implantation. 
Significances compared to control, VPA and TMZ+VPA groups are indicated by */**, ¤/¤¤ and 
#/##/###, respectively. P values <0.05, <0.01 and <0.001 are indicated by */¤/#, **/¤¤/## 
and ***/¤¤¤/###, respectively. Error bars are SEM. 
 
Table 23: A summary of the mean tumour volumes 
Study Groups Mean Tumour Volumes (mm3) +/- SEM 
n Day 28 n Day 42 
Control 8 134.2 +/- 16.2 0 - 
VPA 6 152.9 +/- 34.8 2 713.0 +/- 172.5 
TMZ+VPA 6 195.2 +/- 32.6 3 434.7 +/- 24.0 
TK+GCV 10 39.4 +/- 6.9 6 203.1 +/- 42.5 
TK+GCV+VPA 10 61.3 +/- 14.5 6 294.7 +/- 68.6 
TK+GCV+TMZ 7 36.4 +/- 12.8 7 59.8 +/- 21.3 
TK+GCV+TMZ+VPA 9 52.6 +/- 12.7 7 87.0 +/-31.8 








to enhance the survival significantly compared to the control group (Figure 35B),where
AdHSVtk/GCV alone was not significantly better (Figure 35D) indicative of a possible




survival compared to the control (Figure 35A) (p<0.001), AdHSVtk/GCV (Figure 36A)
(p<0.05),TMZ+VPA(Figure36B)(p<0.001)andAdHSVtk/GCV+VPA(Figure26D)(p<0.01)





would be worthwhile to evaluate the therapeutic benefit of adding TMZ either
simultaneouslywithGCVor immediately followingGCV inMGpatientsaftera through
toxicological evaluation of this approach. The AdHSVtk/GCV+VPA group achieved a
significant (p<0.01) survival benefit compared to the control group (Figure 35B), while
AdHSVtk/GCV+TMZ+VPA group had a significant survival benefit compared to the
control (p<0.001) (Figure 35C) and TMZ+VPA (p<0.05) group (Figure 36C). Table 24
summarises the survival data of the study.AdHSVtk/GCV+TMZ combination increased
theMSby54%,46%and34%comparedtothecontrol,TMZ+VPAandAdHSVtk/GCV
groups,respectively.
One reason for the failure of VPA to enhance the efficacy of TMZ and HSVtk/GCV
therapy invivo could be the reduced availability of VPA in the target site after
subcutaneous administration.There is evidence to suggest that rodents tend to eliminate
VPAtentimesfasterthanhumans[Loscher,1999].Accordingtotheliterature,inmice80
100mg/kg i.p. dosing has resulted in plasma and brain concentrations of 120150 g/ml
(8301040mol/L)and2540g/g(170280mol/L),respectively[Loscher,2002].Thetwice
aday dosing used in the study may not have been frequent enough to maintain the
therapeutic level.Thus, the lackofefficacywithVPAalone isnot surprisingbecause the
doseusedinthisstudywasthemuchsmallerAEDdose.

Table 24: A summary of the survival data 
 
Study Groups 
n Survival in days 
Mean +/- SEM Median 
Control 11 36.3 +/- 0.5 36.0 
VPA 6 36.7 +/- 2-1 37.5 
TMZ+VPA 7 37.1 +/- 3.3 35.0 
TK+GCV 19 39.7 +/- 2.4 41.0 
TK+GCV+VPA 10 42.8 +/- 2.3 42.0 
TK+GCV+TMZ 7 60.7 +/- 7.0 55.0 
TK+GCV+TMZ+VPA 9 49.9 +/- 3.6 48.0 






Figure 35: Kaplan-Meier survival plots comparing the control group with TK+GCV+TMZ (A), 
TK+GCV+VPA (B), TK+GCV+TMZ+VPA (C) and TK+GCV (D). The results are shown in separate 
graphs to improve readability. P values <0.05, <0.01 and <0.001 are indicated by *, ** and 
*** respectively. 
Figure 36: Kaplan-Meier survival plots for the AdHSV-tk/GCV+TMZ group which demonstrated a 




(B) and AdHSV-tk/GCV+VPA (p<0.01) (D) groups but not compared to AdHSV-
tk/GCV+TMZ+VPA group (data not shown), which had a significantly better survival compared 
to TMZ+VPA (p<0.05) (C) group. The results are shown in separate graphs to improve 
readability. P values <0.05, <0.01 and <0.001 are indicated by *, ** and *** respectively. 





Figure 37: Expression of LDLR-avidin fusion-protein targeting construct within the tumours after 
lentivirus vector-mediated local gene transfer was confirmed by IHC using anti-avidin antibody 
(A). Control staining without primary antibody (B). Scale bar 1 mm.  
 
In order to evaluate the invivo efficacy of lentivirusmediated LDLRavidin fusion
proteingenetherapy,Bt90YDOTAwasinjectedi.v. intoBT4CratMGbearingBDIXrats.
The results revealed that the animals treated with Bt90YDOTA following transduction
with the targeting construct using lentivirus vectors survived longer (MS 44.5 days)
comparedtothetwocontrolgroups;untreatedandBt90YDOTAonlygroups(MS=37and
33.5days,respectively).Thesurvivalbenefitswerestatisticallysignificantwhencompared
to the two control groups (Figure 38B and C). TheMS of the animals in the lentivirus
mediated LDLRavidin fusionprotein gene therapy group was 7.5 days (~20%) longer
whencomparedtothecontrolgroupthatreceivednotreatment(p=0.0213),and11days














two steps: 1) Gene transfer of the targeting construct and 2) administration of the
biotinylated therapeutic molecule. The advantage of this gene therapybased targeting
systemoverpretargeting systems is thatno specific targetingmAb is required.Whereas
mAbsarespecific foronlyaparticularantigen (andhencecanbeusedonly inparticular
tumours expressing the antigen), this novel targeting system is universal and can be
appliedtoall tumours.Theresultsconfirmthat the targetingconstruct iscapableofhigh
affinity binding of biotinylatedmolecules invivo, and that it can be used for therapeutic
purposes.Generally, anymolecule that canbebiotinylatedcanbeusedwith thispresent
system for targetingpurposes, includingnanoparticles and liposomespaving theway to
genetherapybasedtargetedchemotherapy.

Figure 38: Kaplan-Meier survival plots comparing the survival of the control group to Bt-90Y-
DOTA alone (A) and lentivirus-mediated gene therapy with Bt-90Y-DOTA group (B), and Bt-90Y-
DOTA alone group to lentivirus-mediated gene therapy with Bt-90Y-DOTA group (C). The results 
are shown in separate graphs to improve readability. P values <0.05, <0.01 and <0.001 are 







On the basis of the salient findings of this thesiswork, the following conclusions canbe
made:

1. The simultaneous combination of adenovirusmediatedHSVtk/GCV suicide gene
therapywithadenovirusmediatedsolubleVEGFR1antiangiogenicgenetherapyis
feasibleforthetreatmentofcancerssuchasMG.Apartfrominhibitingangiogenesis;
other antitumour mechanisms such as reduced infiltration by tumour associated
macrophages/microglia and reduced oedema may contribute to the therapeutic
benefit.

2. AdenovirusmediatedHSVtk/GCV suicide gene therapy enhances the cytotoxicity
of TMZ by locally upregulating the expression of theMMR pathway genes in a
treatment protocoldependant manner in MGMT negative MG. This novel
mechanism of synergism between these two therapies can be maximised by




3. Addition ofVPAdidnot further enhance the synergistic effect ofAdHSVtk/GCV







bind systemically administered biotinylated therapeutics and confer a therapeutic
benefitwasdemonstratedinasyngeneic,orthotopicandimmunocompetentratMG
model.Thisuniversalgenetherapybasedtargetingsystemisfreefromtheneedfor
developing tumour specific antibodies for each tumour type, and is capable of
targeting any biotinylated therapeutic compound including radiopharmaceuticals
and chemotherapeutic agents, which may be particularly advantageous in
inoperabletumours.

Thedevelopmentof treatment resistance is amajorobstacle in cancer care that canbe
overcome,toacertainextent,bycombiningdifferenttherapies.Insummary,theoutcome
of this thesis work confirms the feasibility of successfully combining AdHSVtk/GCV
suicide gene therapy with AdsVEGFR1 antiangiogenic gene therapy, which lacks the
systemic adverse effects of parenteral therapies, for the treatment of aggressive MGs.
Moreover, a novel mechanism of synergism is described between AdHSVtk/GCV and
TMZ thatdoesnot increase the adverse effectprofile,which is theothermaindrawback
associated with chemotherapy. These findings have direct implications when planning
future clinical trialswith these combinations. Furthermore, the results also highlight the
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Gene Therapy Strategies to 
Enhance Anti-Angiogenic Therapy, 
Chemotherapy and Radiotherapy in 
the Treatment of Malignant Glioma
A Pre-Clinical Evaluation
Malignant glioma is a devastating 
cancer with a dismal prognosis. The 
outcome of this thesis work confirms 
the feasibility of successfully com-
bining anti-angiogenic gene therapy 
with suicide gene therapy to treat this 
condition. It also describes a novel 
mechanism to account for the syn-
ergism and a treatment protocol that 
does not increase the adverse effect 
profile when suicide gene therapy is 
combined with temozolomide. Fur-
thermore, the results also highlight 
the efficacy of a novel gene therapy-
based targeted therapy strategy with 
wide therapeutic potential. 
